

Sedation in children and young people

Appendices

SEDATION IN CHILDREN AND YOUNG PEOPLE	1
APPENDICES	1
1 APPENDIX A - SCOPE	4
1.1 GUIDELINE TITLE	4
1.2 SHORT TITLE	4
1.3 BACKGROUND	4
1.4 CLINICAL NEED FOR THE GUIDELINE	4
1.5 THE GUIDELINE	6
1.6 POPULATION	6
1.6.1 <i>Groups that will be covered</i>	6
1.6.2 <i>Groups that will not be covered</i>	7
1.7 HEALTHCARE SETTING	7
1.8 CLINICAL MANAGEMENT	7
1.9 TRAINING AND COMPETENCE	8
1.10 STATUS	8
1.10.1 <i>Scope</i>	8
1.10.2 <i>Guideline</i>	8
1.11 FURTHER INFORMATION	8
1.12 REFERRAL FROM THE DEPARTMENT OF HEALTH	8
2 APPENDIX B - DECLARATIONS OF INTERESTS	9
2.1 INTRODUCTION	9
2.2 DECLARATIONS OF INTERESTS OF THE GDG MEMBERS	9
2.2.1 <i>Prof Mike Sury</i>	9
2.2.2 <i>Dr Paul Averley</i>	10
2.2.3 <i>Dr Peter Crean</i>	11
2.2.4 <i>Dr Nick Croft</i>	12
2.2.5 <i>Prof Nick Girdler</i>	13
2.2.6 <i>Dr Susan King</i>	14
2.2.7 <i>Dr Christina Lioffi</i>	15
2.2.8 <i>Ms Liz McArthur</i>	16
2.2.9 <i>Ms Heather McClelland</i>	17
2.2.10 <i>Dr Neil Morton</i>	18
2.2.11 <i>Ms Farrah Pradhan</i>	19
2.2.12 <i>Dr Daniel Wallis</i>	20
2.2.13 <i>Ms Madeleine Wang</i>	21
2.3 DECLARATIONS OF INTERESTS OF THE NCGC MEMBERS	22
3 APPENDIX C – SEARCH STRATEGIES	23
3.1 SEDATION PATIENT FILTERS	24
3.1.1 <i>Sedation in children</i>	24
3.1.2 <i>Modified patient filter</i>	25
3.2 STUDY DESIGN FILTERS	28
3.2.1 <i>Randomised controlled trial (RCT) filters</i>	28
3.2.2 <i>Systematic Review (SR) filters</i>	29
3.2.3 <i>Observational study filters</i>	29
3.3 EXCLUSIONS FILTER	31
3.4 DRUG EFFICACY	32
3.5 OPIOIDS: SPECIFIC DRUGS AND ROUTES OF ADMINISTRATION	34
3.6 ADVERSE EFFECTS OF DRUGS	35
3.7 ADVERSE EFFECTS OF ENDOSCOPY	37
3.8 PSYCHOLOGICAL PREPARATION FOR PATIENTS UNDERGOING SEDATION	38
3.9 SEDATION SPARING	40
3.10 SEDATION ASSESSMENT TOOLS	42
3.11 FASTING BEFORE PAEDIATRIC SEDATION	44
3.12 FASTING BEFORE PAEDIATRIC ANAESTHESIA	45
3.13 HEALTH ECONOMICS	47
APPENDIX D - EVIDENCE TABLES	50

APPENDIX E- META-ANALYSES FOREST PLOT.....	51
4 APPENDIX F - COST-EFFECTIVENESS ANALYSIS.....	52
4.1 INTRODUCTION	52
4.2 DENTAL PROCEDURES IN CHILDREN.....	54
4.2.1 <i>Methods</i>	54
4.2.2 <i>Results</i>	59
4.3 DENTAL PROCEDURES IN ADOLESCENTS	61
4.3.1 <i>Dental procedures in adolescents</i>	61
4.3.2 <i>Results</i>	64
4.4 SENSITIVITY ANALYSES.....	65
4.4.1 <i>Methods</i>	65
4.4.2 <i>Results</i>	68
4.5 PAINLESS IMAGING PROCEDURES.....	71
4.5.1 <i>Methods</i>	71
4.5.2 <i>Results</i>	73
4.6 OESOPHAGO-GASTROSCOPY	74
4.6.1 <i>Methods</i>	74
4.6.2 <i>Results</i>	75
4.7 COLONOSCOPY	77
4.7.1 <i>Methods</i>	77
4.7.2 <i>Results</i>	78
4.8 DISCUSSION	80
4.9 LITERATURE REVIEW OF ECONOMIC EVALUATIONS.....	82
4.10 COSTING STUDIES.....	85
4.11 REFERENCE LIST (FOR APPENDIX F, COST-EFFECTIVENESS ANALYSIS).....	88
5 APPENDIX G - RECOMMENDATIONS FOR RESEARCH	93
5.1 RECOMMENDATION FOR RESEARCH ON PRE-SEDATION ASSESSMENT.....	93
5.2 RECOMMENDATION FOR RESEARCH ON TRAINING FOR PERSONNEL INVOLVED IN SEDATION	95
5.3 RECOMMENDATION FOR RESEARCH ON DRUGS COMBINATION.....	97
5.4 RECOMMENDATION FOR DEVELOPMENT OF A NATIONAL REGISTRY OF SEDATION	99
6 APPENDIX H-REVIEW PROTOCOL FORM	101
6.1 OBJECTIVE.....	101
6.2 DEFINITION OF SEDATION	101
6.3 SELECTION CRITERIA FOR INTERVENTION REVIEWS	101
7 APPENDIX I - AGREE TOOL	149
8 APPENDIX J – LICENSING INDICATIONS.....	150

1 Appendix A - SCOPE

1.1 Guideline title

Sedation for diagnostic and therapeutic procedures in children and young people

1.2 Short title

Sedation in infants, children and young people

1.3 Background

- A. The National Institute for Health and Clinical Excellence ('NICE' or 'the Institute') has commissioned the National Collaborating Centre for Nursing and Supportive Care to develop a clinical guideline on sedation for diagnostic and therapeutic procedures in children and young people for use in the NHS in England and Wales. This follows referral of the topic by the Department of Health (see appendix). The guideline will provide recommendations for good practice that are based on the best available evidence of clinical and cost effectiveness.
- B. NICE clinical guidelines support the implementation of National Service Frameworks (NSFs) in those aspects of care where a Framework has been published. The statements in each NSF reflect the evidence that was used at the time the Framework was prepared. The clinical guidelines and technology appraisals published by the Institute after an NSF has been issued have the effect of updating the Framework.
- C. NICE clinical guidelines support the role of healthcare professionals in providing care in partnership with patients, taking account of their individual needs and preferences, and ensuring that patients (and their carers and families, if appropriate) can make informed decisions about their care and treatment.

1.4 Clinical need for the guideline

- A. In adults, many procedures can be undertaken with local anaesthesia and reassurance. In children and young people this is often not possible because the procedures are too frightening, too painful and need to be carried out in children who may be ill, or in pain or have behavioural problems. Therefore special consideration is necessary for children and young people undergoing distressing procedures.
- B. It is estimated that more than 2 million children and young people are taken to emergency departments each year following accidental injury. Many of

these children and young people will undergo procedures that require sedation. For example, in 2005–6 there were 866 children aged 14 and younger who required a closed reduction of a dislocated joint. Sedation is also frequently used for invasive diagnostic procedures such as lumbar punctures, bone marrow biopsies and endoscopies. In 2005–6 there were 4700 gastroscopies, 9000 diagnostic spinal punctures and 2100 bone marrow biopsies carried out on children aged 14 and younger. Sedation is also commonly used in dental practice where the use of general anaesthesia is now restricted to the hospital setting.

- C. Sedation is only one of the management options available for children and young people undergoing therapeutic or diagnostic procedures. Non-pharmacological techniques may also be useful in reducing anxiety and managing behaviour, and analgesia may be used to provide pain control. These techniques may be used in combination with sedation or as an alternative to sedation. Another alternative to using sedation for diagnostic or therapeutic procedures is to carry out the procedure under general anaesthesia, in which case the usual standards of care for patients undergoing anaesthesia must be met.
- D. Sedation is a drug-induced depression of consciousness. The aims of sedation during diagnostic or therapeutic procedures may include reducing fear and anxiety, providing pain control and minimising movement. The importance of each of these aims will vary depending on the nature of the procedure and the characteristics of the patient. For example, in younger children sedation may be necessary to ensure that movement is minimised during non-painful procedures such as a magnetic resonance imaging (MRI) scan; in older children sedation may be necessary to minimise the physical and psychological consequences of a painful procedure such as a lumbar puncture.
- E. The effect of sedation drugs on consciousness level is a continuum ranging from the awake state, through progressively deeper levels of sedation to anaesthesia. Anaesthesia is an unresponsive state in which vital airway and breathing reflexes are likely to be suppressed. The American Society of Anaesthesiologists (ASA) has published useful definitions of sedation levels, classifying them as 'minimal', 'moderate' and 'deep'. Minimal sedation equates to anxiolysis and has no appreciable effect on vital reflexes. In a state of moderate sedation the patient is able to breathe adequately without assistance and responds purposefully to verbal stimulus or tactile stimulation. This is often referred to as conscious sedation. During deep sedation, the patient cannot be roused easily but will respond purposefully to repeated or painful stimuli and may require assistance with their airway or breathing. The level of sedation that is appropriate will depend on the nature of the procedure and the needs of the individual. Deeper levels of sedation require more advanced management because the patient's protective reflexes are affected and they have the potential to progress to anaesthesia.
- F. The level of sedation achieved depends on the drug used and the dose at which it is given. When choosing between sedation techniques, healthcare professionals must consider the effectiveness of the drug in achieving the

required level of sedation, the duration of that effect, and the margin of safety between the dose required to achieve sedation and the dose that is likely to cause anaesthesia.

- G. There may be serious adverse effects if the level of sedation is greater than intended. If breathing is unintentionally depressed and this complication is not recognised and managed appropriately, then this may lead to hypoxic brain injury or death. Sedation drugs may also have other unexpected adverse effects such as prolonged emergence, paradoxical excitement or post-sedation nausea and vomiting.
- H. If sedation is unsuccessful, this can result in a painful and traumatic experience for the child. It may be necessary to complete the procedure under general anaesthesia or the procedure may need to be abandoned and rescheduled. If the child becomes distressed due to a failure to provide adequate sedation, their parent or carer may choose to refuse consent for further procedures. A distressing experience may also have long-term psychological consequences for the patient, especially if they are required to undergo repeated procedures.
- I. There is significant variation in practice across the NHS, with sedation being carried out by a variety of healthcare professionals using a wide range of techniques, within different clinical settings. The Scottish Intercollegiate Guidelines Network (SIGN) published a guideline on this topic in 2004. This covered moderate sedation but not deep sedation, and the evidence base it considered has not been updated since 2002. The aim of this guideline is to provide recommendations to both improve the effectiveness and safety of all types of procedural sedation and to reduce current variations in standards of care.

1.5 The guideline

- A. The guideline development process is described in detail in two publications that are available from the NICE website (see 'Further information'). 'The guideline development process: an overview for stakeholders, the public and the NHS' describes how organisations can become involved in the development of a guideline. 'The guidelines manual' provides advice on the technical aspects of guideline development.
- B. This scope defines what this guideline will (and will not) examine, and what the guideline developers will consider. The scope is based on a referral from the Department of Health (see appendix).
- C. The areas that will be addressed by the guideline are described in the following sections. 'Sedation' is used in the following sections to mean a drug-induced depression of consciousness that is not intended to result in anaesthesia.

1.6 Population

1.6.1 Groups that will be covered

- A. Infants, children and young people (under 19 years) receiving sedation by any technique for painful or non-painful diagnostic or therapeutic procedures.

- B. The GDG will consider whether different recommendations are required for different age groups in the population.

1.6.2 Groups that will not be covered

- A. Patients requiring sedation for purposes other than for diagnostic or therapeutic procedures including:
- sedation in critically ill patients requiring mechanical ventilation
 - sedation in palliative care
 - sedation in the treatment of mental health conditions
 - sedation given as premedication for general anaesthesia or as postoperative analgesia
 - night sedation.
- B. Patients having diagnostic or therapeutic procedures under general anaesthesia.

1.7 Healthcare setting

- A. Hospital settings, including inpatients, outpatients, radiology and emergency departments.
- B. Primary care, including dental and medical general practice settings.

1.8 Clinical management

- A. Assessment of the patient to determine whether sedation is appropriate.
- B. Clear communication, in a child-friendly manner, of information relating to the preparation required for the procedure or investigation, and related sedation technique. This will include the needs of the patient and their parents or carers, ensuring that implications (sedation safety and efficacy) are clearly understood by both the patient and their parent or carer prior to informed consent.
- C. Preparation required for the procedure or investigation and related sedation technique.
- D. The clinical environment, including the availability of equipment, facilities and staff.
- E. Patient monitoring during and after sedation and criteria for discharge following sedation.
- F. The effectiveness, safety and limitations of sedation techniques. This will include the use of sedation in combination with non-pharmacological techniques and in combination with analgesia. Note that guideline recommendations will normally fall within licensed indications. Where clearly supported by evidence, use outside

a licensed indication may be recommended. The guideline will assume that prescribers will use a drug's summary of product characteristics and the 'British National Formulary for Children' to inform their decisions for individual patients.

- G. The Guideline Development Group will take reasonable steps to identify ineffective interventions and approaches to care. If robust and credible recommendations for re-positioning the intervention for optimal use, or changing the approach to care to make more efficient use of resources, can be made, they will be clearly stated. If the resources released are substantial, consideration will be given to listing such recommendations in the 'Key priorities for implementation' section of the guideline.

1.9 Training and competence

- A. Training for practitioners involved in procedural sedation, irrespective of specialty background, that will be relevant to the sedation techniques and the clinical environment.
- B. Training that enables practitioners to be competent in the practical aspects of effective and safe delivery of sedation techniques relevant to the clinical situation, and the management of adverse events (for example, airway management skill in the inadvertently anaesthetised patient).

1.10 Status

1.10.1 Scope

This is the final scope.

1.10.2 Guideline

The development of the guideline recommendations will begin in January 2009.

1.11 Further information

The guideline development process is described in:

- 'The guideline development process: an overview for stakeholders, the public and the NHS'
- 'The guidelines manual'.

These are available from the NICE website (www.nice.org.uk/guidelinesmanual). Information on the progress of the guideline will also be available from the website.

1.12 Referral from the Department of Health

The Department of Health asked NICE to develop a guideline on sedation for diagnostic and therapeutic procedures in infants, children and young people up to the age of 19.

2 Appendix B - Declarations of interests

2.1 Introduction

All members of the GDG and all members of the NCC-AC staff were required to make formal declarations of interest at the outset, and these were updated at every subsequent meeting throughout the development process. No interests were declared that required actions.

2.2 Declarations of interests of the GDG members

2.2.1 Prof Mike Sury

<i>GDG meeting</i>	<i>Declaration of Interests</i>
Chair recruitment	None
First GDG meeting (26 January 2009)	No change to declarations
Second GDG Meeting (27 January 2009)	No change to declarations
Third GDG Meeting (19 March 2009)	No change to declarations
Fourth GDG Meeting (27 April 2009)	No change to declarations
Fifth GDG Meeting (28 April 2009)	No change to declarations
Sixth GDG Meeting (11 June 2009)	No change to declarations
Seventh GDG Meeting (23 July 2009)	No change to declarations
Eight GDG Meeting (28 September 2009)	No change to declarations
Ninth GDG Meeting (2 November 2009)	No change to declarations
Tenth GDG Meeting (26 November 2009)	No change to declarations
Eleventh GDG Meeting (11 January 2010)	No change to declarations
Twelfth GDG Meeting (12 January 2010)	No change to declarations
Thirteenth GDG Meeting (9 February 2010)	No change to declarations

2.2.2 Dr Paul Averley

GDG meeting	Declaration of Interests
GDG recruitment	25 June 2008: Persona pecuniary interest: I provide a paediatric sedation NHS service for the provision of dental services in a primary care environment.
First GDG meeting (26 January 2009)	No change to declarations
Second GDG Meeting (27 January 2009)	No change to declarations
Third GDG Meeting (19 March 2009)	No change to declarations
Fourth GDG Meeting (27 April 2009)	No change to declarations
Fifth GDG Meeting (28 April 2009)	No change to declarations
Sixth GDG Meeting (11 June 2009)	No change to declarations
Seventh GDG Meeting (23 July 2009)	No change to declarations
Eight GDG Meeting (28 September 2009)	Personal pecuniary interest: I am the managing partner of Queensway Dental Practice, 170 Queensway, Billingham, Teesside, B2 32NT. This dental practice has a PDS contract to supply NHS sedation services in primary care (dental services).
Ninth GDG Meeting (2 November 2009)	No change to declarations
Tenth GDG Meeting (26 November 2009)	No change to declarations
Eleventh GDG Meeting (11 January 2010)	No change to declarations
Twelfth GDG Meeting (12 January 2010)	No change to declarations
Thirteenth GDG Meeting (9 February 2010)	No change to declarations

2.2.3 Dr Peter Crean

GDG meeting	Declaration of Interests
GDG recruitment	None
First GDG meeting (26 January 2009)	No change to declarations
Second GDG Meeting (27 January 2009)	No change to declarations
Third GDG Meeting (19 March 2009)	No change to declarations
Fourth GDG Meeting (27 April 2009)	No change to declarations
Fifth GDG Meeting (28 April 2009)	No change to declarations
Sixth GDG Meeting (11 June 2009)	No change to declarations
Seventh GDG Meeting (23 July 2009)	No change to declarations
Eight GDG Meeting (28 September 2009)	No change to declarations
Ninth GDG Meeting (2 November 2009)	No change to declarations
Tenth GDG Meeting (26 November 2009)	No change to declarations
Eleventh GDG Meeting (11 January 2010)	No change to declarations
Twelfth GDG Meeting (12 January 2010)	No change to declarations
Thirteenth GDG Meeting (9 February 2010)	No change to declarations

2.2.4 Dr Nick Croft

GDG meeting	Declaration of Interests
GDG recruitment	<p>2 September 2008: Non-personal pecuniary interest</p> <p>None relevant to sedation or endoscopy</p> <p>Schering Plough have funded an IBD nurse specialist for one year (2007-2008) in my department at Barts and the London NHS Trust.</p> <p>Part of the income (for my time) from the below go to my Investigator Fund administered by Barts and the London NHS Trust R&D Department.</p> <p>Chief Investigator and local investigator of a clinical trial in the UK funded by Abbott.</p> <p>Consultancy (one off, 2008) Alizyme Therapeutics, Cambridge.</p>
First GDG meeting (26 January 2009)	No change to declarations
Second GDG Meeting (27 January 2009)	No change to declarations
Third GDG Meeting (19 March 2009)	No change to declarations
Fourth GDG Meeting (27 April 2009)	No change to declarations
Fifth GDG Meeting (28 April 2009)	No change to declarations
Sixth GDG Meeting (11 June 2009)	No change to declarations
Seventh GDG Meeting (23 July 2009)	No change to declarations
Eight GDG Meeting (28 September 2009)	No change to declarations
Ninth GDG Meeting (2 November 2009)	No change to declarations
Tenth GDG Meeting (26 November 2009)	No change to declarations
Eleventh GDG Meeting (11 January 2010)	No change to declarations
Twelfth GDG Meeting (12 January 2010)	No change to declarations
Thirteenth GDG Meeting (9 February 2010)	No change to declarations

2.2.5 Prof Nick Girdler

GDG meeting	Declaration of Interests
GDG recruitment	9 July 2008: Personal non-pecuniary interest: Interest in the topic under consideration: Authorship of published research projects (2002-2007) on paediatric sedation techniques which state conclusions about the safety and effectiveness of oral midazolam sedation, intravenous midazolam (+sevoflurane) sedation, buccal midazolam sedation and nitrous oxide sedation in children. Also, published studies on effectiveness of midazolam, propofol and flumazenil in adults. Published opinions and surveys on dental sedation education, competency in sedation and safe sedation practice endorsing the use of nitrous oxide sedation in children and midazolam in adults (1998-02).
First GDG meeting (26 January 2009)	No change to declarations
Second GDG Meeting (27 January 2009)	No change to declarations
Third GDG Meeting (19 March 2009)	No change to declarations
Fourth GDG Meeting (27 April 2009)	No change to declarations
Fifth GDG Meeting (28 April 2009)	No change to declarations
Sixth GDG Meeting (11 June 2009)	No change to declarations
Seventh GDG Meeting (23 July 2009)	No change to declarations
Eight GDG Meeting (28 September 2009)	No change to declarations
Ninth GDG Meeting (2 November 2009)	No change to declarations
Tenth GDG Meeting (26 November 2009)	No change to declarations
Eleventh GDG Meeting (11 January 2010)	No change to declarations
Twelfth GDG Meeting (12 January 2010)	No change to declarations
Thirteenth GDG Meeting (9 February 2010)	No change to declarations

2.2.6 Dr Susan King

GDG meeting	Declaration of Interests
GDG recruitment	None
First GDG meeting (26 January 2009)	No change to declarations
Second GDG Meeting (27 January 2009)	No change to declarations
Third GDG Meeting (19 March 2009)	No change to declarations
Fourth GDG Meeting (27 April 2009)	No change to declarations
Fifth GDG Meeting (28 April 2009)	No change to declarations
Sixth GDG Meeting (11 June 2009)	No change to declarations
Seventh GDG Meeting (23 July 2009)	No change to declarations
Eight GDG Meeting (28 September 2009)	No change to declarations
Ninth GDG Meeting (2 November 2009)	No change to declarations
Tenth GDG Meeting (26 November 2009)	No change to declarations
Eleventh GDG Meeting (11 January 2010)	No change to declarations
Twelfth GDG Meeting (12 January 2010)	No change to declarations
Thirteenth GDG Meeting (9 February 2010)	No change to declarations

2.2.7 Dr Christina Liossi

GDG meeting	Declaration of Interests
GDG recruitment	None
First GDG meeting (26 January 2009)	No change to declarations
Second GDG Meeting (27 January 2009)	No change to declarations
Third GDG Meeting (19 March 2009)	No change to declarations
Fourth GDG Meeting (27 April 2009)	No change to declarations
Fifth GDG Meeting (28 April 2009)	No change to declarations
Sixth GDG Meeting (11 June 2009)	No change to declarations
Seventh GDG Meeting (23 July 2009)	No change to declarations
Eight GDG Meeting (28 September 2009)	No change to declarations
Ninth GDG Meeting (2 November 2009)	No change to declarations
Tenth GDG Meeting (26 November 2009)	No change to declarations
Eleventh GDG Meeting (11 January 2010)	No change to declarations
Twelfth GDG Meeting (12 January 2010)	No change to declarations
Thirteenth GDG Meeting (9 February 2010)	No change to declarations

2.2.8 Ms Liz McArthur

GDG meeting	Declaration of Interests
GDG recruitment	None
First GDG meeting (26 January 2009)	No change to declarations
Second GDG Meeting (27 January 2009)	No change to declarations
Third GDG Meeting (19 March 2009)	No change to declarations
Fourth GDG Meeting (27 April 2009)	No change to declarations
Fifth GDG Meeting (28 April 2009)	No change to declarations
Sixth GDG Meeting (11 June 2009)	No change to declarations
Seventh GDG Meeting (23 July 2009)	No change to declarations
Eight GDG Meeting (28 September 2009)	No change to declarations
Ninth GDG Meeting (2 November 2009)	No change to declarations
Tenth GDG Meeting (26 November 2009)	No change to declarations
Eleventh GDG Meeting (11 January 2010)	No change to declarations
Twelfth GDG Meeting (12 January 2010)	No change to declarations
Thirteenth GDG Meeting (9 February 2010)	No change to declarations

2.2.9 Ms Heather McClelland

GDG meeting	Declaration of Interests
GDG recruitment	None
First GDG meeting (26 January 2009)	No change to declarations
Second GDG Meeting (27 January 2009)	No change to declarations
Third GDG Meeting (19 March 2009)	No change to declarations
Fourth GDG Meeting (27 April 2009)	No change to declarations
Fifth GDG Meeting (28 April 2009)	No change to declarations
Sixth GDG Meeting (11 June 2009)	No change to declarations
Seventh GDG Meeting (23 July 2009)	No change to declarations
Eight GDG Meeting (28 September 2009)	No change to declarations
Ninth GDG Meeting (2 November 2009)	No change to declarations
Tenth GDG Meeting (26 November 2009)	No change to declarations
Eleventh GDG Meeting (11 January 2010)	No change to declarations
Twelfth GDG Meeting (12 January 2010)	No change to declarations
Thirteenth GDG Meeting (9 February 2010)	No change to declarations

2.2.10 Dr Neil Morton

GDG meeting	Declaration of Interests
GDG recruitment	None
First GDG meeting (26 January 2009)	No change to declarations
Second GDG Meeting (27 January 2009)	No change to declarations
Third GDG Meeting (19 March 2009)	No change to declarations
Fourth GDG Meeting (27 April 2009)	No change to declarations
Fifth GDG Meeting (28 April 2009)	No change to declarations
Sixth GDG Meeting (11 June 2009)	No change to declarations
Seventh GDG Meeting (23 July 2009)	No change to declarations
Eight GDG Meeting (28 September 2009)	No change to declarations
Ninth GDG Meeting (2 November 2009)	Personal non-pecuniary interest: Chairman SIGN guideline 58 working group
Tenth GDG Meeting (26 November 2009)	No change to declarations
Eleventh GDG Meeting (11 January 2010)	No change to declarations
Twelfth GDG Meeting (12 January 2010)	No change to declarations
Thirteenth GDG Meeting (9 February 2010)	No change to declarations

2.2.11 Ms Farrah Pradhan

GDG meeting	Declaration of Interests
GDG recruitment	None
First GDG meeting (26 January 2009)	No change to declarations
Second GDG Meeting (27 January 2009)	No change to declarations
Third GDG Meeting (19 March 2009)	No change to declarations
Fourth GDG Meeting (27 April 2009)	No change to declarations
Fifth GDG Meeting (28 April 2009)	No change to declarations
Sixth GDG Meeting (11 June 2009)	No change to declarations
Seventh GDG Meeting (23 July 2009)	No change to declarations
Eight GDG Meeting (28 September 2009)	No change to declarations
Ninth GDG Meeting (2 November 2009)	No change to declarations
Tenth GDG Meeting (26 November 2009)	No change to declarations
Eleventh GDG Meeting (11 January 2010)	No change to declarations
Twelfth GDG Meeting (12 January 2010)	No change to declarations
Thirteenth GDG Meeting (9 February 2010)	No change to declarations

2.2.12 Dr Daniel Wallis

GDG meeting	Declaration of Interests
GDG recruitment	27 June 2008: Personal non-pecuniary interest I have been invited to speak at meeting(s) where I have been specifically asked to argue a case in a database, in particular that the drug ketamine may be safely used by non-anaesthetists for paediatric sedation. I have given other presentations where I have suggested that subject to important safeguards it may be reasonable practice for specialists in emergency medicine to use this drug for paediatric sedation in appropriate cases.
First GDG meeting (26 January 2009)	No change to declarations
Second GDG Meeting (27 January 2009)	No change to declarations
Third GDG Meeting (19 March 2009)	No change to declarations
Fourth GDG Meeting (27 April 2009)	No change to declarations
Fifth GDG Meeting (28 April 2009)	No change to declarations
Sixth GDG Meeting (11 June 2009)	No change to declarations
Seventh GDG Meeting (23 July 2009)	No change to declarations
Eight GDG Meeting (28 September 2009)	No change to declarations
Ninth GDG Meeting (2 November 2009)	No change to declarations
Tenth GDG Meeting (26 November 2009)	No change to declarations
Eleventh GDG Meeting (11 January 2010)	No change to declarations
Twelfth GDG Meeting (12 January 2010)	No change to declarations
Thirteenth GDG Meeting (9 February 2010)	No change to declarations

2.2.13 Ms Madeleine Wang

GDG meeting	Declaration of Interests
GDG recruitment	28 June 2008: Personal non-pecuniary interest Lay member Northern and Yorkshire REC Lay member NCEPOD Steering Group Lay member/patient representative DH information for cohesion work stream board Commission for Human Medicines Patient Information Expert Advisory Group Lay member NICE General and Acute topic selection panel
First GDG meeting (26 January 2009)	No change to declarations
Second GDG Meeting (27 January 2009)	No change to declarations
Third GDG Meeting (19 March 2009)	No change to declarations
Fourth GDG Meeting (27 April 2009)	No change to declarations
Fifth GDG Meeting (28 April 2009)	No change to declarations
Sixth GDG Meeting (11 June 2009)	No change to declarations
Seventh GDG Meeting (23 July 2009)	No change to declarations
Eight GDG Meeting (28 September 2009)	No change to declarations
Ninth GDG Meeting (2 November 2009)	No change to declarations
Tenth GDG Meeting (26 November 2009)	No change to declarations
Eleventh GDG Meeting (11 January 2010)	No change to declarations
Twelfth GDG Meeting (12 January 2010)	No change to declarations
Thirteenth GDG Meeting (9 February 2010)	No change to declarations

2.3 Declarations of interests of the NCGC members

GDG meeting	Declaration of Interests of NCGC members
First GDG meeting (26 January 2009)	None
Second GDG Meeting (27 January 2009)	None
Third GDG Meeting (19 March 2009)	None
Fourth GDG Meeting (27 April 2009)	None
Fifth GDG Meeting (28 April 2009)	None
Sixth GDG Meeting (11 June 2009)	None
Seventh GDG Meeting (23 July 2009)	None
Eight GDG Meeting (28 September 2009)	None
Ninth GDG Meeting (2 November 2009)	None
Tenth GDG Meeting (26 November 2009)	None
Eleventh GDG Meeting (11 January 2010)	None
Twelfth GDG Meeting (12 January 2010)	None
Thirteenth GDG Meeting (9 February 2010)	None

3 Appendix C – Search Strategies

This appendix details the search strategies used in the identification of relevant studies for the guideline on sedation in infants, children and young people.

All searches were conducted on the following databases with no date restrictions unless otherwise noted below:

Database	Interface	Date searched from
Medline	OVID	1950
Embase	OVID	1980
Cinahl	EBSCO	1982
The Cochrane Library (to 2009 Issue 4)	www.thecochranelibrary.com	All dates searched: 1996 for Cochrane Reviews 1995 for DARE 1898 for CENTRAL 1904 for Methods Studies 1995 for HTA and NHSEED

Search filters were applied where appropriate, including filters for randomised controlled trials (RCT) and systematic reviews (SR). The RCT filter used was based on that recommended by Cochrane (Higgins, 2005). An exclusions filter was designed to remove irrelevant results such as letters and editorials.

The search strategies for each review are reproduced below. Note that the searches make use of controlled vocabulary which varies between databases and between search interfaces. Amendments were made where necessary in order to take these variations into account.

Where possible, searches were restricted to articles written in English. All searches were updated on January 18th 2010.

Hand searching was not undertaken following NICE advice that exhaustive searching on every guideline review topic is not practical. Reference lists of articles were checked for further articles of potential relevance.

3.1 Sedation patient filters

The following patient filters were developed in consultation with the GDG chair. Section 1.1.1 shows the filter used for retrieving studies relating to sedation in children. A modified filter (section 1.1.2) was used when it was necessary to retrieve studies relating to either sedation or anaesthesia.

3.1.1 Sedation in children

Medline

No.	Search terms
1	conscious sedation/
2	deep sedation/
3	sedat\$.ti,ab.
4	dental anxiety/
5	((minimal or light) adj (anesthesia or anaesthesia)).tw.
6	or/1-5
7	exp child/
8	child\$.tw.
9	exp infant/
10	infan\$.tw.
11	(baby or babies).tw.
12	"adolescent"/
13	(pediatric\$1 or paediatric\$1).tw.
14	or/7-14
15	6 and 14

Embase

No.	Search terms
1	conscious sedation/
2	sedation/
3	sedat\$.ti,ab.
4	dental anxiety/
5	((minimal or light) adj (anesthesia or anaesthesia)).tw.
6	or/1-5
7	exp child/
8	child\$.tw.
9	childhood/
10	infancy/
11	infan\$.tw.
12	(baby or babies).tw.
13	exp adolescent/
14	(pediatric\$1 or paediatric\$1).tw.
15	or/7-14
16	6 and 15

Cinahl

No.	Search terms
S15	S14 and S7
S14	S13 or S12 or S11 or S10 or S9 or S8
S13	TX pediatric or TX pediatrics or TX paediatrics or TX paediatrics
S12	TX baby or TX babies
S11	TX infan*
S10	TX child*
S9	(MH "Adolescence+")
S8	(MH "Child+")
S7	S6 or S5 or S4 or S3 or S2 or S1
S6	TI light N1 anesthesia or AB light N1 anesthesia or TI light N1 anaesthesia or AB light N1 anaesthesia
S5	TI minimal N1 anesthesia or AB minimal N1 anesthesia or TI minimal N1 anaesthesia or AB minimal N1 anaesthesia
S4	sedat*
S3	(MH "Dental Anxiety")
S2	(MH "Sedation")
S1	(MH "Conscious Sedation")

The Cochrane Library

No.	Search terms
#1	sedat*:ti,ab,kw
#2	MeSH descriptor Conscious Sedation, this term only
#3	MeSH descriptor Deep Sedation, this term only
#4	MeSH descriptor Dental Anxiety, this term only
#5	((dental or dentist) near/2 (anxiety or anxious or nervous* or fear or panic)):ti,ab,kw
#6	((minimal or light) next (anesthesia or anaesthesia)):ti,ab,kw
#7	(#1 OR #2 OR #3 OR #4 OR #5 OR #6)
#8	child*:ti,ab,kw
#9	infan*:ti,ab,kw
#10	(baby or babies):ti,ab,kw
#11	adolescen*:ti,ab,kw
#12	(pediatric? or paediatric?):ti,ab,kw
#13	(#8 OR #9 OR #10 OR #11 OR #12)
#14	(#7 AND #13)

3.1.2 Modified patient filter**Medline**

No.	Search terms
1	Conscious Sedation/
2	Deep Sedation/
3	sedat\$.ti,ab,hw.
4	(anesthesia or anaesthesia).ti,ab.
5	exp Anesthesia/
6	or/1-5
7	exp child/
8	child\$.tw.

- 9 exp infant/
 - 10 infan\$.tw.
 - 11 (baby or babies).tw.
 - 12 "Adolescent"/
 - 13 (pediatric\$1 or paediatric\$1).tw.
 - 14 or/7-13
-

Embase

No.	Search terms
1	Conscious Sedation/
2	Sedation/
3	sedat\$.ti,ab,hw.
4	(anesthesia or anaesthesia).ti,ab.
5	exp Anesthesia/
6	or/1-5
7	exp child/
8	child\$.tw.
9	childhood/
10	infancy/
11	infan\$.tw.
12	(baby or babies).tw.
13	exp adolescent/
14	(pediatric\$1 or paediatric\$1).tw.
15	or/7-14

Cinahl

No.	Search terms
S15	S7 and S14
S14	(S13 or S12 or S11 or S10 or S9 or S8)
S13	TX pediatric or TX pediatrics or TX paediatrics or TX paediatrics
S12	TX baby or TX babies
S11	TX infan*
S10	TX child*
S9	(MH "Adolescence+")
S8	(MH "Child+")
S7	(S1 or S2 or S3 or S4 or S5 or S6)
S6	(MH "Anesthesia, General+")
S5	(MH "Anesthesia+")
S4	anesthesia or anaesthesia
S3	sedat*
S2	(MH "Sedation")
S1	(MH "Conscious Sedation")

The Cochrane Library

No.	Search terms
#1	sedat*:ti,ab,kw
#2	MeSH descriptor Conscious Sedation, this term only
#3	MeSH descriptor Deep Sedation, this term only

- #4 (anesthesia or anaesthesia):ti,ab,kw
 - #5 (#1 OR #2 OR #3 OR #4)
 - #6 child*:ti,ab,kw
 - #7 infan*:ti,ab,kw
 - #8 (baby or babies):ti,ab,kw
 - #9 adolescen*:ti,ab,kw
 - #10 (pediatric? or paediatric?):ti,ab,kw
 - #11 (#6 OR #7 OR #8 OR #9 OR #10)
 - #12 (#5 AND #11)
-

3.2 Study design filters

3.2.1 Randomised controlled trial (RCT) filters

Medline

No.	Search terms
1	randomized controlled trial\$.pt,sh.
2	clinical trial\$.pt,sh.
3	random allocation/
4	double blind method/
5	single blind method/
6	((clin\$ or control\$) adj5 trial\$).ti,ab.
7	((singl\$ or doubl\$ or trebl\$ or tripl\$) adj25 (blind\$ or mask\$)).ti,ab.
8	placebos/
9	placebo\$.ti,ab.
10	random\$.ti,ab.
11	(volunteer\$ or "control group" or controls or prospective\$).ti,ab.
12	research design/
13	or/1-12
14	animals/ not humans/
15	13 not 14

Embase

No.	Search terms
1	exp randomized controlled trial/
2	(random\$ or placebo\$).ti,ab.
3	((singl\$ or doubl\$ or trebl\$ or tripl\$) adj25 (blind\$ or mask\$)).ti,ab.
4	(clin\$ adj25 trial\$).ti,ab.
5	exp comparative study/
6	exp evaluation/
7	exp follow up/
8	exp prospective study/
9	(control\$ or prospective\$ or volunteer\$).ti,ab.
10	or/1-9
11	exp human/
12	10 and 11

Cinahl

No.	Search terms
S11	(s10 or s9 or s8 or s7 or s6 or s5 or s4 or s3 or s2 or s1)
S10	control* or prospective* or volunteer*
S9	(mh "quantitative studies")
S8	(mh "placebos")
S7	(mh "random assignment")
S6	random* or placebo*
S5	(singl* n25 mask*) or (doubl* n25 mask*) or (trebl* n25 mask*) or (tripl* n25 mask*)
S4	(singl* n25 blind*) or (doubl* n25 blind*) or (trebl* n25 blind*) or (tripl* n25 blind*)
S3	(clin* n25 trial*)

S2 pt clinical trial
 S1 (mh "clinical trials+")

3.2.2 Systematic Review (SR) filters

Medline / Embase

No.	Search terms
1	review.pt. or review.ti. or "review"/
2	(systematic\$ or evidence\$ or methodol\$ or quantitativ\$ or analys\$ or assessment\$).ti,sh,ab.
3	1 and 2
4	meta-analysis.pt.
5	meta-analysis/
6	meta-analysis as topic/
7	"systematic review"/
8	(meta-analy\$ or metanaly\$ or metaanaly\$ or meta analy\$).ti,ab.
9	((systematic\$ or evidence\$ or methodol\$ or quantitativ\$) adj5 (review\$ or survey\$ or overview\$)).ti,ab,sh.
10	((pool\$ or combined or combining) adj2 (data or trials or studies or results)).ti,ab.
11	or/3-10

Cinahl

No.	Search terms
S13	S12 or S11 or S10 or S9 or S8 or S7 or S6
S12	(pool* N2 data) or (combined N2 data) or (combining N2 data) or (pool* N2 trials) or (combined N2 trials) or (combining N2 trials) or (pool* N2 studies) or (combined N2 studies) or (combining N2 studies) or (pool* N2 results) or (combined N2 results) or (combining N2 results)
S11	(systematic* N5 overview*) or (evidence* N5 overview*) or (methodol* N5 overview*) or (quantitativ* N5 overview*)
S10	(systematic* N5 survey*) or (evidence* N5 survey*) or (methodol* N5 survey*) or (quantitativ* N5 survey*)
S9	(systematic* N5 review*) or (evidence* N5 review*) or (methodol* N5 review*) or (quantitativ* N5 review*)
S8	(meta-analy* or metanaly* or metaanaly* or meta analy*)
S7	(MH "Meta Analysis")
S6	S4 and S5
S5	S3 or S2 or S1
S4	(systematic* or evidence* or methodol* or quantitativ* or analys* or assessment*)
S3	TI review
S2	(MH "Systematic Review")
S1	PT review

3.2.3 Observational study filters

Medline

No.	Search terms
1	exp Clinical Trial/
2	exp Clinical Trials as Topic/
3	exp Evaluation Studies/ or follow-up studies/ or prospective studies/

-
- 4 exp epidemiological studies/
 - 5 cohort stud\$.ti,ab.
 - 6 case control stud\$.ti,ab.
 - 7 ((crossover or cross-over or cross over) adj2 (design\$ or stud\$ or procedure\$ or trial\$)).ti,ab.
 - 8 or/1-7
-

Embase

No.	Search terms
1	controlled study/
2	clinical study/ or major clinical study/ or clinical trial/ or phase 1 clinical trial/ or phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical trial/
3	exp Longitudinal Study/
4	exp Cohort Analysis/
5	cohort studies.ti,ab.
6	(cross adj2 over adj2 (study or design)).ti,ab.
7	crossover procedure/
8	or/1-7

3.3 Exclusions Filter

The following filter was designed to remove irrelevant results from searches. If used it was combined into search strategies using the NOT operator.

Medline / Embase

No.	Search terms
1	letter.pt.
2	letter/
3	letter\$/
4	editorial.pt.
5	historical article.pt.
6	anecdote.pt.
7	commentary.pt.
8	note.pt.
9	case report/
10	case report\$.pt.
11	case study/
12	case study.pt.
13	exp animal/ not human/
14	nonhuman/
15	exp animal studies/
16	animals, laboratory/
17	exp experimental animal/
18	exp animal experiment/
19	exp animal model/
20	exp rodentia/
21	exp rodents/
22	exp rodent/
23	or/1-22

3.4 Drug efficacy

The following searches were combined with the sedation patient filter to identify studies on drug efficacy. The medline and embase results were combined with study design filters for RCTs and SRs. The exclusions filter was also used on these two databases.

Clinical question:

- Which sedation technique is the most appropriate (multifactorial)?

Medline

No.	Search terms
1	ketamine/
2	propofol/
3	midazolam/
4	diazepam/
5	morphine/
6	heroin/
7	fentanyl/
8	alfentanil/
9	meperidine/
10	nitrous oxide/
11	sevoflurane.mp.
12	triclofos.mp.
13	(remifentanyl or remifentanil).mp.
14	or/1-13
15	exp "Hypnotics and Sedatives"/
16	exp Anti-Anxiety Agents/
17	exp Analgesics, Opioid/
18	exp Anesthetics, Inhalation/
19	exp anesthetics/
20	exp analgesics/
21	or/15-20
22	14 or 21

Embase

No.	Search terms
1	ketamine/
2	propofol/
3	midazolam/
4	diazepam/
5	morphine/
6	diamorphine/
7	fentanyl/
8	alfentanil/
9	pethidine/
10	nitrous oxide/
11	sevoflurane/
12	triclofos/
13	remifentanil/
14	or/1-13

- 15 exp hypnotic sedative agent/
 - 16 exp anxiolytic agent/
 - 17 exp narcotic analgesic agent/
 - 18 exp inhalation anesthetic agent/
 - 19 exp anesthetic agent/
 - 20 exp analgesic agent/
 - 21 or/15-20
 - 22 14 or 21
-

Cinahl

No.	Search terms
S7	S6 or S5 or S4 or S3 or S2 or S1
S6	TX triclofos or TX remifentanyl or TX remifentanil
S5	(MH "Ketamine") or (MH "Propofol") or (MH "Midazolam") or (MH "Diazepam") or (MH "Morphine") or (MH "Heroin") or (MH "Fentanyl") or (MH "Alfentanil") or (MH "Meperidine") or (MH "Nitrous Oxide") or (MH "Sevoflurane")
S4	(MH "Anesthetics+")
S3	(MH "Analgesics+")
S2	(MH "Antianxiety Agents+")
S1	(MH "Hypnotics and Sedatives+")

The Cochrane Library

No.	Search terms
#1	(ketamine or propofol or midazolam or diazepam or sevoflurane or morphine or diamorphine or heroin or fentanyl or alfentanil or alfentanyl or remifentanil or remifentanyl or meperidine or pethidine or triclofos or nitrous oxide):kw,ti,ab
#2	MeSH descriptor Analgesics explode all trees
#3	MeSH descriptor Anesthetics explode all trees
#4	MeSH descriptor Hypnotics and Sedatives explode all trees
#5	MeSH descriptor Anti-Anxiety Agents explode all trees
#6	(#1 OR #2 OR #3 OR #4 OR #5)

3.5 Opioids: specific drugs and routes of administration

Further searches were carried out to identify studies of the efficacy of opioids. These were limited by the GDG to specific drugs via specific routes of administration. The searches were combined with the sedation patient filter.

Clinical question:

- Which sedation technique is the most appropriate (multifactorial)?

Medline

No.	Search terms
1	fentanyl/
2	morphine/
3	heroin/
4	intravenous.hw.
5	1 or 2
6	4 and 5
7	intranasal.hw.
8	3 and 7
9	6 or 8

Embase

No.	Search terms
1	fentanyl/iv
2	morphine/iv
3	diamorphine/na
4	or/1-3

Cinahl

No.	Search terms
S1	(MH "Morphine") or (MH "Heroin") or (MH "Fentanyl")

The Cochrane Library

No.	Search terms
#1	(intravenous near/2 fentanyl):kw,ti,ab
#2	(intravenous near/2 morphine):kw,ti,ab
#3	(intranasal near/2 heroin):kw,ti,ab
#4	(intranasal near/2 diamorphine):kw,ti,ab
#5	(#1 OR #2 OR #3 OR #4)

3.6 Adverse effects of drugs

The sedation patient filter was combined with the following searches to retrieve papers on the adverse effects of drugs used for sedation.

Clinical question:

- Which sedation technique is the most appropriate (multifactorial)?

Medline

No.	Search terms
1	midazolam/ae, to
2	nitrous oxide/ae, to
3	ketamine/ae, to
4	temazepam/ae, to
5	propofol/ae, to
6	Chloral Hydrate/ae, to
7	triclofos.ti,ab,hw. and (ae or to).fs.
8	isoflurane/ae, to
9	sevoflurane.ti,ab,hw. and (ae or to).fs.
10	exp Analgesics, Opioid/ae, to
11	or/1-10

Embase

No.	Search terms
1	midazolam/ae, to
2	nitrous oxide/ae, to
3	ketamine/ae, to
4	temazepam/ae, to
5	propofol/ae, to
6	triclofos/ae, to
7	Chloral Hydrate/ae, to
8	Isoflurane/ae, to
9	sevoflurane/ae, to
10	exp narcotic analgesic agent/ae, to
11	or/1-10

Cinahl

No.	Search terms
S7	S1 or S2 or S3 or S4 or S5 or S6
S6	MW "adverse effects"
S5	complication* or tolerability
S4	drug* n2 safe*
S3	toxic*
S2	side effect*
S1	adverse* and (effect* OR reaction* OR event*)

The Cochrane Library

No.	Search terms
#1	(ketamine or propofol or midazolam or diazepam or sevoflurane or morphine or diamorphine or heroin or fentanyl or alfentanil or alfentanil or remifentanil or remifentanyl or meperidine or pethidine or triclofos or nitrous oxide or chloral hydrate or isoflurane or temazepam):kw,ti,ab
#2	MeSH descriptor Analgesics explode all trees
#3	MeSH descriptor Anesthetics explode all trees
#4	MeSH descriptor Hypnotics and Sedatives explode all trees
#5	MeSH descriptor Anti-Anxiety Agents explode all trees
#6	(#1 OR #2 OR #3 OR #4 OR #5)
#7	Any MeSH descriptor with qualifiers: AE,TO
#8	((adverse*) near/2 (effect* OR reaction* OR event*)):ti,ab,kw
#9	side effect*:tw,ab,ti
#10	toxic*:ti,ab,kw
#11	drug* near/2 safe*:ti,ab,kw
#12	(complication* or tolerability):ti,ab,kw
#13	(#7 OR #8 OR #9 OR #10 OR #11 OR #12)
#14	(#6 AND #13)

3.7 Adverse effects of endoscopy

The following searches were combined with the modified patient filter.

Clinical question:

- Do the specific complications of endoscopy (perforation/bleed) differ in frequency (or severity - probably much more difficult to measure) when using general anaesthetic versus sedation techniques in children (<18)?

Medline

No.	Search terms
1	exp endoscopy/
2	perforation.hw.
3	Gastrointestinal Hemorrhage/ (bleed* or hematochezia or haematochezia or hemorrhage or haemorrhage or
4	perforat*).ti,ab.
5	or/2-4
6	1 and 5

Embase

No.	Search terms
1	exp endoscopy/
2	perforation.hw.
3	exp bleeding/ (bleed* or hematochezia or haematochezia or hemorrhage or haemorrhage or
4	perforat*).ti,ab.
5	or/2-4
6	1 and 5

Cinahl

No.	Search terms
S6	S1 and S5
S5	(S2 or S3 or S4)
S4	bleed* or hematochezia or haematochezia or hemorrhage or haemorrhage or perforat*
S3	(MH "Gastrointestinal Hemorrhage")
S2	MW perforation
S1	(MH "Endoscopy+")

The Cochrane Library

No.	Search terms
#1	MeSH descriptor Endoscopy explode all trees
#2	*scopy:ti,ab,kw
#3	(#1 OR #2)
#4	(bleed* or hematochezia or haematochezia or hemorrhage or haemorrhage or perforat*):ti,ab,kw
#5	(#3 AND #4)

3.8 Psychological preparation for patients undergoing sedation

These searches were combined with the modified patient filter.

Clinical questions:

- What standard psychological preparation should be used for patients who are going to receive sedation?
- What coping skills should be discussed with patients and their families?

Medline

No.	Search terms
1	exp parents/
2	1 or child filter
3	psychological preparation.ti,ab.
4	stress, psychological/pc
5	anxiety/pc
6	dental anxiety/pc
7	play therapy/
8	adaptation, psychological/
9	patient education as topic/
10	or/3-9
11	2 and 10

Embase

No.	Search terms
1	exp parent/
2	1 or child filter
3	psychological preparation.ti,ab.
4	anxiety/
5	dental anxiety/
6	play therapy/
7	coping behavior/
8	patient education/
9	or/3-8
10	2 and 9

Cinahl

No.	Search terms
S13	S3 and S12
S12	S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11
S11	(MH "Patient Education")
S10	(MH "Adaptation, Psychological")
S9	(MH "Coping")
S8	(MH "Play Therapy")
S7	(MH "Dental Anxiety/PC")
S6	(MH "Anxiety/PC")

S5 (MH "Stress, Psychological/PC")
 S4 psychological preparation
 S3 S1 or S2 or **child filter**
 S2 parent*
 S1 (MH "Parents+")

The Cochrane Library

No.	Search terms
#1	parent*:kw,ab,ti
#2	(#1 OR child filter)
#3	(psychological preparation or play therapy or adaptation or coping or patient prepar* or patient education or patient inform*):ti,ab,kw
#4	((anxiety or stress) near/2 prevent*):ti,ab,kw
#5	(#3 OR #4)
#6	(#2 AND #5)

3.9 Sedation sparing

The following searches were combined with the sedation patient filter.

Clinical question:

- Does a combination of psychological techniques and sedation drugs lead to sedation sparing?

Medline

No.	Search terms
1	exp Hypnosis/
2	breathing exercises/
3	exp parents/ed, px
4	virtual reality.ab,ti.
5	play therapy/
6	music.hw.
7	relaxation/ or relaxation therapy/
8	(psycholog* adj (technique* or strateg* or intervention*)).ti,ab.
9	"Imagery (Psychotherapy)"/
10	distract*.ti,ab.
11	cognitive therapy/
12	memory/
13	or/1-12

Embase

No.	Search terms
1	hypnosis/
2	breathing exercise/
3	virtual reality/
4	play therapy/
5	music.hw.
6	relaxation training/
7	(psycholog* adj (technique* or strateg* or intervention*)).ti,ab.
8	exp psychotherapy/
9	distract*.ti,ab.
10	memory/
11	exp parent/
12	or/1-11

Cinahl

No.	Search terms
S15	S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14
S14	psycholog* and (technique* or strateg* or intervention*)
S13	(MH "Behavior Therapy")
S12	(MH "Cognitive Therapy")
S11	(MH "memory")
S10	(MH "Guided Imagery")
S9	(MH "Distraction")

- S8 (MH "Relaxation Techniques")
 S7 (MH "Music Therapy")
 S6 (MH "Play Therapy")
 S5 (MH "Virtual Reality")
 S4 (MH "Parenting Education")
 S3 (MH "Parents+ /ED/PF")
 S2 (MH "Breathing Exercises")
 S1 (MH "Hypnosis")
-

The Cochrane Library

No.	Search terms
#1	(hypnosis or hypnotis* or parent* or breathing exercise* or virtual reality or play therapy or relaxation or music or imagery or distract* or memory):ti,ab,kw
#2	psychotherapy:ti,ab,kw
#3	(psycholog* near (technique or strateg* or intervention*)):ti,ab,kw
#4	((cognitive or behaviour or behavior) near/2 therapy) or CBT:ti,ab,kw
#5	(#1 or #2 or #3 or #4)

3.10 Sedation Assessment Tools

The following searches were combined with the sedation patient filter. The medline and embase results were combined with study design filters for RCTs, SRs and observational studies. The exclusions filter was also used on these two databases.

Clinical question:

- What validated tools should be used to support assessment?

Medline

No.	Search terms
1	(risk adj2 (engine\$ or equation\$ or calculation\$ or table\$ scor\$)).ti,ab.
2	scor\$ system\$.ti,ab.
3	risk model\$.ti,ab.
4	Disease severity grad\$.ti,ab.
5	(assess\$ adj2 (indice\$ or tool\$)).ti,ab.
6	*Questionnaires/
7	(sedation adj3 questionnaire\$).ti,ab.
8	Predictive value of tests/
9	Severity of illness Index/
10	valid\$ tool\$.ti,ab.
11	algorithms/
12	algorithm\$.ti,ab.
13	*Risk Assessment/
14	*Factor Analysis, Statistical/
15	*Regression Analysis/
16	*Logistic Models/
17	*Analysis Of Variance/
18	*multivariate analysis/
19	or/68-85

Embase

No.	Search terms
1	(risk adj2 (engine\$ or equation\$ or calculation\$ or table\$ scor\$)).ti,ab.
2	scor\$ system\$.ti,ab.
3	risk model\$.ti,ab.
4	Disease severity grad\$.ti,ab.
5	(assess\$ adj2 (indice\$ or tool\$)).ti,ab.
6	Clinical Assessment Tool/
7	*Questionnaire/
8	(sedation adj3 questionnaire\$).ti,ab.
9	"prediction and forecasting"/
10	valid\$ tool\$.ti,ab.
11	exp algorithm/
12	algorithm\$.ti,ab.
13	*Risk Assessment/
14	*Factor Analysis, Statistical/
15	*Regression Analysis/
16	*Logistic Models/
17	*Analysis Of Variance/

- 18 *multivariate analysis/
- 19 *scoring system/
- 20 or/1-19

Cinahl

No.	Search terms
S1	assess* n3 tool* or assess* n3 indice* or sedation n3 questionnaire* or risk n3 assess* or scor* n1 system* or risk n2 engine* or risk n2 calculat* or risk n2 table* or risk n2 scor* or risk n2 model* or algorithim* or valid* n3 tool*

The Cochrane Library

No.	Search terms
#1	MeSH descriptor Predictive Value of Tests explode all trees
#2	MeSH descriptor Severity of Illness Index explode all trees
#3	(assess* near (indice* or tool*)):ti,ab,kw
#4	(Disease severity grad*):ti,ab,kw
#5	(risk near2 (engine* or calculat* or equation*or table* or scor* or model*)):ti,ab,kw
#6	(scor* next system*):ti,ab
#7	(valid* tool*):ti,ab,kw
#8	MeSH descriptor Algorithms explode all trees
#9	(algorithm*):ti,ab,kw
#10	(#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9)

3.11 Fasting before paediatric sedation

The following searches were combined with the sedation patient filter. The medline and embase results were combined with study design filters for RCTs and observational studies.

Clinical question:

- Should patients be fasted before sedation?

Medline

No.	Search terms
1	fasting/ (meal or meals or solids or drink* or eat* or food* or feed* or fasting* or fasted* or
2	starv* or "nil by mouth" or NPO or "nulla per os" or "nothing by mouth").ti,ab.
3	or/1-2

Embase

No.	Search terms
1	exp diet restriction/ (meal or meals or solids or drink* or eat* or food* or feed* or fasting* or fasted* or
2	starv* or "nil by mouth" or NPO or "nulla per os" or "nothing by mouth").ti,ab.
3	1 or 2

Cinahl

No.	Search terms
S3	S1 or S2 (meal or meals or solids or drink* or eat* or food* or feed* or fasting* or fasted* or
S2	starv* or "nil by mouth" or NPO or "nulla per os" or "nothing by mouth")
S1	(MH "Fasting") or (MH "Preprocedural Fasting")

The Cochrane Library

No.	Search terms
#1	MeSH descriptor Fasting explode all trees (meal or meals or solids or drink* or eat* or food* or feed* or fasting* or fasted* or
#2	starv* or "nil by mouth" or NPO or "nulla per os" or "nothing by mouth"):ti,ab,kw
#3	(#1 OR #2)

3.12 Fasting before paediatric anaesthesia

The following searches were performed to update the Royal College of Nursing (RCN) guidance on perioperative fasting in adults and children. These searches were restricted by date to retrieve studies published since 2004, the date of the last search in the RCN guideline. The medline and embase results were combined with study design filters for RCTs and observational studies. The paediatric age group filters (from the sedation patient filters, section 1.1.1 above) were applied to all of the following searches.

Medline

No.	Search terms
1	exp anesthesia/
2	(anesthe\$ or anaesthe\$).ti,ab.
3	or/1-2
4	fasting/
5	(meal or meals or solids or drink* or eat* or food* or feed* or fasting* or fasted* or starv* or "nil by mouth" or NPO or "nulla per os" or "nothing by mouth").ti,ab.
6	or/4-5
7	3 and 6

Embase

No.	Search terms
1	exp anesthesia/
2	(anesthe* or anaesthe*).ti,ab.
3	or/1-2
4	exp diet restriction/
5	(meal or meals or solids or drink* or eat* or food* or feed* or fasting* or fasted* or starv* or "nil by mouth" or NPO or "nulla per os" or "nothing by mouth").ti,ab.
6	or/4-5
7	3 and 6

Cinahl

No.	Search terms
S7	S3 and S6
S6	S4 or S5
S5	(meal or meals or solids or drink* or eat* or food* or feed* or fasting* or fasted* or starv* or "nil by mouth" or NPO or "nulla per os" or "nothing by mouth")
S4	(MH "Fasting") or (MH "Preprocedural Fasting")
S3	S1 or S2
S2	anesthe* or anaesthe*
S1	(MH "Anesthesia+")

The Cochrane Library

No.	Search terms
#1	MeSH descriptor Anesthesia explode all trees
#2	(anesthe* or anaesthe*):ti,ab,kw
#3	(#1 OR #2)

- #4 MeSH descriptor Fasting explode all trees
 - #5 (meal or meals or solids or drink* or eat* or food* or feed* or fasting* or fasted* or starv* or "nil by mouth" or NPO or "nulla per os" or "nothing by mouth"):ti,ab,kw
 - #6 (#4 OR #5)
 - #7 (#3 AND #6)
-

3.13 Health Economics

The sedation in children patient filter was combined with the following filters for health economics and quality of life studies. Searches for health economics were performed on Medline, Embase, the Health Technology Appraisals (HTA) database and the NHS Economic Evaluations Database (NHSEED) in accordance with the NICE Guidelines Manual. The latter two databases were searched via the Cochrane Library with no study design filters applied. Health economics searches were restricted by date on medline and embase to studies published since 2006.

Medline

No.	Search terms
1	exp "costs and cost analysis"/
2	economics/
3	exp economics, hospital/
4	exp economics, medical/
5	exp economics, nursing/
6	exp economics, pharmaceutical/
7	exp "fees and charges"/
8	exp budgets/
9	ec.fs.
10	(economic\$ or pharmaco-economic\$ or price\$ or pricing\$ or cost\$ or budget\$).ti,ab.
11	(value adj2 (money or monetary)).ti,ab.
12	(expenditure not energy).ti,ab.
13	or/1-12
14	((metabolic or energy or oxygen) adj1 cost\$).ti,ab.
15	13 not 14
16	exp quality-adjusted life years/
17	quality adjusted life.tw.
18	exp "quality of life"/
19	value of life/
20	(qaly\$ or qald\$ or qale\$ or qtime\$).tw.
21	disability adjusted life.tw.
22	daly\$.tw.
23	health status indicators/
24	(sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix or shortform thirty six or short form thirtysix or short form thirty six).tw.
25	(sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).tw.
26	(sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short form twelve).tw.
27	(sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or short form sixteen).tw.
28	(sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or short form twenty).tw.
29	(euroqol or euro qol or eq5d or eq 5d).tw.
30	(hql or hqol or h qol or hrqol or hr qol).tw.
31	(hye or hyes).tw.
32	health\$ year\$ equivalent\$.tw.
33	health utilit\$.tw.
34	(hui or hui1 or hui2 or hui3).tw.
35	disutili\$.tw.
36	rosser.tw.
37	quality of well?being.tw.

- 38 qwb.tw.
 39 willingness to pay.tw.
 40 standard gamble\$.tw.
 41 time trade off.tw.
 42 time tradeoff.tw.
 43 tto.tw.
 44 or/16-43
 45 15 or 44

Embase

No.	Search terms
1	health economics/
2	exp economic evaluation/
3	exp health care cost/
4	exp pharmacoeconomics/
5	exp fee/
6	budget/
7	(economic\$ or pharmacoeconomic\$ or cost\$ or price\$ or pricing\$ or budget\$).ti,ab.
8	(value adj2 (money or monetary\$)).ti,ab.
9	(expenditure not energy).ti,ab.
10	or/1-9
11	((metabolic or energy or oxygen) adj1 cost\$).ti,ab.
12	10 not 11
13	quality adjusted life year/
14	quality of life/
15	(qaly\$ or qald\$ or qale\$ or qtime\$).tw.
16	daly\$.tw.
17	quality adjusted life.tw.
18	disability adjusted life.tw.
19	(sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix or shortform thirty six or short form thirtysix or short form thirty six).tw.
20	(sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).tw.
21	(sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short form twelve).tw.
22	(sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or short form sixteen).tw.
23	(sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or short form twenty).tw.
24	(euroqol or euro qol or eq5d or eq 5d).tw.
25	(hql or hqol or h qol or hrqol or hr qol).tw.
26	(hye or hyes).tw.
27	health\$ year\$ equivalent\$.tw.
28	health utilit\$.tw.
29	(hui or hui1 or hui2 or hui3).tw.
30	disutili\$.tw.
31	rosser.tw.
32	quality of well?being.tw.
33	qwb.tw.
34	willingness to pay.tw.
35	standard gamble\$.tw.
36	time trade off.tw.
37	time tradeoff.tw.
38	tto.tw.

39 or/13-38

40 12 or 39

Appendix D - Evidence tables

See separate file.

Appendix E- Meta-analyses forest plot

See separate file.

4 Appendix F - Cost-effectiveness analysis

4.1 Introduction

Appropriate sedation techniques should have the potential to prevent the need to abandon and reschedule procedures when sedation is unsuccessful. This will minimise distress, discomfort for and risk of harm to patients as well as reduce QALY loss due to long term morbidity or mortality. Additionally, it will reduce the use of the National Health Services (NHS).

We have conducted a search of existing economic evaluations that could reliably inform the guideline recommendations. We identified five studies^{19,20,26,33,39} but all had potentially serious limitations (see 4.9 and 4.10 below). We therefore developed a *de novo* economic evaluation to determine the cost-effectiveness of different techniques. The model was constructed to determine the most appropriate sedation technique.

Population

The clinical effectiveness and safety review suggests that different sedation techniques are suitable for different population groups (see chapter 6 on clinical effectiveness of sedation techniques). We developed models for the following common procedures:

- Dental procedures:
 - tooth extraction in children
 - tooth extraction in adolescents
- Short painful procedures: manipulation of forearm fracture
- Painless imaging: CT scan
- Endoscopy:
 - Oesophago-gastroscopy
 - Colonoscopy

A description of these groups is given in section 6.12, 'Further evidence to recommendations: clinical interpretation of evidence by setting'.

Interventions

The techniques are those for which the evidence suggests are clinically effective and safe (see chapter 6 on clinical effectiveness of sedation techniques). The GDG wanted the techniques on the list to capture the majority of techniques routinely used in the NHS. They advised that the techniques in the six population groups below should be evaluated in the model. In each group, the sedative techniques should be compared to general anaesthesia as this is a common alternative to using sedation in the NHS.

The model

The health outcome measure that NICE prefers for cost-effectiveness analysis is quality-adjusted life years (QALYs). It is not likely that the use of sedation techniques will lead to significant differences in QALYs as changes in health related quality of life will only occur over a short period of time. Sedation techniques may be associated with side effects but the GDG suggested that the events observed in the evidence review are not expected to lead to long-term effects that will result in significant QALY differences across different techniques. We therefore carried out a cost-minimisation analysis, that is, we assumed that the quality-adjusted life years would be the same for all treatment strategies.

The success rate of achieving a complete procedure with each technique was not assumed to be equivalent: in the event that a sedation technique fails it is assumed that the procedure would be rescheduled and conducted using general anaesthesia.

We have assessed costs from the perspective of the NHS and personal social services. In economic evaluation it is usual to put a lower weight on costs occurring in the future to reflect both the interest rate and people's time preference – a process known as discounting. However, in the case of this model, all of the included costs occur over a short time horizon and consequently there was no need to discount. The outcome of the analysis was the cost per patient for the whole pathway eventually leading to a successful completion of the procedure, so it includes the cost of the initial procedure plus the cost of any additional procedures required as a result of initial treatment failure.

The cost of sedation includes the time cost of personnel required for the induction and recovery from sedative drug or GA, as well as time cost of the personnel during the procedure. The cost of a strategy also includes the unit cost of drugs for sedation and GA, and the cost of consumables for administering them. We have not included the cost of equipment as it is assumed that these are already available at the point of service delivery and are used for other varied purposes. It would be difficult to estimate the fraction of the cost of equipment attributable to use of sedative drugs or GA.

Some strategies are associated with certain complications and the treatment of complications could result in additional costs.

In the model the expected cost of each strategy is conditional on the strategy's success rate and complication rate as well as the cost of the intervention itself. This can be represented by a decision tree; we present a separate decision tree for each population (see below).

The model was constructed using the best available evidence. Clinical and safety evidence was taken from a systematic review (see chapter 6 on clinical effectiveness and safety review). When the evidence was weak or absent the GDG expert opinion was used to determine the input parameters of the model. The assumptions made in the model and the uncertainties in the input parameters are described explicitly. These were considered by the GDG when interpreting the model results. The impact of uncertainties in the model structure and input parameters were explored through deterministic sensitivity analyses. We did not do a probabilistic sensitivity analysis as the estimates for a number of key input parameters were ascertained by expert opinion. The limitations of the model are discussed.

Cost-effectiveness criteria

The technique with the lowest cost per patient is considered to be the optimal strategy from a cost-effectiveness perspective.

4.2 Dental procedures in children

4.2.1 Methods

Decision tree: The decision tree for the five strategies compared in this group is shown below (**Error! Reference source not found.**). The use of any of the four sedative drugs (nitrous oxide plus oxygen, nitrous oxide plus sevoflurane, nitrous oxide plus iv midazolam, nitrous oxide plus sevoflurane plus iv midazolam) in a cohort of patients would lead to a successful completion of procedure in some patients. This is described as “success” on the decision tree. In other patients the drug would fail and the procedure would not be completed. In the event that the procedure was not completed, the patient would be given GA on a different occasion to enable the procedure to be completed. The sedative drugs are compared to GA. The GDG suggested that GA leads to completion of procedure in all the patients. Apart from N₂O plus iv midazolam, the GDG assumed that the sedative drugs are associated with vomiting in some patients. The GDG also assumed that the GA strategy is not associated with any complication. The basis for this assumption was that most side effects of GA in children are minor and that many safety measures are in place to minimise the risk of complications. The vomiting event at the branch of the tree for patients who failed to complete the procedure (failure), and who were eventually given GA, reflects the fact that the sedative drug leads to vomiting regardless of whether the procedure is completed (success) or not (failure).




Figure 1. A decision tree of four sedative drugs compared to general anaesthesia in dental procedures in children

Table 1. Success rate of sedative drugs and general anaesthesia in dental procedures in children

Strategy	Success rate (%)	Source
N ₂ O+O ₂	52.4	Lahoud & Averley 2002 ²³
N ₂ O+Sevoflurane	89.2	
N ₂ O+Sevoflurane+iv midazolam	93.3	Averley 2004 ³
N ₂ O+iv midazolam	79.7	
GA	100	GDG

Clinical data on success rate, complication rate and duration: The success rate of sedative drugs and GA are described in Table 1. There were two studies that assessed the use of sevoflurane and nitrous oxide in children^{10,23}.

The Lahoud study²³ assessed the efficacy of this drug combination in dental children and the De Sanctis Briggs study¹⁰ assessed the safety in children undergoing MRI. The data on success rate was taken from the Lahoud study and the study has been described fully elsewhere (see chapter 6 the clinical effectiveness). It was an RCT of 411 anxious children undergoing dental procedures randomised to either 0.1 – 0.3% sevoflurane in 40% of N₂O or 40% of N₂O. The group that received sevoflurane plus nitrous oxide had significantly higher completion rate of 89% and this evidence was of moderate quality. There was only one study that assessed the efficacy of nitrous oxide plus sevoflurane plus intravenous midazolam in children³. The study has been described fully elsewhere (see chapter 6 on clinical effectiveness). It was an RCT of 697 anxious children undergoing dental procedures. Study participants were randomised to one of the three arms: 0.3% sevoflurane plus 40% nitrous oxide plus intravenous midazolam, or 40% nitrous oxide plus iv midazolam, or medical air plus intravenous midazolam. The sevoflurane plus nitrous oxide plus midazolam group had a significantly higher completion rate of 93.3% and this was used in the model. The combination strategy, nitrous oxide plus intravenous midazolam was also taken from the Averley study³ and this combination was associated with a higher completion rate of 79.7% when compared to the medical air plus intravenous midazolam group. The evidence from the Averley study³ was of moderate quality. There were a number of RCTs that assessed the efficacy of nitrous oxide and oxygen^{13,34,41,46-50}. The Fauroux study¹³ reported a completion rate but the evidence was low quality. The GDG felt that in clinical practice the patients receiving this sedative drug will have at least 50%. We used the success rate of 52.4% reported in the Lahoud study²³ for patients that received 40% nitrous oxide. The GDG also felt that the patients in the trials are not typical and the selection pattern may not be representative of clinical practice. If patients are assessed and selected for this strategy, success rate could be as high as 95%. We have therefore used 95% in sensitivity analysis. General anaesthesia was assumed to have a success rate of 100%.

The evidence from the systematic review on the timings for induction, procedure and recovery for the sedative drugs and GA was not complete, and when available, it was inconsistent with the GDG's clinical experience. They considered the timings reported in the review and suggested alternative plausible timings to be used in the model and this is shown in Table 2.

Table 2. Timings and vomiting rate for sedative drugs and GA in dental procedures in children

Strategy	Timing (minutes)			Vomiting rate (%)
	Induction	Procedure	Recovery	
N2O+O2	5	30	15	2
N2O+Sevoflurane	5	30	30	2
N2O+Sevoflurane+iv midazolam	15	30	45	2
N2O+iv midazolam	15	30	45	2
GA	10	30	30	

Vomiting rates were reported in the systematic review but these were also inconsistent and could not be used in a comparative way. We assumed a conservative a rate of 2% should be used for all the sedative drugs.

NHS staff required for application of strategy: The GDG suggested that the following NHS staff would be required during the induction, procedure and recovery phases of different strategies (Table 3). We used £23 as the cost per hour for a nurse and anaesthetic assistant. This was based on the median full-time equivalent basic salary for “Agenda for Change Band 5 of the October-December 2007 NHS Staff Earnings” estimates for qualified nurses⁴⁰. The rate for consultant dentist and anaesthetist was assumed to be equivalent to the average consultant (physician) earnings at the NHS and we used a rate of £122 per hour⁴⁰.

Table 3. NHS staff required to apply sedative drugs and general anaesthesia in dental procedures in children*

Strategy	Induction	Procedure	Recovery
N2O+O2	N + Den	N + Den	N
N2O+iv midazolam	N + Den	N + Den	N
N2O+Sevoflurane	N + Den	N + Den (x2)	N
N2O+Sevoflurane+iv midazolam	N + Den	N + Den (x2)	N
GA	ODA + A	N + Den + A + ODA	N

* N=Nurse, Den=Dentist, A=Anaesthetist, ODA=Anaesthetist Assistant, N2O=Nitrous oxide, GA=General Anaesthetic

Cost of drugs, consumables and complications: The unit cost of drugs is listed in Table 4. We could not identify the cost of nitrous oxide and sevoflurane from the British National Formulary (BNF). The cost of nitrous oxide was estimated at £10 per patient by one of the GDG members using data from their primary care facility, and the additional cost of sevoflurane was £1 per patient. This was for gasses only and excludes the cost of the equipment to deliver the gasses, for scavenging or maintenance. The cost of intravenous midazolam was estimated at £0.87 assuming a maximum dose of 7.5mg (BNF: 5mg/mL, 2mL amp = 58p).

Table 4. Unit cost of drugs used in the model for dental procedures in children

Strategy	Route and Dose	Price	Source of price data
N2O+O2	Inhalation, 40% nitrous oxide and oxygen	£10.00	GDG
N2O+iv midazolam	Inhalation: 40% nitrous oxide Injection: Midazolam: max dose of 7.5mg	£10.87	GDG and BNF
N2O+Sevoflurane	Inhalation, 0.1 – 0.3% sevoflurane in 40% nitrous oxide	£11.00	GDG
N2O+Sevoflurane+iv midazolam	Inhalation: 0.3% sevoflurane in 40% nitrous oxide, Injection: Midazolam: max dose of 7.5mg	£11.87	GDG and BNF
GA	Propofol is used for induction. Induction dose: 2.5mg/kg, Maintenance dose: 0.1 – 0.3% sevoflurane in 40% nitrous oxide	£11.73	GDG and BNF

General anaesthesia was assumed to be induced with propofol and maintained with sevoflurane and nitrous oxide. Induction dose was 2.5mg per kilogram and a child of 25kg would require 62.5mg for induction. This would cost £0.73 (BNF prices: 1% injection (emulsion), 10mg/mL, net price 20-mL = £2.33). Maintenance would be 0.1 – 0.3% sevoflurane in 40% nitrous oxide and this would cost £11. The total cost of GA was therefore £11.73.

The GDG produced a list of consumables required for the administration of sedative drugs and GA. We have included the cost of these in the model. The list is shown below in **Table 5** along side their unit costs. The cost data were taken from the NHS purchase and supply chain catalogue³⁷. Apart from the strategy, nitrous oxide plus oxygen, and nitrous oxide plus iv midazolam, all sedative drugs and GA would require all the consumables listed in the table. The GDG advised that the application of nitrous oxide plus oxygen and nitrous oxide plus iv midazolam would not require intravenous capnography and electrocardiographic electrodes but would require the other consumables in the table.

We assumed that the treatment of vomiting would require 30 minutes of nurse's time.

Table 5. Type and unit cost of consumables included in the model for dental procedures in children

Consumables	Unit cost (£)
iv cannula	0.21
Capnography cannula	0.75
Oxygen mask	0.53
Pulse oximetry probe	7.29
Electrocardiographic electrodes	0.19
Laryngoscopes	4.02
Endotracheal tubes	1.65
Laryngeal masks	3.78
Guedel airways	0.23
Intubating bougie	7.40
Bag-valve mask	5.53

Sensitivity Analyses

We carried out a number of sensitivity analyses to test the robustness of model results to our model assumptions. We started by varying the success rates of the sedative drugs to determine the point at which the drug becomes cost saving compared to GA. The GDG felt that a success rate of 52.4% used in the base case for nitrous oxide would be low in patients who have been pre-selected to receive it and they advised that a rate of 95% be used in sensitivity analysis. The GDG advised that the induction time of 10 minutes used in the base case for GA should be increased to 15 minutes in a sensitivity analysis as induction time of this magnitude could be observed in some settings. In addition to its use as a sedative drug, nitrous oxide is used in combination with sevoflurane to maintain GA. In base case, we have used £10 as the cost per patient for using nitrous oxide. The GDG advised that this estimate could be an over-estimate in hospital care facility. It was therefore assumed that the cost of nitrous oxide per patient will be £5. In the other three sedation strategies, sedationist dentist would not be required for induction and during the procedure.

4.2.2 Results

The total cost per patient of each of the five strategies compared in the base case analysis for this population is given in **Table 6** below. N₂O + iv midazolam was the least expensive strategy at £201 per patient.

Drug costs and consumable costs varied little between strategies. Complication costs were negligible because the incidence was low for all strategies. The biggest component of cost was staff time (especially dentist and anaesthetist time). The cost of second line treatment also varied substantially between strategies, decreasing as the success rate increases.

One sedation strategy (Sevoflurane plus nitrous oxide plus iv midazolam) was more expensive than GA despite high success rates. This was because it required a sedationist dentist in addition to the operating dentist.

Table 6. Base case analysis: Cost per patient of different sedation strategies compared with general anaesthesia for dental procedures in children

Strategy	Mean cost of 1st line						Mean cost of 2nd line	Total mean cost
	Drugs	Consumables	Anaesthetist	Dentist	Nurse	Vomiting rate		
N2O + O2	£10	£31	£ -	£71	£19	£0.23	£78	£209
N2O + iv midazolam	£11	£31	£ -	£92	£35	£0.23	£33	£201
Sevoflurane + N2O	£11	£32	£ -	£132	£25	£0.23	£16	£209
Sevoflurane + N2O + iv midazolam	£12	£32	£ -	£153	£35	£0.23	£15	£246
GA	£12	£32	£81	£61	£38			£224

The results of one-way sensitivity analyses are presented in **Table 7** below. We started by varying the success rate of the sedative drug strategies to determine the point at which they become cost-saving compared to the GA strategy. For example, the strategy, nitrous oxide plus oxygen, remained cost saving as long as the success rate of the sedative drug is equal to or greater than 44%. Sevoflurane plus nitrous oxide plus iv midazolam was not cost-saving even at a success rate of 100%.

When the success rate of all sedation techniques was increased to 95% for all strategies, N2O became the lowest cost strategy. On increasing the induction time of GA to 15 minutes (which affects all strategies, as GA is the second-line technique in the sedative drug strategies), the sevoflurane plus nitrous oxide strategy became the least expensive strategy at £217 per patient. This was because it had a much higher success rate than nitrous oxide plus oxygen, and yet it had a shorter induction time than sevoflurane plus nitrous oxide plus iv midazolam. The average cost of all strategies reduced when the unit cost of nitrous oxide was reduced from £10 to £5.

Table 7 Sensitivity analyses on the cost per patient of using different sedation strategies compared with general anaesthesia in dental procedures in children†

Strategy	Mean cost (base case)	Success rate in base case (%)	Success rate at which strategy becomes cost-saving compared to GA (%)	Mean cost when success rate of sedation = 95%	Mean cost when induction time of GA = 15mins	Mean cost when cost of N2O = £5 ‡
N2O + O2	£209	52	44%	£139	£219	£205
N2O + iv midazolam	£201	80	66%	£176	£205	£195
Sevoflurane + N2O	£216	90	86%	£208	£217	£211
Sevoflurane + N2O + iv midazolam	£246	93	*	£242	£247	£240
GA	£224	100	Not applicable	Same as basecase	£236	£219

*not cost-saving even at 100%, †pt=patient, ‡N2O is used in combination with sevoflurane to maintain general anaesthesia

4.3 Dental procedures in adolescents

4.3.1 Dental procedures in adolescents

Decision tree: The decision tree for the two strategies compared in this group is shown below (Figure 2). The application of intravenous midazolam in a cohort of patients would lead to successful completion of procedure in some patients. In other patients it would fail and the procedure would be completed using GA as a second line option. This strategy is compared with using GA as a first line option. General anaesthesia leads to completion of procedure in all the patients and is assumed not to be associated with any complications. Intravenous midazolam is associated with oxygen desaturation of less than 90%. The oxygen desaturation event at the branch of the tree for patients who failed to complete the procedure (failure), reflects the fact that intravenous midazolam leads to oxygen desaturation regardless of whether the procedure is completed or not.




Figure 2. A decision tree of iv midazolam compared to general anaesthesia in dental procedures in adolescents

Clinical data on success rate, complication rate and duration: The success rate of intravenous midazolam and GA are given in Table 8. There was no directly applicable evidence from the review on the success rate for intravenous midazolam. Success rates of 95.2%, 78.9% and 100% were reported in three heterogeneous studies. The first figure was from a study of oral midazolam in children undergoing intravenous insertion²⁷. The second estimate was from a study of intranasal midazolam in children undergoing venipuncture insertion¹⁴. The third estimate was from a study of oral and intranasal midazolam in children undergoing suture and laceration repair⁸. GDG consensus was that a success rate of 95% be used in the model for this group.

Table 8. Success rate of sedative drugs and general anaesthesia in dental procedures in adolescents

Strategy	Success rate (%)	Source
iv midazolam	95	GDG
GA	100	GDG

There was no applicable evidence on the duration of the strategies. The GDG considered the existing evidence from the clinical effectiveness review and made timing estimates that reflect their clinical experience. They suggested that the following estimates should be used in the model (Table 9).

Table 9 Timing for sedative drugs and GA in dental procedures in adolescents

Strategy	Timing (minutes)		
	Induction	Procedure	Recovery
iv midazolam	15	60	45
GA	10	60	30

NHS staff required for application of strategy: The GDG suggested that the following NHS staff would be required during the induction, procedure and recovery phases of the two strategies (Table 10). The unit cost of time spent by the nurse, dentist, anaesthetist and anaesthetist assistant has been described above in the section on “NHS staff required for application of strategy” under “Dental procedure in children”.

Table 10 NHS staff required to apply sedative drug and general anaesthesia in dental procedures in adolescents*

Strategy	Induction	Procedure	Recovery
iv midazolam	N + Den	N + Den	N
GA	ODA + A	N + Den + A + ODA	N

* N=Nurse, Den=Dentist, A=Anaesthetist, ODA=Anaesthetist Assistant, N2O=Nitrous oxide, GA=General Anaesthetic

Cost of drugs, consumables and complications: The cost of intravenous midazolam and GA used in the model was £0.87 and £11.73 respectively. We have described how these were arrived at in the section on ‘Cost of drugs, consumables and complications’ under ‘Dental procedures in children’. The GDG advised that the application of intravenous midazolam would not require iv capnography and electrocardiographic electrodes but would require the other consumables in Table 5 above. The cost of consumables for intravenous midazolam was estimated at £31, and for GA, £32. The cost of GA includes the cost of all consumables listed above in **Table 5**. Oxygen desaturation that is less than 90% is a complication associated with midazolam. Some other interventions considered in this economic analysis are also associated with this

complication. The GDG decided that this was unlikely to be associated with a treatment cost.

4.3.2 Results

We have compared two strategies in this group and the total cost per patient in the base case analysis for each of them is shown in Table 11 below. Midazolam was less expensive at £248.

The cost of consumables was similar for both strategies but the cost of drugs was more for the GA strategy. The biggest component of cost was staff time (especially dentist and anaesthetist time).

Table 11. Base case analysis: Cost per patient of using iv midazolam compared with general anaesthesia in dental procedures in adolescent

Strategy	Mean cost of 1st line					Mean cost of 2nd line
	Drugs	Consumables	Anaesthetist	Dentist	Nurse	
iv midazolam	£1	£31	£ -	£153	£46	£18
GA	£12	£32	£142	£122	£61	

We have described the results of one-way sensitivity analyses in Table 12 below. The cost per patient of the midazolam remained lower than the cost of the GA as long as the success rate of midazolam is not below 63%. Midazolam remained associated with lower costs for all the sensitivity analyses conducted.

Table 12 Sensitivity analyses on the cost per patient of using iv midazolam compared with general anaesthesia in dental procedures in adolescents †

Strategy	Mean cost (base case)	Success rate in base case (%)	Success rate at which strategy becomes cost-saving compared to GA (%)	Mean cost when induction time of GA = 15mins	Mean cost when cost of N2O = £5 ‡	Mean cost with nurse-led sedation
iv midazolam	£248	95	63	£249	£248	£218
GA	£369	100	Not applicable	£381	£364	Same as basecase

†pt=patient, ‡ N2O is used in combination with sevoflurane to maintain general anaesthesia

4.4 Sensitivity Analyses

The robustness of the results to our model assumptions was tested using sensitivity analyses. We varied the success rate of intravenous midazolam to determine the point at which the drug becomes more cost saving compared to GA. We also increased the induction time of GA to 15 minutes from 10 minutes as the GDG suggested that an induction time of this magnitude could be observed in some settings. Nitrous oxide is used in combination with sevoflurane to maintain GA. The GDG suggested that the cost of nitrous oxide used in the base case analysis could be an over-estimate in a hospital care facility and in a sensitivity analysis, we assumed that the cost of nitrous oxide per patient would be £5. Short painful procedures

4.4.1 Methods

Decision tree: The decision tree for the three strategies compared in this group is shown below (**Figure 3**). The application of intravenous ketamine or intravenous fentanyl plus propofol in a cohort of patients would lead to successful completion of procedure in some patients. In others the drug would fail and the procedure would be completed using GA as a second line option. These strategies are compared to using GA as a first line option. General anaesthesia leads to completion of procedure in all the patients and is assumed not to be associated with complications. Intravenous ketamine is associated with vomiting, and both of the sedative drug strategies compared in this group are associated with hypotension and respiratory complications as well as with oxygen desaturation less than 90%.




Figure 3. A decision tree of two sedative drugs compared to general anaesthesia in short painful procedures

Clinical data on success rate, complication rate and duration: The success rates of the sedative drugs and GA are described in Table 13. There was no evidence on the appropriate success rate to apply in the model for intravenous ketamine. The GDG was of the view that up to 1% of procedures are not successfully completed under ketamine sedation. They advised that a success rate of 99% should be used in the model. They suggested that the 100% reported in Cechvala 2008⁷ for intravenous fentanyl plus propofol was clinically credible, and this rate was used in the model.

Table 13 Success rate of sedative drugs and general anaesthesia in short painful procedures

Strategy	Success rate (%)	Source
Ketamine	99	GDG
Fentanyl+propofol	100	Cechvala 2008 ⁷
GA	100	GDG

The Cechvala study⁷ was an RCT carried out in 22 children undergoing lumbar puncture for diagnosis of acute leukaemia or lymphoma. It compared intravenous fentanyl (1mcg/kg) plus intravenous propofol (1-2mg/kg/min) plus oxygen supplementation plus topical anaesthesia with placebo (normal saline) plus intravenous propofol (1-2mg/kg/min) plus oxygen supplementation plus topical anaesthesia. All study patients completed the procedure and this evidence was judged as moderate quality. General anaesthesia was assumed to have a success rate of 100%. Vomiting and oxygen desaturation rate less than 90% were reported for ketamine in several heterogenous studies included in the systematic review of efficacy and the GDG advised that a rate of 6.65% for vomiting and 0.9% for oxygen desaturation rate less than 90% should be taken from the study with the largest sample size¹⁶. They also suggested from their clinical experience that ketamine would be associated with up to one percent rate of hypotension and respiratory intervention. Hypotension and respiratory intervention rate of 18% was reported in only the Cechvala study⁷ for intravenous fentanyl plus propofol, and this rate was used in the model. The rate of oxygen desaturation less than 90% was reported as 5% in one study⁴. These studies have been described in the sections on the efficacy and safety of sedation techniques.

After considering the limited evidence from the review the GDG provided the following estimates as the timings for the three strategies (Table 14).

Table 14 Timings and vomiting rate for sedative drugs and GA in short painful procedures

Strategy	Timing (minutes)		
	Induction	Procedure	Recovery
Ketamine	10	30	30
Fentanl+propofol	10	30	30
GA	10	30	30

NHS staff required for application of strategy: The GDG suggested that the following NHS staff would be required during the application of the three strategies compared here (**Table 15**). The unit cost of the time spent by the personnel has been described above (dental procedure in children).

Table 15 NHS staff required to apply sedative drug and general anaesthesia in short painful procedures

Strategy	Induction	Procedure	Recovery
Ketamine	N + D	N (x2) + D	N
Fentanyl+propofol	N + D	N (x2) + D (x2)	N
GA	ODA + A	N + D + A + ODA	N

* N=Nurse, D=Physician, A=Anaesthetist, ODA=Anaesthetist Assistant, GA=General Anaesthetic

Cost of drugs, consumables and complications: We assumed a median dose of 30mg for ketamine⁴². This would cost £0.76 (BNF: 10mg/mL, 20-mL vial = £5.06). The dosage in Cechvala 2008⁷ for intravenous fentanyl was 1mcg/kg. For a 25 kg child requiring 25mcg, it would cost £0.14 (BNF: 50mcg/mL, net price 2-mL amp = 54p). The dosage for propofol in Cechvala 2008⁷ was 1-2mg/kg/min infusion. We assumed that 25kg child would require 38mg for one minute. The child would require about 4mL which would cost £0.46. (BNF: 1% injection (emulsion), 10mg/mL. net price 20-mL amp = £2.33). The total cost of administering this combination therapy would therefore be £0.60. The cost of GA used in the model was £11.73, and the cost of consumables for all strategies was £32. A description of how these were arrived at has been given above (dental procedure in children). The cost of consumables includes the cost of all consumables listed above in **Table 5**.

Oxygen desaturation that is less than 90% is a complication associated with the sedative drugs compared in this group but there would be no additional treatment cost for this. We assumed that 30 minutes of nurse's time would be required both for the treatment of vomiting and for hypotension and respiratory interventions.

Sensitivity Analyses

A number of sensitivity analyses were done to test the robustness of the model results. We varied the success rates of the two sedative drug strategies to determine the point at which any of the strategies becomes more cost saving compared to GA. We did the same sensitivity analyses described in the section for dental procedures in adolescents regarding GA induction time, cost of nitrous oxide and the nurse as the only personnel required for the application of sedative drugs. In the case of ketamine and fentanyl plus propofol, sedationist physician would not be required for induction. In the case of fentanyl plus propofol, only one physician would be required during the procedure.

4.4.2 Results

The average cost of the strategies compared in this model population in the base case analysis is given below in **Table 16**. Ketamine was the least expensive strategy at £155, and GA was the most expensive strategy at £224.

The cost of consumables for the three strategies was the same but the cost of the GA drugs was higher than the cost of the sedative drugs. The highest cost component was the cost of staff time, particularly the cost of physician and anaesthetist time. Fentanyl plus iv midazolam was actually more expensive than ketamine because it required a sedationist dentist in addition to an operating dentist for its administration.

The complication costs associated with ketamine were low because of low incidence while the cost of complications associated with fentanyl plus propofol was slightly higher because of higher incidence.

Table 16 Base case analysis: Cost per patient of using sedation strategies compared with general anaesthesia in short painful procedures

Strategy	Mean cost of 1st line							Mean cost of 2nd line	Mean cost
	Drugs	Consumables	Anaesthetist	Physician	Nurse	Vomiting rate	Hypo / Resp intervention		
Ketamine	£1	£32	£ -	£81	£38	£0.77	£0.13	£2	£155
Fentanyl + Propofol	£1	£32	£ -	£142	£38	£ -	£2.09	£ -	£215
GA	£12	£32	£81	£61	£38				£224

The results of one-way sensitivity analyses are presented in **Table 17** below. We varied the success rate of the sedative drug strategies to determine the point at which they become cost-saving compared to GA strategy. Ketamine remained cost saving as long as the success rate of using it is not below 69%. The combination drug, fentanyl plus propofol remained cost-saving as long as the success rate of the drug combination is not below 95%.

Ketamine remained the cost-saving compared with the other strategies when the GA induction time is 15 minutes or the cost of nitrous oxide is £5. Unlike ketamine, the other two strategies require physician sedationist in addition to operating physician and this makes it less expensive. When we assumed that sedation was administered by a nurse, fentanyl plus propofol became cost-saving when compared with ketamine and GA.

Table 17 Sensitivity analyses on the cost per patient of using different sedation strategies compared with general anaesthesia in short painful procedures †

Strategy	Mean cost (base case)	Success rate in base case (%)	Success rate at which it becomes cost-saving compared to GA (%)	Mean cost when induction time of GA = 15mins	Mean cost when cost of N2O = £5 ‡	Mean cost with nurse-led sedation
Ketamine	£155	99	69	£155	£155	£135
Fentanyl + Propofol	£215	100	95	Same as basecase	Same as basecase	£134
GA	£224	100	Not applicable	£236	£219	Same as basecase

†pt=patient, ‡ N2O is used in combination with sevoflurane to maintain general anaesthesia

4.5 Painless imaging procedures

4.5.1 Methods

Decision tree: The decision tree for the two strategies compared in this group is shown below (Figure 4). The use of high dose chloral hydrate as a sedative drug in a cohort of patients would lead to successful completion of procedure in some patients, and in others it would fail. In the event of failure, the procedure would be completed using GA as a second line treatment option. This strategy is compared to using GA as a first line option to enable completion of procedure. General anaesthesia is assumed to lead to completion of procedure in all the patients and would not be associated with any complication. High dose chloral hydrate is associated with vomiting.




Figure 4. A decision tree of chloral hydrate compared to general anaesthesia in painless imaging procedures

Clinical data on success rate, complication rate and duration: The success rate of oral chloral hydrate was reported in two studies^{18,32}. The Marti-Bonmati study³² was carried out in children undergoing MRI and the Houpt study¹⁸ was in children undergoing dental procedure. The GDG felt that the success rate reported in the former study should be used as it is a more applicable study for this model group. The Marti-Bonmati study³² has been described before in the section on clinical effectiveness and safety. In the study, high dose chloral hydrate (96mg/kg) was compared to intermediate dose (70mg/kg). It was reported that high dose chloral hydrate had a completion rate of 100% and we have used this rate in the model. The study was judged to be of moderate quality. We have assumed the success rate of GA to be 100%.

Table 18 Success rate of sedative drugs and general anaesthesia in painless imaging procedures

Strategy	Success rate (%)	Source
Chloral hydrate (high dose)	95	Marti-Bonmati 1995 ³²
GA	100	GDG

After considering the evidence on the timings reported in the review the GDG suggested that it would be more clinically realistic to use the following timings in the model.

Table 19 Timing for sedative drugs and GA in painless imaging procedures

Strategy	Timing (minutes)		
	Induction	Procedure	Recovery
Chloral hydrate (high dose)	20	50	40
GA	10	50	30

NHS staff required for application of strategy: The GDG also suggested that the following NHS staff would be required during the different phases of applying the two strategies (Table 20). The unit cost of time spent by the personnel has been described above (dental procedure in children). We used £29 as the cost per hour for a radiographer. This was based on the median full-time equivalent basic salary for “Agenda for Change Band 5 of the October-December 2007 NHS Staff Earnings” estimates⁴⁰.

Table 20 NHS staff required to apply sedative drug and general anaesthesia in painless imaging procedures*

Strategy	Induction	Procedure	Recovery
Chloral hydrate (high dose)	N + D	N + D + R	N
GA	ODA + A	N + A + ODA	N

N=Nurse, D=Physician, A=Anaesthetist, ODA=Anaesthetist Assistant, R=Radiographer, GA=General Anaesthetic

Cost of drugs, consumables and complications: The maximum dose of chloral hydrate in the BNF is 2g (BNF, chloral betaine 707mg (=chloral hydrate 414mg): net price 30-tab pack =£7.90). A maximum of five tablets would cost £1.32. The cost of GA used in the model was £11.73 and we have described elsewhere how we arrived at this figure (dental procedure in children). The cost of consumables for each of the two strategies compared here was £32. This included the cost of all consumables listed above in Table 5. The treatment cost of vomiting was assumed to be equivalent of 30 minutes of nurse’s time.

Sensitivity Analyses

In order to test the robustness of the model for chloral hydrate and GA, we carried out the same set of sensitivity analyses described above in the section on short painful procedures. We conducted a sensitivity analysis to explore the impact on the result of assuming a success rate of 95% for high dose chloral hydrate. We assumed that a sedationist physician would not be required for induction of high dose chloral hydrate.

4.5.2 Results

We compared two strategies in this population and the result of the base case analysis showed that GA was less expensive at £224 than high dose chloral hydrate (Table 21). This was not surprising as the administration of the sedative drug requires a physician unlike the administration of GA.

The highest cost component of these strategies remained the cost of staff time especially physician and anaesthetist time. The cost of complication was low because of low incidence. The cost of consumables for the two strategies was the same but the cost of GA drugs was higher.

Table 21 Base case analysis: Cost per patient of high dose chloral hydrate compared with general anaesthesia in painless imaging

Strategy	Mean cost of 1st line							Mean cost
	Drugs	Consumables	Anaesthetist	Physician	Nurse	Radio-grapher	Vomiting rate	
Chloral hydrate (high dose)	£1	£32	£ -	£142	£42	£24	£0.03	£242
GA	£12	£32	£122	£ -	£35	£24		£224

The results of one-way sensitivity analyses are presented in Table 22 below. We changed the success rate of high dose chloral hydrate and, at 95% this strategy was even more expensive. Other results of the sensitivity analysis suggest that the GA strategy would be associated with less cost. The sedative drug strategy became less expensive only when the nurse was the only personnel that will apply the sedative drug.

Table 22 Sensitivity analyses on the cost per patient of using high dose chloral hydrate compared with general anaesthesia in short painless imaging †

Strategy	Mean cost (base case)	Success rate in base case (%)	Success rate of chloral hydrate = 95%	Mean cost when induction time of GA = 15mins	Mean cost when cost of N2O = £5 ‡	Mean cost with nurse-led sedation
Chloral hydrate (high dose)	£242	100	£252	Same as basecase	Same as basecase	£201
GA	£224	100	Same as basecase	£236	£219	Same as basecase

†pt=patient, ‡ N2O is used in combination with sevoflurane to maintain general anaesthesia

4.6 Oesophago-gastroscopy

4.6.1 Methods

Decision tree: We compared intravenous midazolam and GA and the decision tree is the same as the one used to compare intravenous midazolam and GA in dental procedures in adolescents (Figure 2. A decision tree of iv midazolam compared to general anaesthesia in dental procedures in adolescents). The use of intravenous midazolam in a cohort of patients would lead to a successful completion of the procedure in some patients but would fail in others. In the patients where it failed, GA would be used to complete the procedure. The use of GA as a first line option would lead to completion of procedure in all patients. Intravenous midazolam is associated with oxygen desaturation level less than 90% and GA is assumed not to be associated with complications.

Clinical data on success rate, complication rate and duration: There was no directly applicable evidence from the review on the success rate for intravenous midazolam in patients undergoing oesophago-gastroscopy. Indirect evidence from three heterogeneous studies was considered by the GDG^{8,14,27}. The first study was on oral midazolam in children undergoing intravenous insertion, and reported a success rate of 95.2%. The second was on intranasal midazolam in children undergoing venipuncture insertion, and reported a rate of 78.9%. The last study was on oral and intranasal midazolam in children undergoing suture and laceration repair, and reported a rate of 100%. The GDG agreed that a rate of 95% be used in the model. A success rate of 100% was used for GA. There was also no directly applicable evidence on the duration of the strategies for this group. The GDG considered other estimates reported in the review and made timing estimates that reflect their clinical experience. They suggested the estimate in the table below should be used (Table 23).

Table 23 Timings for sedative drugs and GA in oesophago-gastroscopy

Strategy	Timing (minutes)		
	Induction	Procedure	Recovery
iv midazolam	10	15	45
GA	10	15	30

NHS staff required for application of strategy: The GDG suggested that the following NHS staff would be required during the application of the strategies (Table 24). The unit cost of the time spent by the staff is described above (dental procedure in children).

Table 24 NHS staff required to apply sedative drug and general anaesthesia in oesophago-gastroscopy *

Strategy	Induction	Procedure	Recovery
Ketamine	N + D	N (x2) + D	N
GA	ODA + A	N + D + A + ODA	N

* N=Nurse, D=Physician, A=Anaesthetist, ODA=Anaesthetist Assistant, GA=General Anaesthetic

Cost of drugs, consumables and complications: The cost of intravenous midazolam and GA used are £0.87 and £11.73 respectively and a description of how we arrived at these estimates is given above (dental procedure in children). The cost of consumables for the two respective strategies is £31 and £32. The GDG advised that the application of intravenous midazolam would not require intravenous capnography and electrocardiographic electrodes but would require the other consumables in Table 5 above. The cost of consumables for GA includes the cost of all consumables listed above in Table 5. Oxygen desaturation less than 90% would not be associated with additional treatment cost.

Sensitivity Analyses

In order to test the robustness of the model, we carried out the same set of sensitivity analyses described above in the section on dental procedure in adolescents. We assumed that a sedationist physician would not be required for the induction of iv midazolam.

4.6.2 Results

There were two strategies compared in this population and the total cost per patient in the base case analysis is given in Table 25 below. Midazolam was less expensive at £122.

The cost of consumables was similar but drug cost was higher for GA. The highest cost component was cost of staff time particularly physician and anaesthetist time.

Table 25 Base case analysis: Cost per patient of using iv midazolam compared with general anaesthesia in oesophago-gastroscopy

Strategy	Mean cost of 1st line					Mean cost of 2nd line	Mean cost
	Drugs	Consumables	Anaesthetist	Physician	Nurse		
iv midazolam	£1	£31	£ -	£51	£33	£8	£122
GA	£12	£32	£51	£31	£27		£151

The results of one-way sensitivity analyses are described in Table 26 below. The cost per patient of the iv midazolam strategy remained lower than the cost of the GA strategy as long as the success rate of midazolam strategy is not below 75%. The midazolam strategy remained associated with lower costs for all the sensitivity analyses conducted.

Table 26 Sensitivity analyses on the cost per patient of using iv midazolam compared with general anaesthesia in oesophago-gastroscopy †

Strategy	Mean cost (base case)	Success rate in base case (%)	Success rate at which it becomes cost-saving compared to GA (%)	Mean cost when induction time of GA = 15mins	Mean cost when cost of N ₂ O = £5 ‡	Mean cost with nurse-led sedation
iv midazolam	£122	95	75	£123	Same as basecase	£102
GA	£151	100	Not applicable	£164	£146	Same as basecase

†pt=patient, ‡ N₂O is used in combination with sevoflurane to maintain general anaesthesia

4.7 Colonoscopy

4.7.1 Methods

Decision tree: The decision tree that was used for the model for this group is shown below (Figure 5). The use of the combination technique, intravenous midazolam plus intravenous fentanyl in a cohort of patients would lead to a successful completion of the procedure in some patients but would fail in others. In the patients where it fails, GA would be used to complete the procedure. The use of GA as a first line option would lead to completion of procedure in all patients. The combination technique is associated with vomiting and oxygen desaturation less than 90%.




Figure 5 A decision tree of a combination sedation technique compared to general anaesthesia in colonoscopy

Clinical data on success rate, complication rate and duration: There was no directly applicable study in the systematic review that reported the success rate for this drug combination. Indirect evidence from one study was considered²⁹. The study compared intravenous fentanyl plus midazolam with intravenous midazolam plus ketamine in 57 children undergoing placement of intravenous line. All patients were reported to have completed the procedure. The consensus was that a rate of 95% is a clinically realistic rate and should be used in the model. A success rate of 100% for GA was assumed. There were a number of heterogeneous studies on the safety of the combination sedation option and the GDG advised that we use rates from the study with largest sample size. A rate of 5.22% was reported for vomiting³⁸, and 2.56% for oxygen desaturation less than 90%³¹.

There were no directly applicable timing estimates for the strategies and the following estimates were made based on the clinical experience of the GDG (Table 27).

Table 27 Timings for sedative drug and GA in colonoscopy

Strategy	Timing (minutes)		
	Induction	Procedure	Recovery
iv midazolam+fentanyl	10	45	45
GA	10	45	30

NHS staff required for application of strategy: The following NHS staff in Table 28 below was suggested by the GDG to be required for the application of the strategies. The unit cost of time spent by the personnel has been described above (dental procedure in children).

Table 28 NHS staff required to apply sedative drug and general anaesthesia in colonoscopy*

Strategy	Induction	Procedure	Recovery
iv midazolam+fentanyl	N + D	N (x2) + D	N
GA	ODA + A	N + D + A + ODA	N

* N=Nurse, D=Physician, A=Anaesthetist, ODA=Anaesthetist Assistant, GA=General Anaesthetic

Cost of drugs, consumables and complications: The cost of midazolam plus fentanyl was estimated based on the dosage reported in Lucas da Silva 2007²⁹ (midazolam, 0.15mg per kg; fentanyl, 1µg per kg). We assumed a maximum dose of 7.5mg reported in the BNF for midazolam which would cost £0.87. For a child 25kg, 25µg fentanyl would cost £0.14 (BNF for fentanyl: 50mcg/mL, net price 2-mL amp = 54p; BNF for midazolam: 5mg/mL, 2mL amp = 58p, 7.5mg would cost 87p). The total cost of this drug combination used in the model was therefore £1.01. The cost of GA was £11.73 and we have described how we arrived at this (dental procedure in children). The cost of consumables for each of the respective strategies was £32. This includes the cost of all consumables listed above in Table 5. The treatment cost of vomiting was assumed to be equivalent of 30 minutes of nurse's time.

Sensitivity Analyses

The robustness of the model results to our assumptions was tested using the same set of sensitivity analyses described above for gastroscopy. We assumed that a sedationist physician would not be required for the induction of iv midazolam plus fentanyl.

4.7.2 Results

The total cost per patient for each of the two strategies compared in this population in the base case analysis is given in Table 29 below. The combination strategy, iv midazolam plus fentanyl, was less expensive at £215.

The cost of GA drug was higher but the cost of consumables for both strategies was the same. The greatest cost component was the cost of staff time especially anaesthetist and physician time. The cost of complication was low because of low incidence.

Table 29 Base case analysis: Cost per patient of using iv midazolam plus fentanyl compared with general anaesthesia in colonoscopy

Strategy	Mean cost of 1st line						Mean cost of 2nd line	Mean cost
	Drugs	Consumables	Anaesthetist	Physician	Nurse	Vomiting rate		
iv midazolam + Fentanyl	£1	£32	£ -	£112	£56	£0.60	£15	£215
GA	£12	£32	£112	£92	£50			£296

We have described the results of one-way sensitivity analyses in Table 30 below. We varied the success rate of the combination strategy to determine the point at which it becomes cost-saving compared to GA strategy. The combination strategy is cost saving as long as the success rate of using it is equal to or greater than 68%. The combination strategy remained cost saving compared to the GA strategy for all the sensitivity analyses conducted here.

Table 30 Sensitivity analyses on the cost per patient of using iv midazolam plus fentanyl compared with general anaesthesia in colonoscopy †

Strategy	Mean cost (base case)	Success rate in base case (%)	Success rate at which it becomes cost-saving compared to GA (%)	Mean cost when induction time of GA = 15mins	Mean cost when cost of N2O = £5 ‡	Mean cost with nurse-led sedation
iv midazolam + fentanyl	£215	95	68	£216	Same as basecase	£195
GA	£296	100	Not applicable	£309	£291	Same as basecase

†pt=patient, ‡ N2O is used in combination with sevoflurane to maintain general anaesthesia

4.8 Discussion

We have attempted to evaluate the economic impact of using different sedation strategies, and we have compared the use of these strategies to the use of general anaesthesia (GA). We included staff costs, costs of drugs and consumables, complication costs and cost of sedation failure. We found that sedation is clearly cost-saving compared to GA in cases where the operating physician or dentist is able to administer sedation without the addition of a sedationist physician or dentist (typically for minimal and moderate sedation). In this case, quite a low success rate is required for sedation to be cost-saving.

In cases where the addition of a sedationist physician or dentist is required (typically for deep sedation), sedation could still be cost saving but this will depend primarily on

- The facility and equipment costs: We have not captured this in our analysis. It is particularly important when evaluating sedation techniques being carried out in primary care (for example dental procedures). However, facility costs may also be cheaper in A&E, for example, compared to a surgical theatre.
- The success rate: As the success rate gets lower, the cost of a sedation strategy increases.
- The speed at which the operation can be conducted under each technique: It seems unclear whether procedures can be delivered more or less quickly with sedation techniques.

Data in these areas seems to be lacking. The economic analysis we have carried out has a number of limitations and these were considered by the GDG when interpreting the results of the analysis. If facility costs do not vary between settings, then by omitting them we have biased our findings in favour of sedation because we have omitted them from the second line treatment. Second line treatment would require additional facility cost as this would happen on a different occasion. However, in evaluating sedation in primary dental care, the facility costs are likely to be far less and in this case, it is likely that the model biases in favour of GA.

Careful patient selection for sedation is important as this will optimise success rates and consequently both improve patient outcomes and minimise costs. The success rates we used in some of our analyses were not based on direct randomised controlled trial results. This was either where there was no trial data or where the available data was judged by the GDG as inapplicable. At these instances the GDG considered the available evidence and used expert opinion to inform the most appropriate rate that was used in the model. The GDG reported that very high rates of success (above 95%) are achievable with all techniques if patients are selected carefully. We used deterministic sensitivity analyses to explore the impact of alternative success rate on the model results.

The timing used in the model was based on the GDG's expert opinion. The GDG considered any existing timing data reported in the clinical review. There were discussions regarding claims that procedures can be conducted quicker under GA than using sedation but the evidence is unclear. The timing of sedation and GA strategies is an area that might benefit from further research.

There may be rare but serious complications arising from anaesthesia or sedation but these were not found in the evidence from the safety review (see chapter 6 on clinical effectiveness and safety review). The GDG felt that we need not include the impact of GA complications as most side effects are minor, especially in children, and that many safety measures are in place to minimise the risk of complications. Given the rarity of serious complications, we think it reasonable to omit the cost and health loss associated with these events.

We have not estimated quality-adjusted life years but we think this unlikely to affect our conclusions. There will be some disutility (reduced health related quality of life) associated with sedation failure. However, these changes will occur over a short period of time and therefore differences in mean quality-adjusted life years between strategies are likely to be negligible.

The impact of uncertainty in model input parameters on model results can be explored using probabilistic sensitivity analysis. We have not conducted this analysis on this occasion. However, we do not feel that this is a serious omission given that the model has been built mainly on expert opinion and therefore it is difficult to accurately ascertain the distribution and variances for a number of model parameters. Furthermore, we have done a number of deterministic sensitivity analyses in areas where we felt that alternative model assumptions could impact on results.

In one of the studies included in the economic review⁴³, it was suggested that sedation would cost less than GA. Nitrous oxide in oxygen was suggested to be less expensive than GA for dental procedure in children⁵. In another study³⁹, for children requiring manipulation of a forearm fracture in the emergency department, propofol plus fentanyl was compared with ketamine plus iv midazolam, fentanyl plus iv midazolam, and axillary approach to brachial plexus regional block with midazolam premedication. Propofol plus fentanyl was found to be the dominant strategy because it had the lowest cost and the shortest emergency department duration. However, these three studies were considered as having potentially serious limitations. Another study²⁰ also suggested that sedation is cheaper than GA in children undergoing dental procedure. This study was judged as having minor limitations and could be considered to be directly applicable to the UK NHS dental services.

In summary, the economic model has allowed a comparison of relevant interventions in different populations groups and has produced results that are directly applicable. Sedation strategies are likely to be cost-saving compared with general anaesthesia. The cost of drugs is less important than the cost of the staff involved. The most cost-effective sedation technique is likely to be those that don't require the addition of a sedationist physician or dentist, essentially those with a wider margin of safety. It will also depend on appropriate patient selection, which will both increase success rate and reduce cost, and the cost of the facility where the procedure is carried out.

4.9 Literature review of economic evaluations

The five studies^{19,20,26,33,39} identified in the review of existing economic evaluation are described below. A description of potentially useful costing studies^{5,20,43} is also given below.

Martinez 2002³³

Martinez 2002³³ was a randomised double blind study comparing diazepam with midazolam as a premedication administered in conjunction with meperidine prior to procedural sedation with propofol in children having upper endoscopy. It is considered to be a partial economic evaluation as the only costs reported were the costs of the study drugs themselves which was \$25.95 for midazolam and \$0.92 for diazepam. It is therefore not useful for decision making as it does not estimate the overall resource use and costs of the alternative sedation strategies. For example, it does not consider the cost of treating adverse events.

Iannalfi 2005¹⁹

Iannalfi 2005¹⁹ was a randomised controlled trial comparing moderate sedation with general anaesthesia in children having lumbar puncture and/or bone marrow aspiration. It only enrolled 31 children and therefore there were less than 20 patients in each arm. RCTs with less than 20 patients in each arm are excluded from the clinical effectiveness reviews as the groups are not sufficiently large for randomisation to provide groups who are reliably comparable for known and unknown confounders. We have therefore not considered it any further as the clinical effectiveness outcomes are potentially open to bias.

Lee 2000²⁶ and Jameson 2007²⁰

These two studies were model based cost minimisation studies which estimated the cost per patient treated and assumed that the health benefits would be equivalent^{20,26}. In both cases the studies compare sedation with anaesthesia for patients undergoing dental treatment. After considering the clinical review evidence, the GDG agreed that it is not likely that the use of sedation techniques will lead to significant changes in quality-adjusted life years as changes in health-related quality of life will only occur over a short period of time. The GDG also suggested that the adverse events observed in the clinical review are not expected to lead to long-term effects that will result in significant QALY differences across different techniques. However, the results of these studies could not be used as the GDG wanted to compare four different sedation strategies with GA in children undergoing dental procedure.

Pershad 2006³⁹

The final model based evaluation³⁹ used clinical evidence from RCT and non-RCT sources to compare four different procedural sedation and analgesia (PSA) techniques for use in children requiring manipulation of a forearm fracture in the emergency department (ED). The four techniques were:

- Deep sedation with ketamine / midazolam (K/M)
- Deep sedation with propofol / fentanyl (P/F)
- Deep sedation with fentanyl / midazolam (F/M)

- Axillary approach to brachial plexus regional block with midazolam premedication (ABRA/M)

The model incorporated evidence on adverse event rates, duration of sedation, and likelihood of PSA failure. The clinical effectiveness and adverse effects data were derived from published literature following a systematic literature search, but the methods for selecting papers has not been explicitly reported. Some additional data from an unpublished trial undertaken in the author's institution were also incorporated in the analysis. The methods described in the paper suggest that the estimates obtained from the RCTs were synthesised in a way which did not maintain randomisation. The adverse events considered in the model were emesis, recovery agitation, respiratory depression requiring assisted ventilation and lidocaine toxicity. It was assumed that deep sedation with P/F would be used when axillary block failed. It was assumed that deep sedation would be 100% successful for all three techniques based on existing data showing that success rates are between 98% and 100% with K/M and F/M.

Resource use included medication costs for sedation and analgesia techniques, staffing costs for administering sedation and treating adverse events, and ED overhead costs based on duration of ED stay which was assumed to vary according to the total sedation time. Duration of ED stay was used as the clinical effectiveness outcomes so that the cost-effectiveness was reported as the cost per hour of time in the ED avoided. Unit costs were reported for staff time, ED overheads and medication costs. Costs were calculated from the hospital's perspective and were reported in US\$, but the price year was not reported. Uncertainty was examined deterministically using one-way and two way sensitivity analysis. A probabilistic sensitivity analysis was used to consider the importance of parameter uncertainty but the authors simply report that the model was "robust" through 1000 iterations.

P/F was found to be the dominant strategy as it had the lowest cost and the shortest ED stay which was the sole effectiveness outcome considered. However this conclusion was sensitive to several key assumptions. The conclusions would be different if the rate of respiratory depression for P/F were to increase from 1.1% to 6.9%, if the rate of lidocaine toxicity were to be reduced from 2.5% to less than 1%, or if the rate of failure of axillary block were to be reduced from 6.8% to less than 2%. Small increases (e.g 3 mins) in the duration of physician time required to administer deep sedation would result in axillary block being the lowest cost option, which is quite possible given that this duration was not well defined by the evidence base. This economic evaluation is considered to be only partially applicable as it is a US based study and the assumptions regarding resource use and unit costs that have been used to populate the model may not be relevant in a UK NHS setting. It is also not clear whether the PSA regimens compared are equivalent in terms of reducing pain and discomfort for patients or whether the main outcome measure, length of emergency department stay, is an important outcome for patients and their families and carers. It is considered to have potentially serious limitations due to uncertainty around the selection and synthesis of effectiveness data and the sensitivity of the conclusions to key assumptions regarding physician time.

Primary details	Design	Patient characteristics	Interventions	Outcome measures	Results	Comments
Author, Year: Pershad 2006 ³⁹ Country: US Funding: Not stated Type of analysis: Cost-effectiveness	Study design: Decision tree model Time horizon: Duration of emergency department stay Discounting: NA Perspective: Hospital Cost year: Not stated	Theoretical cohort or 10 year olds requiring manipulation of fractured forearm in the emergency department	1) Deep sedation with ketamine/midazolam 2) Deep sedation with fentanyl/midazolam 3) Deep sedation with propofol/fentanyl 4) Axillary Block/ midazolam	Effectiveness: Duration of emergency department stay Cost: Staff costs for clinical contact time plus overheads based on length of stay, medication costs ICER: cost per hour of stay avoided	1) 1.75 hours 2) 2.19 hours 3) 0.55 hours 4) 1.06 hours 1) US\$ 105.32 2) US\$ 159.79 3) US\$ 84.06 4) US\$ 88.18 Not relevant as 3) dominates all others	Sensitivity analysis shows that results are not robust to small changes in physician time required It is unclear whether the method of evidence synthesis for clinical effectiveness outcomes maintained randomisation

4.10 Costing studies

The review of costing studies was restricted to UK studies as costs are likely to vary significantly between different healthcare settings.

Blain 1998⁵

This costing study compares the cost of inhaled sedation (nitrous oxide in oxygen, titrated up to a maximum of 40%) with local anaesthesia to general anaesthesia (intravenous induction with inhalational maintenance) for children having dental extractions from a UK NHS perspective. Treatment was provided in a UK secondary care setting. The costing analysis was restricted to staffing costs during treatment and recovery. If treatment took place over more than one visit then the total duration over multiple visits was used. Staff costs were based on the agreed minimum staffing level for each service and 1994 salary scales. These were used to calculate the ratio of staff costs per minute during treatment and recovery for the two services and overall costs were reported using units that represent one minute of care within the sedation service (see Table 31 below). The duration of treatment and recovery was taken from a case-control study conducted in the UK which was also reported within Blain 1998⁵. Children who were not suitable for treatment with sedation were excluded from both the sedation and anaesthesia cohorts before 265 matched pairs (matched for age and gender) were selected. The mean age was 7.63 (SD 2.45) and 7.54 (SD 2.46) for the sedation and anaesthesia groups respectively. However, there were a much larger number of patients rejected from the sedation group (42% versus 16%) suggesting that the groups may not be comparable. The overall costs were 64.3 units for sedation and 80.8 units for anaesthesia. It is not possible to convert these back to UK£ from the data provided. This study is directly applicable as it takes a UK NHS perspective although its usefulness is limited as it does not report the actual costs and therefore these cannot be uplifted to reflect current prices. The duration of treatment and recovery are key factors in the costing analysis and these have potentially serious limitations as they are based on a case-control study, in which there were considerably more patients excluded from one group.

Table 31 Staffing levels, cost ratios and duration of treatment and recovery associated with sedation and general anaesthesia

	Sedation	General anaesthesia
Staffing levels during treatment	Registrar Dentist, Dental Nurse	Consultant Anaesthetist, Registrar Dentist, 2 x Dental Nurse
Staffing levels during recovery	Dental Nurse	Staff Nurse, Dental Nurse
Cost ratio during treatment	1	2.8
Cost ratio during recovery	1	2.2
Duration of treatment (minutes)	45.1	7.4
Duration of recovery (minutes)	19.2	27.3
Total costs (units)	64.3	80.8

Shaw 1996⁴³

This was a prospective study that evaluated treatment success, assessed parents' and children's satisfaction, and compared the cost of inhalation sedation with that of existing general anaesthesia. It was carried out in children having dental extractions or minor

oral surgery in a UK NHS secondary care setting. Treatment was judged as successful by the clinician if the procedure was completed. Data on treatment satisfaction was collected by questionnaire. Cost was based on hospital data and included staff cost only. It excluded the cost of other hospital overheads, such as the equipment, anaesthetic gases and reception staff. Ninety percent of children treated with sedation completed treatment. Thirteen children were treated with general anaesthesia. The cost per patient of providing treatment with sedation was reported to be 30% less than that for outpatient general anaesthesia and 57% less than day-stay general anaesthesia. More detailed cost information was not reported. This study has a number of limitations and should be cautiously interpreted. The number of patients studied for general anaesthesia was small. Cost data included only staff cost and this was not reported in enough details to allow judgement on quality. The study sample was not randomised. There were no sensitivity analyses on the results.

Jameson 2007²⁰

This paper compares the cost of providing advanced conscious sedation in a primary care-based service with the cost of treatment under a dental general anaesthetic (DGA) in a hospital based community dental service. The cost analysis for advanced conscious sedation takes into account the rate of referrals for DGA after initial assessment and the rate of sedation failure, which are estimated from 2,771 patient records. The rate of failure under DGA is not considered and is therefore assumed to be 100%.

The cost of treatment under DGA is presented using both NHS reference costs¹² and a bottom-up costing using local audit data. The bottom-up costing included salary costs for anaesthetists, dental staff and administration staff and the cost of consumables, equipment, portering and the availability of inpatient beds reserved for use by the service. Separate costs were estimated for long and short procedures and an average cost was derived using weighting list data to estimate the ratio of long to short procedures. Using the HRG costs, the cost for short and long procedures was £568 and £616 respectively, with a mean cost of £590.21. The average cost estimate based on the local audit data was much lower at £359.91.

The cost of treatment under sedation was estimated using the patient list data from 205 patients and applying the relevant fees paid to the primary care based sedation service by the NHS, giving a cost per patient of £223.78. Once the additional cost of referring patients who had failed under sedation for a DGA are included, the cost is £245.57 per patient treated.

Sensitivity analyses were conducted on the rate of sedation failures, the rate of referrals for DGA following sedation failure and the rate of referrals for DGA following assessment. The rate of failure would need to increase to 77% before DGA became the lowest cost option, whilst the rate of referral following failure was not found to be a significant factor. If the rate of referrals following assessment at the sedation service were to increase to above 36.32% then DGA would be the lowest cost option, however the current rate is only 4-5%.

It is not clear whether the patients receiving care under the two services are similar. It is not known whether the age profile of the two cohorts was similar or how many patients receiving DGA had special needs meaning that they would not be able to receive treatment in a primary care setting. The fact that 56.7% of those failing under sedation (1.98% of all those receiving sedation) were referred back to their GP as there was insufficient justification for a DGA suggests that the cohorts may not be comparable. This

study is considered to have minor limitations as there is uncertainty regarding the comparability of the cohorts being treated in the different settings, but the sensitivity analyses suggest that the conclusions are unlikely to be affected by small differences in the case mix. The results are considered to be directly applicable to the UK NHS dental services as a whole with the caveat that there would need to be sufficient demand within a particular region to meet the upfront costs of establishing a primary care based sedation service such as this as an alternative to DGA.

Table 32 Excluded studies and reasons for exclusion

Author, year	Reason for exclusion from cost-effectiveness review
Blain 1998* ⁵	Excluded as non-RCT design for outcomes
Bluemke 2000 ⁶	Excluded as non-RCT design for outcomes
DeLoach 2005 ¹¹	Excluded as non-RCT design for outcomes
Foglia 2004 ¹⁵	Excluded as non-RCT design for outcomes
Harned 2001 ¹⁷	Excluded as non-RCT design for outcomes
Jameson 2007* ²⁰	Excluded as equivalence assumed but not demonstrated
Kezerashvili 2008 ²¹	Excluded as non-RCT design for outcomes
Lalwani 2007 ²⁴	Excluded as non-RCT design for outcomes
Lawrence 1998 ²⁵	Excluded as non-RCT design for outcomes
Lee 2000 ²⁶	Excluded as equivalence assumed but not demonstrated
Movaghar 2000 ³⁵	Excluded as non-RCT design for outcomes
Nelson 2000 ³⁶	Excluded as non-RCT design for outcomes
Squires 1995 ⁴⁴	Excluded as non-RCT design for outcomes
Yen 2008 ⁵¹	Excluded as age 16+ and high mean age, 49+-22 and 46+-19)
Westrup 2007 ⁴⁵	Excluded as comparison not relevant
Loewy 2006 ²⁸	Excluded as no cost data
De Amorim E Silva 2006 ⁹	Excluded as no cost data
Mamede 2008 ³⁰	Excluded due to age range (16-72, mean 47.5)
Adams 2007 ²	Excluded as no cost data
Khan 2007 ²²	Excluded as no cost data
Shaw 1996* ⁴³	Excluded as non-comparative study
Iannalfi 2005 ¹⁹	Excluded as RCT with N<20 in each arm
Martinez 2002 ³³	Excluded as cost data limited to drug costs only

* Relevant UK costing studies.

4.11 Reference List (for Appendix F, Cost-effectiveness analysis)

- 1 *Perioperative Fasting in Adults and Children. An RCN Guideline for the Multidisciplinary Team.* London: Royal College Of Nursing; 2005. (Guideline Ref ID 15993)
- 2 Adams K, Pennock N, Phelps B, Rose W, Peters M. Anesthesia Services Outside of the Operating Room. *Pediatric Nursing.* 2007; 33(3):232, 234, 236-232, 234, 237. (Guideline Ref ID 16019)
- 3 Averley PA, Girdler NM, Bond S, Steen N, Steele J. A Randomised Controlled Trial of Paediatric Conscious Sedation for Dental Treatment Using Intravenous Midazolam Combined With Inhaled Nitrous Oxide or Nitrous Oxide/Sevoflurane. *Anaesthesia.* 2004; 59(9):844-852. (Guideline Ref ID 486)
- 4 Bassett KE, Anderson JL, Pribble CG, Guenther E. Propofol for Procedural Sedation in Children in the Emergency Department. *Annals of Emergency Medicine.* 2003; 42(6):773-782. (Guideline Ref ID 591)
- 5 Blain KM, Hill FJ. The Use of Inhalation Sedation and Local Anaesthesia As an Alternative to General Anaesthesia for Dental Extractions in Children. *British Dental Journal.* 1998; 184:608-611. (Guideline Ref ID 241)
- 6 Bluemke DA, Breiter SN. Sedation Procedures in MR Imaging: Safety, Effectiveness, and Nursing Effect on Examinations. *Radiology.* 2000; 216(3):645-652. (Guideline Ref ID 2574)
- 7 Cechvala MM, Christenson D, Eickhoff JC, Hollman GA. Sedative Preference of Families for Lumbar Punctures in Children With Acute Leukemia: Propofol Alone or Propofol and Fentanyl. *Journal of Pediatric Hematology/Oncology.* 2008; 30(2):142-147. (Guideline Ref ID 48)
- 8 Connors K, Terndrup TE. Nasal Versus Oral Midazolam for Sedation of Anxious Children Undergoing Laceration Repair. *Annals of Emergency Medicine.* 1994; 24(6):1074-1079. (Guideline Ref ID 1286)
- 9 De Amorim E Silva C, Mackenzie A, Hallowell LM, Stewart SE, Ditchfield MR. Practice MRI: Reducing the Need for Sedation and General Anaesthesia in Children Undergoing MRI. *Australasian Radiology.* 2006; 50(4):319-323. (Guideline Ref ID 4212)
- 10 De Sanctis Briggs V. Magnetic Resonance Imaging Under Sedation in Newborns and Infants: a Study of 640 Cases Using Sevoflurane. *Paediatric Anaesthesia.* 2005; 15(1):9-15. (Guideline Ref ID 8289)
- 11 DeLoach Walworth D. Procedural-Support Music Therapy in the Healthcare Setting: a Cost-Effectiveness Analysis. *Journal of Pediatric Nursing.* 2005; 20:276-284. (Guideline Ref ID 234)
- 12 Department of Health. *NHS Reference Costs 2003.* London: Department of Health; 2003. (Guideline Ref ID 16020)

- 13 Fauroux B, Onody P, Gall O, Tourniaire B, Koscielny S, Clement A. The Efficacy of Premixed Nitrous Oxide and Oxygen for Fiberoptic Bronchoscopy in Pediatric Patients: a Randomized, Double-Blind, Controlled Study. *Chest*. 2004; 125(1):315-321. (Guideline Ref ID 546)
- 14 Fishbein M, Lugo RA, Woodland J, Lininger B, Linscheid T. Evaluation of Intranasal Midazolam in Children Undergoing Esophagogastroduodenoscopy. *Journal of Pediatric Gastroenterology and Nutrition*. 1997; 25(3):261-266. (Guideline Ref ID 1089)
- 15 Foglia RP, Moushey R, Meadows L, Seigel J, Smith M. Evolving Treatment in a Decade of Pediatric Burn Care. *Journal of Pediatric Surgery*. 2004; 39:957-960. (Guideline Ref ID 226)
- 16 Green SM, Rothrock SG, Lynch EL, Ho M, Harris T, Hasdalen R, Hopkins GA, Garrett W, Westcott K. Intramuscular Ketamine for Pediatric Sedation in the Emergency Department: Safety Profile in 1,022 Cases. *Annals of Emergency Medicine*. 1998; 31(6):688-697. (Guideline Ref ID 4172)
- 17 Harned RK, Strain JD. MRI-Compatible Audio/Visual System: Impact on Pediatric Sedation. *Pediatric Radiology*. 2001; 31:247-250. (Guideline Ref ID 229)
- 18 Houpt MI, Sheskin RB, Koenigsberg SR, DesJardins PJ, Shey Z. Assessing Chloral Hydrate Dosage for Young Children. *ASDC Journal of Dentistry for Children*. 1985; 52(5):364-369. (Guideline Ref ID 3625)
- 19 Iannalfi A, Bernini G, Caprilli S, Lippi A, Tucci F, Messeri A. Painful Procedures in Children With Cancer: Comparison of Moderate Sedation and General Anesthesia for Lumbar Puncture and Bone Marrow Aspiration. *Pediatric Blood and Cancer*. 2005; 45(7):933-938. (Guideline Ref ID 2174)
- 20 Jameson K, Averley PA, Shackley P, Steele J. A Comparison of the 'Cost Per Child Treated' at a Primary Care-Based Sedation Referral Service, Compared to a General Anaesthetic in Hospital. *British Dental Journal*. 2007; 203(6):E13. (Guideline Ref ID 4213)
- 21 Kezerashvili A, Fisher JD, DeLaney J, Mushiyevev S, Monahan E, Taylor V, Kim SG, Ferrick KJ, Gross JN, Palma EC, Krumerman AK. Intravenous Sedation for Cardiac Procedures Can Be Administered Safely and Cost-Effectively by Non-Anesthesia Personnel. *Journal of Interventional Cardiac Electrophysiology*. 2008; 21(1):43-51. (Guideline Ref ID 109)
- 22 Khan JJ, Donnelly LF, Koch BL, Curtwright LA, Dickerson JM, Hardin JL, Hutchinson S, Wright J, Gessner KE. A Program to Decrease the Need for Pediatric Sedation for CT and MRI. *Applied Radiology*. 2007; 36(4):30-33. (Guideline Ref ID 1682)
- 23 Lahoud GY, Averley PA. Comparison of Sevoflurane and Nitrous Oxide Mixture With Nitrous Oxide Alone for Inhalation Conscious Sedation in Children Having Dental Treatment: a Randomised Controlled Trial. *Anaesthesia*. 2002; 57(5):446-450. (Guideline Ref ID 739)
- 24 Lalwani K, Kitchin J, Lax P. Office-Based Dental Rehabilitation in Children With Special Healthcare Needs Using a Pediatric Sedation Service Model. *Journal of Oral and Maxillofacial Surgery*. 2007; 65(3):427-433. (Guideline Ref ID 51)

- 25 Lawrence LM, Wright SW. Sedation of Pediatric Patients for Minor Laceration Repair: Effect on Length of Emergency Department Stay and Patient Charges. *Pediatric Emergency Care*. 1998; 14:393-395. (Guideline Ref ID 3757)
- 26 Lee JY, Vann WF, Roberts MW. A Cost Analysis of Treating Pediatric Dental Patients Using General Anesthesia Versus Conscious Sedation. *Pediatric Dentistry*. 2000; 22:27-32. (Guideline Ref ID 4214)
- 27 Liacouras CA, Mascarenhas M, Poon C, Wenner WJ. Placebo-Controlled Trial Assessing the Use of Oral Midazolam As a Premedication to Conscious Sedation for Pediatric Endoscopy. *Gastrointestinal Endoscopy*. 1998; 47(6):455-460. (Guideline Ref ID 1029)
- 28 Loewy J, Hallan C, Friedman E, Martinez C. Sleep/Sedation in Children Undergoing EEG Testing: a Comparison of Chloral Hydrate and Music Therapy. *American Journal of Electroneurodiagnostic Technology*. 2006; 46(4):343-355. (Guideline Ref ID 3010)
- 29 Lucas da Silva PS, Oliveira Iglesias SB, Leao FV, Aguiar VE, Brunow dC. Procedural Sedation for Insertion of Central Venous Catheters in Children: Comparison of Midazolam/Fentanyl With Midazolam/Ketamine. *Paediatric Anaesthesia*. 2007; 17(4):358-363. (Guideline Ref ID 153)
- 30 Mamede RC, Rafal H. Comparison Between General Anesthesia and Superficial Cervical Plexus Block in Partial Thyroidectomies. *Revista Brasileira De Otorrinolaringologia*. 2008; 74(1):99-105. (Guideline Ref ID 18)
- 31 Mamula P, Markowitz JE, Neiswender K, Zimmerman A, Wood S, Garofolo M, Nieberle M, Trautwein A, Lombardi S, Sargent-Harkins L, Lachewitz G, Farace L, Morgan V, Puma A, Cook-Sather SD, Liacouras CA. Safety of Intravenous Midazolam and Fentanyl for Pediatric GI Endoscopy: Prospective Study of 1578 Endoscopies. *Gastrointestinal Endoscopy*. 2007; 65(2):203-210. (Guideline Ref ID 16)
- 32 Marti-Bonmati L, Ronchera-Oms CL, Casillas C, Poyatos C, Torrijo C, Jimenez NV. Randomised Double-Blind Clinical Trial of Intermediate- Versus High-Dose Chloral Hydrate for Neuroimaging of Children. *Neuroradiology*. 1995; 37(8):687-691. (Guideline Ref ID 1204)
- 33 Martinez JL, Sutters KA, Waite S, Davis J, Medina E, Montano N, Merzel D, Marquez C. A Comparison of Oral Diazepam Versus Midazolam, Administered With Intravenous Meperidine, As Premedication to Sedation for Pediatric Endoscopy. *Journal of Pediatric Gastroenterology and Nutrition*. 2002; 35(1):51-58. (Guideline Ref ID 717)
- 34 McCann W, Wilson S, Larsen P, Stehle B. The Effects of Nitrous Oxide on Behavior and Physiological Parameters During Conscious Sedation With a Moderate Dose of Chloral Hydrate and Hydroxyzine. *Pediatric Dentistry*. 1996; 18(1):35-41. (Guideline Ref ID 1195)
- 35 Movaghar M, Kodsí S, Merola C, Doyle J. Probing for Nasolacrimal Duct Obstruction With Intravenous Propofol Sedation. *Journal of the American Association for Pediatric Ophthalmology and Strabismus*. 2000; 4:179-182. (Guideline Ref ID 3753)
- 36 Nelson DS, Hoagland JR, Kunkel NC. Costs of Sedation Using Oral Midazolam: Money, Time, and Parental Attitudes. *Pediatric Emergency Care*. 2000; 16:80-84. (Guideline Ref ID 222)

- 37 PASA. *NHS Supply Chain Catalogue*. 2009. (Guideline Ref ID 16018)
- 38 Peña BMG, Krauss B. Adverse Events of Procedural Sedation and Analgesia in a Pediatric Emergency Department. *Annals of Emergency Medicine*. 1999; 34(4 1):483-491. (Guideline Ref ID 384)
- 39 Pershad J, Todd K, Waters T. Cost-Effectiveness Analysis of Sedation and Analgesia Regimens During Fracture Manipulation in the Pediatric Emergency Department. *Pediatric Emergency Care*. 2006; 22:729-736. (Guideline Ref ID 3745)
- 40 Personal Social Services Research Unit. *Unit Costs of Health and Social Care*. 2008. (Guideline Ref ID 16017)
- 41 Primosch RE, Buzzi IM, Jerrell G. Effect of Nitrous Oxide-Oxygen Inhalation With Scavenging on Behavioral and Physiological Parameters During Routine Pediatric Dental Treatment. *Pediatric Dentistry*. 1999; 21(7):417-420. (Guideline Ref ID 965)
- 42 Roback MG, Wathen JE, MacKenzie T, Bajaj L. A Randomized, Controlled Trial of I.v. Versus I.m. Ketamine for Sedation of Pediatric Patients Receiving Emergency Department Orthopedic Procedures. *Annals of Emergency Medicine*. 2006; 48(5):605-612. (Guideline Ref ID 212)
- 43 Shaw AJ, Meechan JG, Kilpatrick NM, Welbury RR. The Use of Inhalation Sedation and Local Anaesthesia Instead of General Anaesthesia for Extractions and Minor Oral Surgery in Children: a Prospective Study. *International Journal of Paediatric Dentistry*. 1996; 6:7-11. (Guideline Ref ID 242)
- 44 Squires RH, Morriss F, Schluterman S, Drews B, Galyen L, Brown KO. Efficacy, Safety, and Cost of Intravenous Sedation Versus General Anesthesia in Children Undergoing Endoscopic Procedures. *Gastrointestinal Endoscopy*. 1995; 41:99-104. (Guideline Ref ID 3749)
- 45 Westrup B, Sizun J, Lagercrantz H. Family-Centered Developmental Supportive Care: A Holistic and Humane Approach to Reduce Stress and Pain in Neonates. *Journal of Perinatology*. 2007; 27(SUPPL. 1):S12-S18. (Guideline Ref ID 160)
- 46 Wilson KE, Girdler NM, Welbury RR. Randomized, Controlled, Cross-Over Clinical Trial Comparing Intravenous Midazolam Sedation With Nitrous Oxide Sedation in Children Undergoing Dental Extractions. *British Journal of Anaesthesia*. 2003; 91(6):850-856. (Guideline Ref ID 589)
- 47 Wilson KE, Girdler NM, Welbury RR. A Comparison of Oral Midazolam and Nitrous Oxide Sedation for Dental Extractions in Children. *Anaesthesia*. 2006; 61(12):1138-1144. (Guideline Ref ID 204)
- 48 Wilson KE, Welbury RR, Girdler NM. A Randomised, Controlled, Crossover Trial of Oral Midazolam and Nitrous Oxide for Paediatric Dental Sedation. *Anaesthesia*. 2002; 57(9):860-867. (Guideline Ref ID 711)
- 49 Wilson KE, Welbury RR, Girdler NM. A Study of the Effectiveness of Oral Midazolam Sedation for Orthodontic Extraction of Permanent Teeth in Children: a Prospective, Randomised, Controlled, Crossover Trial. *British Dental Journal*. 2002; 192(8):457-462. (Guideline Ref ID 729)

- 50 Wilson KE, Welbury RR, Girdler NM. Comparison of Transmucosal Midazolam With Inhalation Sedation for Dental Extractions in Children. A Randomized, Cross-Over, Clinical Trial. *Acta Anaesthesiologica Scandinavica*. 2007; 51(8):1062-1067. (Guideline Ref ID 111)
- 51 Yen KG, Elnor VM, Musch DC, Nelson CC. Periocular Versus General Anesthesia for Ocular Enucleation. *Ophthalmic Plastic and Reconstructive Surgery*. 2008; 24(1):24-28. (Guideline Ref ID 22)

5 Appendix G - Recommendations for research

5.1 Recommendation for research on pre-sedation assessment

<p>PICO question</p>	<p>For children and young people under the age of 19 undergoing diagnostic and therapeutic procedures under sedation techniques, what factors are needed to develop a tool, or what tools should be used to standardise assessment and/or monitoring, in establishing the need for sedation and in reducing the potential risk of adverse events?</p> <p><i>Question:</i> What factors determine the need for sedation?</p> <p><i>Population:</i> Children requiring sedation for procedures</p> <p><i>Intervention:</i> Assessment of factors that could determine whether sedation is the best choice for the patient. Development of an assessment tool. Application of the assessment tool to predict whether sedation is an effective and safe option for patients undergoing procedures.</p> <p><i>Comparison:</i> Children assessed versus not assessed by an “Assessment tool”</p> <p><i>Outcome:</i> Quality of care (patient/carer/healthcare professional feedback) and incidence of complications of sedation.</p>
<p>Importance to patients or the population</p>	<p>Patients want to receive the best care. Healthcare professionals may need a tool to help them advise patients/carers on the best choice of technique for a procedure. If sedation is ineffective the patient will have to be anaesthetised later – perhaps the</p>

	following day or in another hospital.
Relevance to NICE	There is variation on practice across the NHS.
Relevance to the NHS	NHS resources could be used more effectively if patients were managed with effective techniques. Sedation failure is expensive. Anaesthesia is always effective but is expensive and limited resource.
National priorities	Making correct choices for the type of sedation/anaesthesia proposed should reduce costs.
Current evidence base	There are no published assessment tools for sedation
Study design	Observational study to determine the important factors. Consensus study to develop a tool Randomised comparison of children assessed versus not assessed using the tool.
Feasibility	Large teaching hospitals have many patient who need procedures under sedation.
Other comments	Funding is needed for a research worker to develop the assessment tool and to coordinate the consensus and assessment studies. This person could work alongside workers mentioned in the other priority research projects.
Importance	Developing an assessment tool should improve quality of care.

5.2 Recommendation for research on training for personnel involved in sedation

<p>PICO question</p>	<p>For personnel involved in delivering sedation to children and young people under the age of 19 undergoing diagnostic and therapeutic procedures what training is required to both achieve and maintain essential skills?</p> <p>Question: Does airway training using a manikin improve airway skills required for safe sedation practice?</p> <p><i>Population:</i> Healthcare professionals training to deliver sedation</p> <p><i>Intervention:</i> Airway training using a manikin in addition to standard airway training on anaesthetised patients. Two intervention groups: (1) manikin training every 3 months, and (2) manikin training every month.</p> <p><i>Comparison:</i> Standard airway training on anaesthetised patients (no manikin training)</p> <p><i>Outcome:</i> Time taken to achieve successful management of airway problems in anaesthetised patients</p>
<p>Importance to patients or the population</p>	<p>Airway problems in sedated patients should be infrequent. Consequently, when they do occur healthcare professionals' airway skills may be slow and patients may be at risk of hypoxia. Healthcare professional administering sedation have standard airway training but this may not be sufficient. Special airway training may be necessary.</p>
<p>Relevance to NICE</p>	<p>Currently there is much variation in airway skills in healthcare professional who deliver sedation. Training in airway skills needs to be developed and proven to be effective. Once established, airway training should be undertaken by all sedationists so that, across the NHS, there is a high standard of managing airway problems.</p>
<p>Relevance to the NHS</p>	<p>Safe airway management should improve patient safety. Airway training should improve flexibility of working for healthcare professional because any member to the team, whichever professional group, can achieve airway skills.</p>
<p>National priorities</p>	<p>Patient safety. Delivery of high standard of care within current staffing resources</p>

Current evidence base	Training on manikins can improve performance. Airway training for sedation in children and young people has not been developed.
Study design	Randomized controlled comparison of three methods of training airway skills. Assessment of skills will be by a "single blind" independent assessor.
Feasibility	Trainee and established healthcare professionals (doctors, dentists and nurses) are available in large teaching hospitals. These hospitals should benefit from having effective airway training.
Other comments	Manikins are available in most teaching institutions however funding maybe required for new manikins. Funding will be required for a study coordinator.
Importance	Airway training is an essential skill in many areas of healthcare delivery.

5.3 Recommendation for research on drugs combination

<p>PICO question</p>	<p>For children and young people under the age of 19 undergoing diagnostic or therapeutic procedures, what drugs can be combined with midazolam to achieve sedation (at mild, moderate, and deep levels) with low risk of loss of consciousness for sedation in different settings?</p> <p>Question: What dose of fentanyl can be combined with midazolam for effective and safe sedation in children and young people?</p> <p><i>Population:</i> Children undergoing painful procedures in Emergency Department setting</p> <p><i>Intervention:</i> fentanyl</p> <p><i>Comparison:</i> three doses of fentanyl</p> <p><i>Outcome:</i> observation score of distress during procedure. Incidence and severity of complications</p>
<p>Importance to patients or the population</p>	<p>Many patients require moderate sedation for painful procedures in the Emergency Department setting. A sedation technique is needed that can be applied across a wide range of painful procedures</p>
<p>Relevance to NICE</p>	<p>There is wide variation of standards of sedation practice across the NHS</p>
<p>Relevance to the NHS</p>	<p>Healthcare professionals need guidance on the safe doses of common drugs in children</p>
<p>National priorities</p>	<p>Midazolam and fentanyl are widely used sedation drugs yet little data are available to inform on the effective and safe doses for moderate sedation</p>
<p>Current evidence base</p>	<p>Dose finding studies have not been carried out in children for this combination of drugs</p>
<p>Study design</p>	<p>Randomised double blind comparison of three doses of fentanyl combined with midazolam</p>

	(dose compatible with moderate sedation)
Feasibility	Sufficient numbers of children requiring sedation may not be available in a single Emergency Department. The study would therefore need to be multi-centre
Other comments	Funding would be required for coordinators of this study. These people could work alongside workers mentioned in the other priority research projects.
Importance	The combination of midazolam and fentanyl could be useful across a wide range of situations involving sedation for painful procedures

5.4 Recommendation for development of a national registry of sedation

PICO question	<p>Establishment of a national registry for paediatric sedation, to provide a database with sufficient power to give more useful data on safety and efficacy</p> <p>Question: What are the safety and efficacy profiles of sedation techniques in current practice?</p> <p><i>Population:</i> Children and young people undergoing sedation in selected hospitals in the UK</p> <p><i>Intervention:</i> Observational audit of clinical practice. Self completed reporting.</p> <p><i>Comparison:</i> N/A</p> <p><i>Outcome:</i> Incidence of complications and quality of patient experience.</p>
Importance to patients or the population	Patients and healthcare professionals need to know the safety and efficacy profile of current sedation practice
Relevance to NICE	There is variation in standards of practice. A national data base could aid implementation of NICE guidance
Relevance to the NHS	Safety data on sedation is important to the service
National priorities	Safety is a high priority
Current evidence base	Safety data from a large sample of patient are not available in the UK
Study design	Large scale audit program of practice
Feasibility	Involving all hospitals will be difficult. Selecting paediatric hospitals who have a

	large sedation practice and who want to take part should be feasible
Other comments	Funding will be necessary to employ a coordinator of this audit project. This person could work alongside workers mentioned in the other priority research projects.
importance	Planning services of children depends upon accurate estimation of demand, quality and safety. Data on sedation will help planning, training and implementation of sedation services

6 Appendix H-Review protocol form

6.1 Objective

To determine the effectiveness of sedation for children and young people (under the age of 19 years).

6.2 Definition of sedation

Sedation is a technique which involves the depression of consciousness by drugs. The aim of sedation during diagnostic or therapeutic procedures includes reducing fear and anxiety, and minimising movement. The importance of each of these aims will vary depending on the nature of the procedure and the characteristics of the patient. For example, in younger children sedation may be necessary to ensure that movement is minimised during non-painful procedures such as a magnetic resonance imaging (MRI) scanning; in older children sedation may be necessary to minimise the physical and psychological consequences of a painful procedure such as a lumbar puncture.

6.3 Selection criteria for intervention reviews

Studies will be included if they meet the following selection criteria:

1. Types of studies

- randomised trials (RCTs)
- quasi-randomised studies (e.g. allocation by alternation, date of birth, etc)
- other study designs will be considered in discussion with GDG if RCTs are not found
- in accordance with NICE methods, studies will be restricted to the English language (unless recommended otherwise by the GDG)
- studies with fewer than 20 patients in each arm will not be considered

- studies in indirect populations will be considered if there are none in direct populations (e.g. adults)

2. Healthcare settings

- Hospital settings, including inpatients, outpatients, radiology and emergency departments
- Primary care, including dental and medical general practice

3. Types of participants

Included

Infants, children and young people under the age of 19 who are receiving sedation by any technique for diagnostic or therapeutic procedures including dental surgery and minor operations carried out under local anaesthesia.

Excluded

- Patients requiring sedation for purposes other than for diagnostic or therapeutic procedures including:
 - sedation for critically ill patients requiring mechanical ventilation
 - sedation in palliative care
 - sedation in the treatment of mental health conditions
 - sedation given as premedication for general anaesthesia or as postoperative analgesia
 - night sedation
- Patients having diagnostic or therapeutic procedures under general anaesthesia

4. Types of interventions

The following pharmacological interventions, described in the children's BNF, will be included. Individual drugs will be considered separately and in combination. A class effect is not assumed.

- Drug class: Benzodiazepines; drugs: Midazolam
- Drug class: Inhalational anaesthetics; drug: Nitrous oxide
- Drug class: IV anaesthetics; drugs: Ketamine (painful procedures) and Propofol
- Drug class: Choral and derivatives; drugs: Chloral hydrate and Triclofos sodium (painless procedures)

- Drug class: Opioids; drugs: Morphine, Pethidine (Meperidine), Fentanyl, Alfentanil, Remifentanyl
- Drug class: Inhalation anaesthetics; drugs Sevoflurane and Isoflurane

Combinations of drugs

Any combination will be considered.

All doses will be included. We will also record how the authors determined the dose that is needed to achieve the desired level of cooperation and/or anxiolysis.

For all sedative agents except ketamine and opioids, any route of administration will be considered including buccal, oral, intravenous, inhalation, rectal, intramuscular, transmucosal. Bolus and titrated doses will be included. Ketamine will be considered when given by intramuscular and intravenous routes. For opioids, fentanyl and morphine will be considered when administered by intravenous routes and diamorphine when administered by intranasal route.

Techniques of administration including patient control, operator control and control by a separate sedationist will be considered. Interventions will be included regardless of who administered them and this will be noted, e.g. nurses, anaesthetist, trained sedationist.

The guideline will not review non-pharmacological treatments alone for diagnostic or therapeutic procedures because these are not sedation by definition. However, combinations of sedation with non-pharmacological treatments will be compared with non-pharmacological treatment alone, i.e. investigating adjunctive effects of sedation.

Any non-pharmacological intervention will be included as part of the combination treatment, provided it is a definite intervention, as distinct from usual care.

5. Types of comparisons

The following comparisons will be included.

- intervention (including combinations) versus no intervention or placebo or usual care
- intervention A versus B
- intervention A + B versus B
- pharmacological versus non-pharmacological
- pharmacological + non-pharmacological versus non-pharmacological
- pharmacological + analgesia versus analgesia
- pharmacological versus general anaesthesia

- dose A versus dose B
- duration 1 versus duration 2
- route of administration 1 versus 2

6. Types of outcome measures

The following outcomes will be considered.

Primary outcome:

- Successful completion of diagnostic or therapeutic procedure
 - measured as the number of patients for whom the diagnostic or therapeutic procedure was carried out and completed.

Secondary outcomes:

- Behavioural ratings including:
 - pain as assessed by the patient or parent or other observer using validated pain scales e.g. Visual Analogue Scale (VAS), Children's Hospital of Eastern Ontario Pain Scale (CHEOPS), FACE,.
 - procedural distress and/or anxiety as assessed by the patient or parent or other observer using validated scales e.g. Visual Analogue Scale (VAS), Observation Scale of Behavioral Distress (OSBD).
 - patient or parent satisfaction including preference
- Sedation timing including
 - length of induction: time from administration of sedation drug to initiation of procedure
 - duration of procedure
 - length of recovery: time from completion of procedure to recovery criteria being met or recovery to pre-sedation state (includes prolonged drowsiness)
 - total: time from administration of intervention to when patient has been transferred to the recovery area or has been discharged

Adverse events:

- Aspiration
- Respiratory intervention, including:
 - oral-pharyngeal airway

- endotracheal intubation
- assisted ventilation
- Cardiac arrest requiring either/or:
 - external cardiac massage
 - defibrillation
- Oxygen desaturation <90%
- Vomiting

APPRAISAL OF METHODOLOGICAL QUALITY

The methodological quality of each study will be assessed by one reviewer and randomly checked by a second. Quality items will also be assessed by type of study. For randomised trials, the following factors will be considered in assessing the potential for bias:

1. *A priori* sample size calculation:
 - whether or not this was carried out
2. Method of generation of the randomisation sequence:
 - the means by which interventions are distributed amongst the participants
 - whether the method was reported or unclear (i.e. no details given)
 - whether the reported method was adequate, inadequate or partial (Table 1)
3. Allocation concealment at randomisation:
 - the means of preventing the treatment assignment being known before the time of allocation
 - whether the method was reported or unclear (no details)
 - whether the reported method was adequate, inadequate or partial (Table 1)
4. Baseline comparability of treatment groups
 - Age, procedure for which sedation is required, mental state, anxiety state, disease state, fasting state
5. Patients stated to be blinded
6. Outcome assessor stated to be blinded
7. No loss to follow up for each outcome:
 - studies with at least 20% of data missing from any group were considered to be potentially biased, more so if there was differential drop out from any one group or if the missing data was known to be significantly different from the remaining data

- those with moderate loss to follow up (20 to 50%) were considered in sensitivity analyses
 - those with 50% or more patients missing from any one group were regarded as flawed and not analysed further
8. Intention to treat analysis:
- Trial participants should be analysed in the groups to which they were randomised regardless of which (or how much) treatment they actually received, and regardless of other protocol irregularities and
 - all participants should be included regardless of whether their outcomes were actually collected

METHODS OF THE REVIEW

Data synthesis

Meta-analysis of similar trials, where appropriate, will be carried out using The Cochrane Collaboration's analysis software, Review Manager (Version 5). Trials will be pooled using a fixed effects model and plotted on forest plots. Where there is significant heterogeneity, a random effects model will be used as a sensitivity analysis.

Crossover trials will be treated separately from parallel trials unless there is sufficient data to allow their combination. First period only results will be treated with caution.

For dichotomous studies, intention to treat analyses will be used (including all participants according to their assigned groups) where reported by the study authors, and failing that, available case analyses (all those reporting an outcome) as reported by the authors will be used. Where there are incomplete data reported (more than 20% missing in any one group), sensitivity analyses will be carried out, excluding these studies.

Where it is possible to combine studies, outcomes will be summarised for dichotomous data using relative risks or Peto odds ratios (where there are studies with no events in one arm). Numbers needed to treat, with their 95% confidence intervals and the control group rate (range of rates) to which they apply, will be calculated from the risk difference where appropriate. The number needed to treat (NNT) is the number of patients who would have to be treated for one to have an improved outcome.

For continuous data, weighted mean differences will be used and where the studies have different scales, standardised mean differences will be used. Studies reporting final values or change scores will be combined if the scales used are the same across studies, otherwise they will be reported separately. If both final values and change scores are reported, the former will be used. Summary statistics and their 95% confidence intervals (95% CI) will be reported where sufficient detail allows their calculation, together with the control group range.

We will assess heterogeneity between trials by visual inspection of forest plots, noting where there is poor overlap of horizontal lines, and by using statistical measures: the χ^2 test for heterogeneity and the level of inconsistency, I^2 ($I^2 = [(\chi^2 - df) / \chi^2] \times 100\%$, where df is the degrees of freedom). We will consider that there is heterogeneity if the heterogeneity p-value is less than 0.1 and/or I^2 is greater than 50%. Any heterogeneity

will be explored further and unexplained heterogeneous results will not be used as the basis for recommendations.

Stratification

Studies will be stratified by:

- weight: all babies with weight of less than 5 kg will be considered separately
- route of administration
- type of procedure: painful and non-painful; repetitive procedures will not be treated separately

Combining studies

Studies will be combined regardless of:

- dose
- duration of intervention
- procedure (within painful and non-painful groups)
- setting (e.g. dentistry, A&E etc)
- age

Subgroup analyses

The following subgroups will be considered if there is heterogeneity:

9. Drug dose

10. Age groups

- 1 year and below
- 1-5 years
- 5-12 years
- over 12 years (physiologically similar to adults)

11. Population/patient type:

- special needs and non-special needs, e.g. physical and learning disabilities

12. sedation level using ASA grading:

- Minimal: formerly anxiolysis
- Moderate (conscious sedation)
- Deep

13. route of delivery of sedation (bolus/titration):

14. ASA classification (Appendix II)

- ASA I and II versus ASA III to V

15. Procedure

16. who administered sedation technique(s)

Review Protocol – Fasting

Component	Description
Review question	For children and young people under the age of 19 undergoing diagnostic and therapeutic procedures under sedation techniques should fasting versus no fasting be implemented to prevent adverse outcomes?
Objectives	To establish whether the patient should be fasted and for how long before the procedure under sedation to minimize adverse events.
Population	<p><u>Included (for the search strategy 1 only):</u> Infants, children and young people under the age of 19 who are receiving sedation by any technique for diagnostic or therapeutic procedures including dental surgery and minor operations carried out under local anaesthesia.</p> <p><u>Excluded (for the search strategy 1 only):</u> Patients requiring sedation for purposes other than for diagnostic or therapeutic procedures including:</p> <ul style="list-style-type: none"> • sedation in critically ill patients requiring mechanical ventilation • sedation in palliative care • sedation in the treatment of mental health conditions • sedation given as premedication for general anaesthesia or as postoperative analgesia • night sedation. <p><u>Included (for the search strategy 2 only):</u> Healthy children and young people ASA I-II who were undergoing elective surgery under general anaesthesia</p> <p><u>Excluded (for the search strategy 2 only):</u> Children and young people with gastrointestinal disease</p>
Intervention	<ul style="list-style-type: none"> • Fasting before general anaesthesia • Fasting before sedation with one of the following drugs: midazolam, ketamine, propofol, chloral hydrate, nitrous oxide, sevoflurane, fentanyl IV, morphine IV or diamorphine IN
Comparison	Fasting versus no fasting
Outcomes	Outcomes for adverse events as evidenced by: <ul style="list-style-type: none"> • Aspiration • Respiratory intervention, including: <ul style="list-style-type: none"> – oral-pharyngeal airway – endotracheal intubation – assisted ventilation • Cardiac arrest requiring either/or: <ul style="list-style-type: none"> – external cardiac massage – defibrillation • Oxygen desaturation <90% • Vomiting

Search strategy

1) A full search of the literature relevant to fasting for paediatric sedation was conducted. The databases searched were Medline (from 1950 to Jan 18th 2010), Embase (from 1980 to Jan 18th 2010), The Cochrane Library (all dates available to 2009 Issue 4) and CINAHL (from 1982 to Jan 18th 2010).

Studies were restricted to English language only.

Searches were restricted by study design to RCTs and non RCT observational studies.

2) To update the RCN guideline on fasting¹ a literature search was conducted for perioperative fasting in children. The databases searched were Medline (from 2004 to Jan 18th 2010), Embase (from 2004 to Jan 18th 2010), The Cochrane Library (2004 to 2009 Issue 4) and CINAHL (from 2004 to Jan 18th 2010).

Studies were restricted to English language only.

Searches were restricted by study design to RCTs and non RCT observational studies.

The review strategy

The review for this question consisted of three evaluation processes:

1) The RCN guideline Perioperative fasting in adults and children, 2005¹ was assessed using the Agree Instrument for appraisal of clinical guidelines.

2) An update search was conducted for perioperative fasting in children and young people from 2004 to 2009, using key words 'anaesthesia,' 'fasting,' and 'children.' The purpose of this search was to identify recent publications which might impact recommendations in the RCN guideline Perioperative fasting in adults and children, 2005¹.

3) A full search of the literature relevant to fasting for sedation in children and young people, using key words 'sedation,' 'fasting,' and 'children' was conducted.

One RCT met inclusion criteria. Six observational studies were also included in this review, due to lack of further RCT data.

Review Protocol – Psychological Preparation

Component	Description
Review question	For children and young people under the age of 19 undergoing diagnostic and therapeutic procedures under sedation techniques what standard psychological preparation, coping skills and strategies should be used?
Objectives	To provide advice on psychological techniques for an effective patient management.
Population	<p><u>Included:</u> Infants, children and young people under the age of 19 who are receiving sedation by any technique for diagnostic or therapeutic procedures including dental surgery and minor operations carried out under local anaesthesia.</p> <p><u>Excluded:</u></p> <ul style="list-style-type: none"> • Patients requiring sedation for purposes other than for diagnostic or therapeutic procedures including: <ul style="list-style-type: none"> ○ sedation in critically ill patients requiring mechanical ventilation ○ sedation in palliative care ○ sedation in the treatment of mental health conditions ○ night sedation. • Patients having diagnostic or therapeutic procedures under general anaesthesia.
Intervention	Psychological preparation pre-sedation
Comparison	<ul style="list-style-type: none"> • No intervention, usual care • Pre-medication with drug therapy • Another non-pharmacological treatment
Outcomes	<p>Outcomes for efficacy of psychological preparation:</p> <ol style="list-style-type: none"> 1. Completion of procedure 2. Behavioural ratings including: <ol style="list-style-type: none"> a. Pain as assessed using validated pain scales such as FACE, VAS, CHEOPS, Spielberger State-Trait Anxiety Inventory (STAI). b. procedural distress as assessed by validated scales such as OSBD c. Parent/patient satisfaction 3. Sedation timing including <ol style="list-style-type: none"> a. Length of induction (defined as time from administration of sedation drug to initiation of procedure) b. Length of recovery (defined as time from completion of procedure to recovery criteria being met) <p>The search for psychological preparation for paediatric sedation included both quantitative and qualitative literature. Only two RCTs were identified and therefore the review for this intervention was primarily a narrative review of observational studies and randomized controlled clinical trials conducted in</p>

other relevant contexts i.e., induction for anaesthesia and medical procedures

**Search
strategy**

The databases searched were Medline (from 1950 to Jan 18th 2010), Embase (from 1980 to Jan 18th 2010), The Cochrane Library (all dates available to 2009 Issue 4) and CINAHL (from 1982 to Jan 18th 2010).

Studies were restricted to English language only.

Searches were not restricted by study design and included general anaesthesia literature.

**The review
strategy**

Meta-analyses of *RCTs* will be conducted where possible and that if there is heterogeneity subgroup analysis will be conducted as appropriate

Review Protocol – Validated tools

Component	Description
Review question	For children and young people under the age of 19 undergoing diagnostic and therapeutic procedures under sedation techniques, what validated tools should be used to support assessment?
Objectives	<p>To establish what validated tools should be used to support clinicians to assess and decide whether the child:</p> <ul style="list-style-type: none"> • should receive sedation OR • have general anaesthesia OR • have some other kind of pain/anxiety management • Note: this is not about measuring how deep a child is sedated
Population	<p><u>Included:</u> Infants, children and young people under the age of 19 who are receiving sedation by any technique for diagnostic or therapeutic procedures including dental surgery and minor operations carried out under local anaesthesia.</p> <p><u>Excluded:</u></p> <ul style="list-style-type: none"> ○ Patients requiring sedation for purposes other than for diagnostic or therapeutic procedures including: <ul style="list-style-type: none"> ○ sedation in critically ill patients requiring mechanical ventilation ○ sedation in palliative care ○ sedation in the treatment of mental health conditions ○ sedation given as premedication for general anaesthesia or as postoperative analgesia ○ night sedation. ○ Patients having diagnostic or therapeutic procedures under general anaesthesia.
Intervention	Validated instrument/tools/equations/algorithms
Comparison	Standard care or head-to-head comparison with another validated instrument/tools/equations/algorithms
Outcomes	<p>Outcomes for efficacy for sedation sparing:</p> <ol style="list-style-type: none"> 1. Completion of procedure
Search strategy	<p>The databases searched were Medline (from 1950 to Jan 18th 2010), Embase (from 1980 to Jan 18th 2010), The Cochrane Library (all dates available to 2009 Issue 4) and CINAHL (from 1982 to Jan 18th 2010).</p> <p>Studies were restricted to English language only.</p> <p>Searches were restricted using study design filters for RCTs, systematic reviews and observational studies</p>

The review strategy

The review for drug efficacy will be based on RCT evidence only. Study details, methodology and results will be extracted into an Access database. Further statistical analysis and meta analysis will be conducted where possible and carried out in Rev Man as required. The methods of reviewing are detailed in Chapter 2. An evidence profile and quality assessment will be then entered into GRADE.

Review Protocol – Midazolam (efficacy)

Component	Description
Review question	For children and young people under the age of 19 undergoing diagnostic or therapeutic procedures, is midazolam (with or without: analgesia, another drug or psychological techniques) effective for sedation (at minimal, moderate, and deep levels) in comparison with usual care, with analgesia alone, with another sedation drug, with psychological techniques or with general anaesthesia?
Objectives	To estimate the effectiveness of midazolam.
Population	<p><u>Included:</u> Infants, children and young people (under 19 years) receiving sedation by any technique for painful or non-painful diagnostic or therapeutic procedures including dental surgery and minor operations carried out under local anaesthesia.</p> <p><u>Excluded:</u></p> <ul style="list-style-type: none"> • Patients requiring sedation for purposes other than for diagnostic or therapeutic procedures including: <ul style="list-style-type: none"> ○ sedation in critically ill patients requiring mechanical ventilation ○ sedation in palliative care ○ sedation in the treatment of mental health conditions ○ sedation given as premedication for general anaesthesia or as postoperative analgesia ○ night sedation. • Patients having diagnostic or therapeutic procedures under general anaesthesia.
Intervention	Sedation for diagnostic or therapeutic procedures
Comparison	<p>The following comparisons will be included.</p> <ul style="list-style-type: none"> • intervention (including combinations) versus no intervention or placebo or usual care • intervention A versus B • intervention A + B versus B • pharmacological versus non-pharmacological • pharmacological + non-pharmacological versus non-pharmacological • pharmacological + analgesia versus analgesia • pharmacological versus general anaesthesia • dose A versus dose B • duration 1 versus duration 2 • route of administration 1 versus 2
Outcomes	<p>Outcomes for efficacy of midazolam:</p> <ol style="list-style-type: none"> 1. Completion of procedure 2. Behavioural ratings including: <ol style="list-style-type: none"> a. pain as assessed using validated pain scales such as FACE, VAS, CHEOPS, Spielberger State-Trait Anxiety Inventory (STAI).

- b. procedural distress as assessed by validated scales such as OSBD
- c. parent/patient satisfaction
- 3. Sedation timing including
 - a. length of induction: time from administration of sedation drug to initiation of procedure
 - b. duration of procedure
 - c. length of recovery: time from completion of procedure to recovery criteria being met or recovery to pre-sedation state (includes prolonged drowsiness)
 - d. total: time from administration of intervention to when patient has been transferred to the recovery area or has been discharged

Search strategy

The databases searched were Medline (from 1950 to Jan 18th 2010), Embase (from 1980 to Jan 18th 2010), The Cochrane Library (all dates available to 2009 Issue 4) and CINAHL (from 1982 to Jan 18th 2010).

Studies were restricted to English language only.

Searches were restricted using study design filters for RCTs and systematic reviews.

The review strategy

The review for drug efficacy will be based on RCT evidence only. Study details, methodology and results will be extracted into an Access database. Further statistical analysis and meta analysis will be conducted where possible and carried out in Rev Man as required. The methods of reviewing are detailed in Chapter 2. An evidence profile and quality assessment will be then entered into GRADE.

Review Protocol – Midazolam (safety)

Component	Description
Review question	For children and young people under the age of 19 undergoing diagnostic or therapeutic procedures, is midazolam (with or without: analgesia, another drug or psychological techniques) safe for sedation (at mild, moderate, and deep levels) in different settings?
Objectives	To estimate the safety of midazolam.
Population	<p><u>Included:</u> Infants, children and young people (under 19 years) receiving sedation by any technique for painful or non-painful diagnostic or therapeutic procedures including dental surgery and minor operations carried out under local anaesthesia.</p> <p><u>Excluded:</u></p> <ul style="list-style-type: none"> • Patients requiring sedation for purposes other than for diagnostic or therapeutic procedures including: <ul style="list-style-type: none"> ○ sedation in critically ill patients requiring mechanical ventilation ○ sedation in palliative care ○ sedation in the treatment of mental health conditions ○ sedation given as premedication for general anaesthesia or as postoperative analgesia ○ night sedation. • Patients having diagnostic or therapeutic procedures under general anaesthesia.
Intervention	Sedation for diagnostic or therapeutic procedures.
Comparison	<p>The following comparisons will be included.</p> <ul style="list-style-type: none"> • intervention (including combinations) versus no intervention or placebo or usual care • intervention A versus B • intervention A + B versus B • pharmacological versus non-pharmacological • pharmacological + non-pharmacological versus non-pharmacological • pharmacological + analgesia versus analgesia • pharmacological versus general anaesthesia • dose A versus dose B • duration 1 versus duration 2 • route of administration 1 versus 2
Outcomes	<p>Outcomes for safety of midazolam::</p> <ul style="list-style-type: none"> • Aspiration • Respiratory intervention, including: <ul style="list-style-type: none"> ○ oral-pharyngeal airway ○ endotracheal intubation ○ assisted ventilation • Cardiac arrest requiring either/or:

- external cardiac massage
- defibrillation
- Oxygen desaturation <90%
- Vomiting

Search strategy

The databases searched were Medline (from 1950 to Jan 18th 2010), Embase (from 1980 to Jan 18th 2010), The Cochrane Library (all dates available to 2009 Issue 4) and CINAHL (from 1982 to Jan 18th 2010).

Studies were restricted to English language only.

Searches were not restricted by study design.

The review strategy

The review for drug safety will be based upon both RCT and non-RCT observational evidence. For RCT evidence, study details, methodology and results will be extracted into an Access database. Further statistical analysis and meta analysis will be conducted where possible and carried out in Rev Man as required. For non-RCT observational evidence, study details and results will be extracted into tables and rates of adverse events will be calculated as required. All evidence will be reviewed by the GDG. An evidence profile and quality assessment will be then entered into GRADE. The methods of reviewing are detailed in Chapter 2.

Review Protocol – Ketamine (efficacy)

Component	Description
Review question	For children and young people under the age of 19 undergoing diagnostic or therapeutic procedures, is ketamine (with or without: analgesia, another drug or psychological techniques) effective for sedation (at minimal, moderate, and deep levels) in comparison with usual care, with analgesia alone, with another sedation drug, with psychological techniques or with general anaesthesia?
Objectives	To estimate the effectiveness of ketamine.
Population	<p><u>Included:</u> Infants, children and young people (under 19 years) receiving sedation by any technique for painful or non-painful diagnostic or therapeutic procedures including dental surgery and minor operations carried out under local anaesthesia.</p> <p><u>Excluded:</u></p> <ul style="list-style-type: none"> • Patients requiring sedation for purposes other than for diagnostic or therapeutic procedures including: <ul style="list-style-type: none"> ○ sedation in critically ill patients requiring mechanical ventilation ○ sedation in palliative care ○ sedation in the treatment of mental health conditions ○ sedation given as premedication for general anaesthesia or as postoperative analgesia ○ night sedation. • Patients having diagnostic or therapeutic procedures under general anaesthesia.
Intervention	Sedation for diagnostic or therapeutic procedures
Comparison	<p>The following comparisons will be included.</p> <ul style="list-style-type: none"> • intervention (including combinations) versus no intervention or placebo or usual care • intervention A versus B • intervention A + B versus B • pharmacological versus non-pharmacological • pharmacological + non-pharmacological versus non-pharmacological • pharmacological + analgesia versus analgesia • pharmacological versus general anaesthesia • dose A versus dose B • duration 1 versus duration 2 • route of administration 1 versus 2
Outcomes	<p>Primary outcome: Successful completion of diagnostic or therapeutic procedure measured as the number of patients for whom the diagnostic or therapeutic procedure was carried out and completed.</p> <p>Secondary outcomes:</p> <ul style="list-style-type: none"> • complications – respiratory support

- pain as assessed by the patient or parent or other observer
- distress/anxiety as assessed by the patient or parent or other observer
- patient or parent satisfaction, including preference
- length of stay or time to recover to pre-sedation state (includes prolonged drowsiness)

Search strategy

The databases searched were Medline (from 1950 to Jan 18th 2010), Embase (from 1980 to Jan 18th 2010), The Cochrane Library (all dates available to 2009 Issue 4) and CINAHL (from 1982 to Jan 18th 2010).

Studies were restricted to English language only.

Searches were restricted using study design filters for RCTs and systematic reviews.

The review strategy

The review for drug efficacy was based on RCT evidence only. Study details, methodology and results were extracted into an Access database. Further statistical analysis and meta analysis was carried out in Rev Man as required. An evidence profile and quality assessment was then entered into GRADE.

Review Protocol – Ketamine (safety)

Component	Description
Review question	For children and young people under the age of 19 undergoing diagnostic or therapeutic procedures, is ketamine (with or without: analgesia, another drug or psychological techniques) safe for sedation (at mild, moderate, and deep levels) in different settings?
Objectives	To estimate the safety of ketamine.
Population	<p><u>Included:</u> Infants, children and young people (under 19 years) receiving sedation by any technique for painful or non-painful diagnostic or therapeutic procedures including dental surgery and minor operations carried out under local anaesthesia.</p> <p><u>Excluded:</u></p> <ul style="list-style-type: none"> • Patients requiring sedation for purposes other than for diagnostic or therapeutic procedures including: <ul style="list-style-type: none"> ○ sedation in critically ill patients requiring mechanical ventilation ○ sedation in palliative care ○ sedation in the treatment of mental health conditions ○ sedation given as premedication for general anaesthesia or as postoperative analgesia ○ night sedation. • Patients having diagnostic or therapeutic procedures under general anaesthesia.
Intervention	Sedation for diagnostic or therapeutic procedures.
Comparison	<p>The following comparisons will be included.</p> <ul style="list-style-type: none"> • intervention (including combinations) versus no intervention or placebo or usual care • intervention A versus B • intervention A + B versus B • pharmacological versus non-pharmacological • pharmacological + non-pharmacological versus non-pharmacological • pharmacological + analgesia versus analgesia • pharmacological versus general anaesthesia • dose A versus dose B • duration 1 versus duration 2 • route of administration 1 versus 2
Outcomes	<p>Adverse events:</p> <ul style="list-style-type: none"> • Aspiration • Respiratory intervention, including: <ul style="list-style-type: none"> ○ oral-pharyngeal airway ○ endotracheal intubation ○ assisted ventilation • Cardiac arrest requiring either/or:

- external cardiac massage
- defibrillation
- Oxygen desaturation <90%
- Vomiting

Search strategy

The databases searched were Medline (from 1950 to Jan 18th 2010), Embase (from 1980 to Jan 18th 2010), The Cochrane Library (all dates available to 2009 Issue 4) and CINAHL (from 1982 to Jan 18th 2010).

Studies were restricted to English language only.

Searches were not restricted by study design.

The review strategy

The review for drug safety was based upon both RCT and non RCT observational evidence. Study details and results were extracted into tables for review by the GDG. Rates of adverse events were calculated as required.

Review Protocol – Chloral Hydrate (efficacy)

Component	Description
Review question	For children and young people under the age of 19 undergoing diagnostic or therapeutic procedures, is chloral hydrate (with or without: analgesia, another drug or psychological techniques) effective for sedation (at minimal, moderate, and deep levels) in comparison with usual care, with analgesia alone, with another sedation drug, with psychological techniques or with general anaesthesia?
Objectives	To estimate the effectiveness of chloral hydrate.
Population	<p><u>Included:</u> Infants, children and young people (under 19 years) receiving sedation by any technique for painful or non-painful diagnostic or therapeutic procedures including dental surgery and minor operations carried out under local anaesthesia.</p> <p><u>Excluded:</u></p> <ul style="list-style-type: none"> • Patients requiring sedation for purposes other than for diagnostic or therapeutic procedures including: <ul style="list-style-type: none"> ○ sedation in critically ill patients requiring mechanical ventilation ○ sedation in palliative care ○ sedation in the treatment of mental health conditions ○ sedation given as premedication for general anaesthesia or as postoperative analgesia ○ night sedation. • Patients having diagnostic or therapeutic procedures under general anaesthesia.
Intervention	Sedation for diagnostic or therapeutic procedures
Comparison	<p>The following comparisons will be included.</p> <ul style="list-style-type: none"> • intervention (including combinations) versus no intervention or placebo or usual care • intervention A versus B • intervention A + B versus B • pharmacological versus non-pharmacological • pharmacological + non-pharmacological versus non-pharmacological • pharmacological + analgesia versus analgesia • pharmacological versus general anaesthesia • dose A versus dose B • duration 1 versus duration 2 • route of administration 1 versus 2
Outcomes	<p>Primary outcome: Successful completion of diagnostic or therapeutic procedure measured as the number of patients for whom the diagnostic or therapeutic procedure was carried out and completed.</p> <p>Secondary outcomes:</p>

- complications – respiratory support
- pain as assessed by the patient or parent or other observer
- distress/anxiety as assessed by the patient or parent or other observer
- patient or parent satisfaction, including preference
- length of stay or time to recover to pre-sedation state (includes prolonged drowsiness)

Search strategy

The databases searched were Medline (from 1950 to Jan 18th 2010), Embase (from 1980 to Jan 18th 2010), The Cochrane Library (all dates available to 2009 Issue 4) and CINAHL (from 1982 to Jan 18th 2010).

Studies were restricted to English language only.

Searches were restricted using study design filters for RCTs and systematic reviews.

The review strategy

The review for drug efficacy was based on RCT evidence only. Study details, methodology and results were extracted into an Access database. Further statistical analysis and meta analysis was carried out in Rev Man as required. An evidence profile and quality assessment was then entered into GRADE.

Review Protocol – Chloral Hydrate (safety)

Component	Description
Review question	For children and young people under the age of 19 undergoing diagnostic or therapeutic procedures, is chloral hydrate (with or without: analgesia, another drug or psychological techniques) safe for sedation (at mild, moderate, and deep levels) in different settings?
Objectives	To estimate the safety of chloral hydrate.
Population	<p><u>Included:</u> Infants, children and young people (under 19 years) receiving sedation by any technique for painful or non-painful diagnostic or therapeutic procedures including dental surgery and minor operations carried out under local anaesthesia.</p> <p><u>Excluded:</u></p> <ul style="list-style-type: none"> • Patients requiring sedation for purposes other than for diagnostic or therapeutic procedures including: <ul style="list-style-type: none"> ○ sedation in critically ill patients requiring mechanical ventilation ○ sedation in palliative care ○ sedation in the treatment of mental health conditions ○ sedation given as premedication for general anaesthesia or as postoperative analgesia ○ night sedation. • Patients having diagnostic or therapeutic procedures under general anaesthesia.
Intervention	Sedation for diagnostic or therapeutic procedures.
Comparison	<p>The following comparisons will be included.</p> <ul style="list-style-type: none"> • intervention (including combinations) versus no intervention or placebo or usual care • intervention A versus B • intervention A + B versus B • pharmacological versus non-pharmacological • pharmacological + non-pharmacological versus non-pharmacological • pharmacological + analgesia versus analgesia • pharmacological versus general anaesthesia • dose A versus dose B • duration 1 versus duration 2 • route of administration 1 versus 2
Outcomes	<p>Adverse events:</p> <ul style="list-style-type: none"> • Aspiration • Respiratory intervention, including: <ul style="list-style-type: none"> ○ oral-pharyngeal airway ○ endotracheal intubation ○ assisted ventilation • Cardiac arrest requiring either/or:

- external cardiac massage
- defibrillation
- Oxygen desaturation <90%
- Vomiting

Search strategy

The databases searched were Medline (from 1950 to Jan 18th 2010), Embase (from 1980 to Jan 18th 2010), The Cochrane Library (all dates available to 2009 Issue 4) and CINAHL (from 1982 to Jan 18th 2010).

Studies were restricted to English language only.

Searches were not restricted by study design.

The review strategy

The review for drug safety was based upon both RCT and non RCT observational evidence. Study details and results were extracted into tables for review by the GDG. Rates of adverse events were calculated as required.

Review Protocol – Nitrous Oxide (efficacy)

Component	Description
Review question	For children and young people under the age of 19 undergoing diagnostic or therapeutic procedures, is Nitrous Oxide (with or without: analgesia, another drug or psychological techniques) effective for sedation (at minimal, moderate, and deep levels) in comparison with usual care, with analgesia alone, with another sedation drug, with psychological techniques or with general anaesthesia?
Objectives	To estimate the effectiveness of Nitrous Oxide.
Population	<p><u>Included:</u> Infants, children and young people (under 19 years) receiving sedation by any technique for painful or non-painful diagnostic or therapeutic procedures including dental surgery and minor operations carried out under local anaesthesia.</p> <p><u>Excluded:</u></p> <ul style="list-style-type: none"> • Patients requiring sedation for purposes other than for diagnostic or therapeutic procedures including: <ul style="list-style-type: none"> ○ sedation in critically ill patients requiring mechanical ventilation ○ sedation in palliative care ○ sedation in the treatment of mental health conditions ○ sedation given as premedication for general anaesthesia or as postoperative analgesia ○ night sedation. • Patients having diagnostic or therapeutic procedures under general anaesthesia.
Intervention	Sedation for diagnostic or therapeutic procedures
Comparison	<p>The following comparisons will be included.</p> <ul style="list-style-type: none"> • intervention (including combinations) versus no intervention or placebo or usual care • intervention A versus B • intervention A + B versus B • pharmacological versus non-pharmacological • pharmacological + non-pharmacological versus non-pharmacological • pharmacological + analgesia versus analgesia • pharmacological versus general anaesthesia • dose A versus dose B • duration 1 versus duration 2 • route of administration 1 versus 2
Outcomes	<p>Primary outcome: Successful completion of diagnostic or therapeutic procedure measured as the number of patients for whom the diagnostic or therapeutic procedure was carried out and completed.</p> <p>Secondary outcomes:</p>

- complications – respiratory support
- pain as assessed by the patient or parent or other observer
- distress/anxiety as assessed by the patient or parent or other observer
- patient or parent satisfaction, including preference
- length of stay or time to recover to pre-sedation state (includes prolonged drowsiness)

Search strategy

The databases searched were Medline (from 1950 to Jan 18th 2010), Embase (from 1980 to Jan 18th 2010), The Cochrane Library (all dates available to 2009 Issue 4) and CINAHL (from 1982 to Jan 18th 2010).

Studies were restricted to English language only.

Searches were restricted using study design filters for RCTs and systematic reviews.

The review strategy

The review for drug efficacy was based on RCT evidence only. Study details, methodology and results were extracted into an Access database. Further statistical analysis and meta analysis was carried out in Rev Man as required. An evidence profile and quality assessment was then entered into GRADE.

Review Protocol – Nitrous Oxide (safety)

Component	Description
Review question	For children and young people under the age of 19 undergoing diagnostic or therapeutic procedures, is Nitrous Oxide (with or without: analgesia, another drug or psychological techniques) safe for sedation (at mild, moderate, and deep levels) in different settings?
Objectives	To estimate the safety of Nitrous Oxide.
Population	<p><u>Included:</u> Infants, children and young people (under 19 years) receiving sedation by any technique for painful or non-painful diagnostic or therapeutic procedures including dental surgery and minor operations carried out under local anaesthesia.</p> <p><u>Excluded:</u></p> <ul style="list-style-type: none"> • Patients requiring sedation for purposes other than for diagnostic or therapeutic procedures including: <ul style="list-style-type: none"> ○ sedation in critically ill patients requiring mechanical ventilation ○ sedation in palliative care ○ sedation in the treatment of mental health conditions ○ sedation given as premedication for general anaesthesia or as postoperative analgesia ○ night sedation. • Patients having diagnostic or therapeutic procedures under general anaesthesia.
Intervention	Sedation for diagnostic or therapeutic procedures.
Comparison	<p>The following comparisons will be included.</p> <ul style="list-style-type: none"> • intervention (including combinations) versus no intervention or placebo or usual care • intervention A versus B • intervention A + B versus B • pharmacological versus non-pharmacological • pharmacological + non-pharmacological versus non-pharmacological • pharmacological + analgesia versus analgesia • pharmacological versus general anaesthesia • dose A versus dose B • duration 1 versus duration 2 • route of administration 1 versus 2
Outcomes	<p>Adverse events:</p> <ul style="list-style-type: none"> • Aspiration • Respiratory intervention, including: <ul style="list-style-type: none"> ○ oral-pharyngeal airway ○ endotracheal intubation ○ assisted ventilation • Cardiac arrest requiring either/or:

- external cardiac massage
- defibrillation
- Oxygen desaturation <90%
- Vomiting

Search strategy

The databases searched were Medline (from 1950 to Jan 18th 2010), Embase (from 1980 to Jan 18th 2010), The Cochrane Library (all dates available to 2009 Issue 4) and CINAHL (from 1982 to Jan 18th 2010).

Studies were restricted to English language only.

Searches were not restricted by study design.

The review strategy

The review for drug safety was based upon both RCT and non RCT observational evidence. Study details and results were extracted into tables for review by the GDG. Rates of adverse events were calculated as required.

Review Protocol – Opioids (efficacy)

Component	Description
Review question	For children and young people under the age of 19 undergoing diagnostic or therapeutic procedures, are opioids (with or without: analgesia, another drug or psychological techniques) effective for sedation (at minimal, moderate, and deep levels) in comparison with usual care, with analgesia alone, with another sedation drug, with psychological techniques or with general anaesthesia?
Objectives	To estimate the effectiveness of opioids.
Population	<p><u>Included:</u> Infants, children and young people (under 19 years) receiving sedation by any technique for painful or non-painful diagnostic or therapeutic procedures including dental surgery and minor operations carried out under local anaesthesia.</p> <p><u>Excluded:</u></p> <ul style="list-style-type: none"> • Patients requiring sedation for purposes other than for diagnostic or therapeutic procedures including: <ul style="list-style-type: none"> ○ sedation in critically ill patients requiring mechanical ventilation ○ sedation in palliative care ○ sedation in the treatment of mental health conditions ○ sedation given as premedication for general anaesthesia or as postoperative analgesia ○ night sedation. • Patients having diagnostic or therapeutic procedures under general anaesthesia.
Intervention	Sedation for diagnostic or therapeutic procedures
Comparison	<p>The following comparisons will be included.</p> <ul style="list-style-type: none"> • intervention (including combinations) versus no intervention or placebo or usual care • intervention A versus B • intervention A + B versus B • pharmacological versus non-pharmacological • pharmacological + non-pharmacological versus non-pharmacological • pharmacological + analgesia versus analgesia • pharmacological versus general anaesthesia • dose A versus dose B • duration 1 versus duration 2 • route of administration 1 versus 2
Outcomes	<p>Outcomes for efficacy of opioids:</p> <ol style="list-style-type: none"> 4. Completion of procedure 5. Behavioural ratings including: <ol style="list-style-type: none"> d. pain as assessed using validated pain scales such as FACE, VAS, CHEOPS, Spielberger State-Trait Anxiety Inventory (STAI).

- e. procedural distress as assessed by validated scales such as OSBD
- f. parent/patient satisfaction
- 6. Sedation timing including
 - a. length of induction: time from administration of sedation drug to initiation of procedure
 - b. duration of procedure
 - c. length of recovery: time from completion of procedure to recovery criteria being met or recovery to pre-sedation state (includes prolonged drowsiness)
 - d. total: time from administration of intervention to when patient has been transferred to the recovery area or has been discharged

Search strategy

The databases searched were Medline (from 1950 to Jan 18th 2010), Embase (from 1980 to Jan 18th 2010), The Cochrane Library (all dates available to 2009 Issue 4) and CINAHL (from 1982 to Jan 18th 2010).

Studies were restricted to English language only.

Searches were not restricted by study design.

The review strategy

The review for drug efficacy will be based on RCT evidence only. Study details, methodology and results will be extracted into an Access database. Further statistical analysis and meta analysis will be conducted where possible and carried out in Rev Man as required. The methods of reviewing are detailed in Chapter 2. An evidence profile and quality assessment will be then entered into GRADE.

Review Protocol – Opioids (safety)

Component	Description
Review question	For children and young people under the age of 19 undergoing diagnostic or therapeutic procedures, are opioids (with or without: analgesia, another drug or psychological techniques) safe for sedation (at mild, moderate, and deep levels) in different settings?
Objectives	To estimate the safety of opioids.
Population	<p><u>Included:</u> Infants, children and young people (under 19 years) receiving sedation by any technique for painful or non-painful diagnostic or therapeutic procedures including dental surgery and minor operations carried out under local anaesthesia.</p> <p><u>Excluded:</u></p> <ul style="list-style-type: none"> • Patients requiring sedation for purposes other than for diagnostic or therapeutic procedures including: <ul style="list-style-type: none"> ○ sedation in critically ill patients requiring mechanical ventilation ○ sedation in palliative care ○ sedation in the treatment of mental health conditions ○ sedation given as premedication for general anaesthesia or as postoperative analgesia ○ night sedation. • Patients having diagnostic or therapeutic procedures under general anaesthesia.
Intervention	Sedation for diagnostic or therapeutic procedures.
Comparison	<p>The following comparisons will be included.</p> <ul style="list-style-type: none"> • intervention (including combinations) versus no intervention or placebo or usual care • intervention A versus B • intervention A + B versus B • pharmacological versus non-pharmacological • pharmacological + non-pharmacological versus non-pharmacological • pharmacological + analgesia versus analgesia • pharmacological versus general anaesthesia • dose A versus dose B • duration 1 versus duration 2 • route of administration 1 versus 2
Outcomes	<p>Outcomes for safety of opioids:</p> <ul style="list-style-type: none"> • Aspiration • Respiratory intervention, including: <ul style="list-style-type: none"> ○ oral-pharyngeal airway ○ endotracheal intubation ○ assisted ventilation • Cardiac arrest requiring either/or:

- external cardiac massage
- defibrillation
- Oxygen desaturation <90%
- Vomiting

Search strategy

The databases searched were Medline (from 1950 to Jan 18th 2010), Embase (from 1980 to Jan 18th 2010), The Cochrane Library (all dates available to 2009 Issue 4) and CINAHL (from 1982 to Jan 18th 2010).

Studies were restricted to English language only.

Searches were not restricted by study design.

The review strategy

The review for drug safety will be based upon both RCT and non-RCT observational evidence. For RCT evidence, study details, methodology and results will be extracted into an Access database. Further statistical analysis and meta analysis will be conducted where possible and carried out in Rev Man as required. For non-RCT observational evidence, study details and results will be extracted into tables and rates of adverse events will be calculated as required. All evidence will be reviewed by the GDG. An evidence profile and quality assessment will be then entered into GRADE. The methods of reviewing are detailed in Chapter 2.

Review Protocol – Propofol (efficacy)

Component	Description
Review question	For children and young people under the age of 19 undergoing diagnostic or therapeutic procedures, is propofol (with or without: analgesia, another drug or psychological techniques) effective for sedation (at minimal, moderate, and deep levels) in comparison with usual care, with analgesia alone, with another sedation drug, with psychological techniques or with general anaesthesia?
Objectives	To estimate the effectiveness of propofol.
Population	<p><u>Included:</u> Infants, children and young people (under 19 years) receiving sedation by any technique for painful or non-painful diagnostic or therapeutic procedures including dental surgery and minor operations carried out under local anaesthesia.</p> <p><u>Excluded:</u></p> <ul style="list-style-type: none"> • Patients requiring sedation for purposes other than for diagnostic or therapeutic procedures including: <ul style="list-style-type: none"> ○ sedation in critically ill patients requiring mechanical ventilation ○ sedation in palliative care ○ sedation in the treatment of mental health conditions ○ sedation given as premedication for general anaesthesia or as postoperative analgesia ○ night sedation. • Patients having diagnostic or therapeutic procedures under general anaesthesia.
Intervention	Sedation for diagnostic or therapeutic procedures
Comparison	<p>The following comparisons will be included.</p> <ul style="list-style-type: none"> • intervention (including combinations) versus no intervention or placebo or usual care • intervention A versus B • intervention A + B versus B • pharmacological versus non-pharmacological • pharmacological + non-pharmacological versus non-pharmacological • pharmacological + analgesia versus analgesia • pharmacological versus general anaesthesia • dose A versus dose B • duration 1 versus duration 2 • route of administration 1 versus 2
Outcomes	<p>Outcomes for efficacy of propofol:</p> <ol style="list-style-type: none"> 7. Completion of procedure 8. Behavioural ratings including: <ol style="list-style-type: none"> g. pain as assessed using validated pain scales such as FACE, VAS, CHEOPS, Spielberger State-Trait Anxiety Inventory (STAI).

- h. procedural distress as assessed by validated scales such as OSBD
- i. parent/patient satisfaction
- 9. Sedation timing including
 - a. length of induction: time from administration of sedation drug to initiation of procedure
 - b. duration of procedure
 - c. length of recovery: time from completion of procedure to recovery criteria being met or recovery to pre-sedation state (includes prolonged drowsiness)
 - d. total: time from administration of intervention to when patient has been transferred to the recovery area or has been discharged

Search strategy

The databases searched were Medline (from 1950 to Jan 18th 2010), Embase (from 1980 to Jan 18th 2010), The Cochrane Library (all dates available to 2009 Issue 4) and CINAHL (from 1982 to Jan 18th 2010).

Studies were restricted to English language only.

Searches were restricted using study design filters for RCTs and systematic reviews.

The review strategy

The review for drug efficacy will be based on RCT evidence only. Study details, methodology and results will be extracted into an Access database. Further statistical analysis and meta analysis will be conducted where possible and carried out in Rev Man as required. The methods of reviewing are detailed in Chapter 2. An evidence profile and quality assessment will be then entered into GRADE.

Review Protocol – Propofol (safety)

Component	Description
Review question	For children and young people under the age of 19 undergoing diagnostic or therapeutic procedures, is propofol (with or without: analgesia, another drug or psychological techniques) safe for sedation (at mild, moderate, and deep levels) in different settings?
Objectives	To estimate the safety of propofol.
Population	<p><u>Included:</u> Infants, children and young people (under 19 years) receiving sedation by any technique for painful or non-painful diagnostic or therapeutic procedures including dental surgery and minor operations carried out under local anaesthesia.</p> <p><u>Excluded:</u></p> <ul style="list-style-type: none"> • Patients requiring sedation for purposes other than for diagnostic or therapeutic procedures including: <ul style="list-style-type: none"> ○ sedation in critically ill patients requiring mechanical ventilation ○ sedation in palliative care ○ sedation in the treatment of mental health conditions ○ sedation given as premedication for general anaesthesia or as postoperative analgesia ○ night sedation. • Patients having diagnostic or therapeutic procedures under general anaesthesia.
Intervention	Sedation for diagnostic or therapeutic procedures.
Comparison	<p>The following comparisons will be included.</p> <ul style="list-style-type: none"> • intervention (including combinations) versus no intervention or placebo or usual care • intervention A versus B • intervention A + B versus B • pharmacological versus non-pharmacological • pharmacological + non-pharmacological versus non-pharmacological • pharmacological + analgesia versus analgesia • pharmacological versus general anaesthesia • dose A versus dose B • duration 1 versus duration 2 • route of administration 1 versus 2
Outcomes	<p>Outcomes for safety of propofol:</p> <ul style="list-style-type: none"> • Aspiration • Respiratory intervention, including: <ul style="list-style-type: none"> ○ oral-pharyngeal airway ○ endotracheal intubation ○ assisted ventilation • Cardiac arrest requiring either/or:

- external cardiac massage
- defibrillation
- Oxygen desaturation <90%
- Vomiting

Search strategy

The databases searched were Medline (from 1950 to Jan 18th 2010), Embase (from 1980 to Jan 18th 2010), The Cochrane Library (all dates available to 2009 Issue 4) and CINAHL (from 1982 to Jan 18th 2010).

Studies were restricted to English language only.

Searches were not restricted by study design.

The review strategy

The review for drug safety will be based upon both RCT and non-RCT observational evidence. For RCT evidence, study details, methodology and results will be extracted into an Access database. Further statistical analysis and meta analysis will be conducted where possible and carried out in Rev Man as required. For non-RCT observational evidence, study details and results will be extracted into tables and rates of adverse events will be calculated as required. All evidence will be reviewed by the GDG. An evidence profile and quality assessment will be then entered into GRADE. The methods of reviewing are detailed in Chapter 2.

Review Protocol – Sevoflurane (efficacy)

Component	Description
Review question	For children and young people under the age of 19 undergoing diagnostic or therapeutic procedures, is sevoflurane (with or without: analgesia, another drug or psychological techniques) effective for sedation (at minimal, moderate, and deep levels) in comparison with usual care, with analgesia alone, with another sedation drug, with psychological techniques or with general anaesthesia?
Objectives	To estimate the effectiveness of sevoflurane.
Population	<p><u>Included:</u> Infants, children and young people (under 19 years) receiving sedation by any technique for painful or non-painful diagnostic or therapeutic procedures including dental surgery and minor operations carried out under local anaesthesia.</p> <p><u>Excluded:</u></p> <ul style="list-style-type: none"> • Patients requiring sedation for purposes other than for diagnostic or therapeutic procedures including: <ul style="list-style-type: none"> ○ sedation in critically ill patients requiring mechanical ventilation ○ sedation in palliative care ○ sedation in the treatment of mental health conditions ○ sedation given as premedication for general anaesthesia or as postoperative analgesia ○ night sedation. • Patients having diagnostic or therapeutic procedures under general anaesthesia.
Intervention	Sedation for diagnostic or therapeutic procedures
Comparison	<p>The following comparisons will be included.</p> <ul style="list-style-type: none"> • intervention (including combinations) versus no intervention or placebo or usual care • intervention A versus B • intervention A + B versus B • pharmacological versus non-pharmacological • pharmacological + non-pharmacological versus non-pharmacological • pharmacological + analgesia versus analgesia • pharmacological versus general anaesthesia • dose A versus dose B • duration 1 versus duration 2 • route of administration 1 versus 2
Outcomes	<p>Outcomes for efficacy of sevoflurane:</p> <ol style="list-style-type: none"> 10. Completion of procedure 11. Behavioural ratings including: <ol style="list-style-type: none"> i. pain as assessed using validated pain scales such as FACE, VAS, CHEOPS, Spielberger State-Trait Anxiety Inventory

- (STAI).
- k. procedural distress as assessed by validated scales such as OSBD
- l. parent/patient satisfaction
- 12. Sedation timing including
 - a. length of induction: time from administration of sedation drug to initiation of procedure
 - b. duration of procedure
 - c. length of recovery: time from completion of procedure to recovery criteria being met or recovery to pre-sedation state (includes prolonged drowsiness)
 - d. total: time from administration of intervention to when patient has been transferred to the recovery area or has been discharged

Search strategy

The databases searched were Medline (from 1950 to Jan 18th 2010), Embase (from 1980 to Jan 18th 2010), The Cochrane Library (all dates available to 2009 Issue 4) and CINAHL (from 1982 to Jan 18th 2010).

Studies were restricted to English language only.

Searches were restricted using study design filters for RCTs and systematic reviews.

The review strategy

The review for drug efficacy will be based on RCT evidence only. Study details, methodology and results will be extracted into an Access database. Further statistical analysis and meta analysis will be conducted where possible and carried out in Rev Man as required. The methods of reviewing are detailed in Chapter 2. An evidence profile and quality assessment will be then entered into GRADE.

Review Protocol – Sevoflurane (safety)

Component	Description
Review question	For children and young people under the age of 19 undergoing diagnostic or therapeutic procedures, is sevoflurane (with or without: analgesia, another drug or psychological techniques) safe for sedation (at mild, moderate, and deep levels) in different settings?
Objectives	To estimate the safety of sevoflurane.
Population	<p><u>Included:</u> Infants, children and young people (under 19 years) receiving sedation by any technique for painful or non-painful diagnostic or therapeutic procedures including dental surgery and minor operations carried out under local anaesthesia.</p> <p><u>Excluded:</u></p> <ul style="list-style-type: none"> • Patients requiring sedation for purposes other than for diagnostic or therapeutic procedures including: <ul style="list-style-type: none"> ○ sedation in critically ill patients requiring mechanical ventilation ○ sedation in palliative care ○ sedation in the treatment of mental health conditions ○ sedation given as premedication for general anaesthesia or as postoperative analgesia ○ night sedation. • Patients having diagnostic or therapeutic procedures under general anaesthesia.
Intervention	Sedation for diagnostic or therapeutic procedures.
Comparison	<p>The following comparisons will be included.</p> <ul style="list-style-type: none"> • intervention (including combinations) versus no intervention or placebo or usual care • intervention A versus B • intervention A + B versus B • pharmacological versus non-pharmacological • pharmacological + non-pharmacological versus non-pharmacological • pharmacological + analgesia versus analgesia • pharmacological versus general anaesthesia • dose A versus dose B • duration 1 versus duration 2 • route of administration 1 versus 2
Outcomes	<p>Outcomes for safety of sevoflurane:</p> <ul style="list-style-type: none"> • Aspiration • Respiratory intervention, including: <ul style="list-style-type: none"> ○ oral-pharyngeal airway ○ endotracheal intubation ○ assisted ventilation • Cardiac arrest requiring either/or:

- external cardiac massage
- defibrillation
- Oxygen desaturation <90%
- Vomiting

Search strategy

The databases searched were Medline (from 1950 to Jan 18th 2010), Embase (from 1980 to Jan 18th 2010), The Cochrane Library (all dates available to 2009 Issue 4) and CINAHL (from 1982 to Jan 18th 2010).

Studies were restricted to English language only.

Searches were not restricted by study design.

The review strategy

The review for drug safety will be based upon both RCT and non-RCT observational evidence. For RCT evidence, study details, methodology and results will be extracted into an Access database. Further statistical analysis and meta analysis will be conducted where possible and carried out in Rev Man as required. For non-RCT observational evidence, study details and results will be extracted into tables and rates of adverse events will be calculated as required. All evidence will be reviewed by the GDG. An evidence profile and quality assessment will be then entered into GRADE. The methods of reviewing are detailed in Chapter 2.

Review Protocol – Triclofos Sodium (efficacy)

Component	Description
Review question	For children and young people under the age of 19 undergoing diagnostic or therapeutic procedures, is triclofos sodium (with or without: analgesia, another drug or psychological techniques) effective for sedation (at minimal, moderate, and deep levels) in comparison with usual care, with analgesia alone, with another sedation drug, with psychological techniques or with general anaesthesia?
Objectives	To estimate the effectiveness of triclofos sodium.
Population	<p><u>Included:</u> Infants, children and young people (under 19 years) receiving sedation by any technique for painful or non-painful diagnostic or therapeutic procedures including dental surgery and minor operations carried out under local anaesthesia.</p> <p><u>Excluded:</u></p> <ul style="list-style-type: none"> • Patients requiring sedation for purposes other than for diagnostic or therapeutic procedures including: <ul style="list-style-type: none"> ○ sedation in critically ill patients requiring mechanical ventilation ○ sedation in palliative care ○ sedation in the treatment of mental health conditions ○ sedation given as premedication for general anaesthesia or as postoperative analgesia ○ night sedation. • Patients having diagnostic or therapeutic procedures under general anaesthesia.
Intervention	Sedation for diagnostic or therapeutic procedures
Comparison	<p>The following comparisons will be included.</p> <ul style="list-style-type: none"> • intervention (including combinations) versus no intervention or placebo or usual care • intervention A versus B • intervention A + B versus B • pharmacological versus non-pharmacological • pharmacological + non-pharmacological versus non-pharmacological • pharmacological + analgesia versus analgesia • pharmacological versus general anaesthesia • dose A versus dose B • duration 1 versus duration 2 • route of administration 1 versus 2
Outcomes	<p>Outcomes for efficacy of triclofos sodium:</p> <ol style="list-style-type: none"> 1. Completion of procedure 2. Behavioural ratings including: <ol style="list-style-type: none"> m. pain as assessed using validated pain scales such as FACE, VAS, CHEOPS, Spielberger State-Trait Anxiety Inventory

- (STAI).
- n. procedural distress as assessed by validated scales such as OSBD
- o. parent/patient satisfaction
- 3. Sedation timing including
 - a. length of induction: time from administration of sedation drug to initiation of procedure
 - b. duration of procedure
 - c. length of recovery: time from completion of procedure to recovery criteria being met or recovery to pre-sedation state (includes prolonged drowsiness)
 - d. total: time from administration of intervention to when patient has been transferred to the recovery area or has been discharged

Search strategy

The databases searched were Medline (from 1950 to Jan 18th 2010), Embase (from 1980 to Jan 18th 2010), The Cochrane Library (all dates available to 2009 Issue 4) and CINAHL (from 1982 to Jan 18th 2010).

Studies were restricted to English language only.

Searches were restricted using study design filters for RCTs and systematic reviews.

The review strategy

The review for drug efficacy will be based on RCT evidence only. Study details, methodology and results will be extracted into an Access database. Further statistical analysis and meta analysis will be conducted where possible and carried out in Rev Man as required. The methods of reviewing are detailed in Chapter 2. An evidence profile and quality assessment will be then entered into GRADE.

Review Protocol – triclofos sodium (safety)

Component	Description
Review question	For children and young people under the age of 19 undergoing diagnostic or therapeutic procedures, is triclofos sodium (with or without: analgesia, another drug or psychological techniques) safe for sedation (at mild, moderate, and deep levels) in different settings?
Objectives	To estimate the safety of triclofos sodium.
Population	<p><u>Included:</u> Infants, children and young people (under 19 years) receiving sedation by any technique for painful or non-painful diagnostic or therapeutic procedures including dental surgery and minor operations carried out under local anaesthesia.</p> <p><u>Excluded:</u></p> <ul style="list-style-type: none"> • Patients requiring sedation for purposes other than for diagnostic or therapeutic procedures including: <ul style="list-style-type: none"> ○ sedation in critically ill patients requiring mechanical ventilation ○ sedation in palliative care ○ sedation in the treatment of mental health conditions ○ sedation given as premedication for general anaesthesia or as postoperative analgesia ○ night sedation. • Patients having diagnostic or therapeutic procedures under general anaesthesia.
Intervention	Sedation for diagnostic or therapeutic procedures.
Comparison	<p>The following comparisons will be included.</p> <ul style="list-style-type: none"> • intervention (including combinations) versus no intervention or placebo or usual care • intervention A versus B • intervention A + B versus B • pharmacological versus non-pharmacological • pharmacological + non-pharmacological versus non-pharmacological • pharmacological + analgesia versus analgesia • pharmacological versus general anaesthesia • dose A versus dose B • duration 1 versus duration 2 • route of administration 1 versus 2
Outcomes	<p>Outcomes for safety of triclofos sodium:</p> <ul style="list-style-type: none"> • Aspiration • Respiratory intervention, including: <ul style="list-style-type: none"> ○ oral-pharyngeal airway ○ endotracheal intubation ○ assisted ventilation • Cardiac arrest requiring either/or:

- external cardiac massage
- defibrillation
- Oxygen desaturation <90%
- Vomiting

Search strategy

The databases searched were Medline (from 1950 to Jan 18th 2010), Embase (from 1980 to Jan 18th 2010), The Cochrane Library (all dates available to 2009 Issue 4) and CINAHL (from 1982 to Jan 18th 2010).

Studies were restricted to English language only.

Searches were not restricted by study design.

The review strategy

The review for drug safety will be based upon both RCT and non-RCT observational evidence. For RCT evidence, study details, methodology and results will be extracted into an Access database. Further statistical analysis and meta analysis will be conducted where possible and carried out in Rev Man as required. For non-RCT observational evidence, study details and results will be extracted into tables and rates of adverse events will be calculated as required. All evidence will be reviewed by the GDG. An evidence profile and quality assessment will be then entered into GRADE. The methods of reviewing are detailed in Chapter 2.

Review Protocol – Sedation sparing (efficacy and safety)

Component	Description
Review question	For children and young people under the age of 19 undergoing diagnostic or therapeutic procedures, does a combination of psychological techniques and sedation drugs lead to sedation sparing?
Objectives	To establish whether non-pharmacological intervention(s) reduce the amount of the sedative agent required and used in each arm.
Population	<p><u>Included:</u> Infants, children and young people (under 19 years) receiving sedation by any technique for painful or non-painful diagnostic or therapeutic procedures including dental surgery and minor operations carried out under local anaesthesia.</p> <p><u>Excluded:</u></p> <ul style="list-style-type: none"> • Patients requiring sedation for purposes other than for diagnostic or therapeutic procedures including: <ul style="list-style-type: none"> ○ sedation in critically ill patients requiring mechanical ventilation ○ sedation in palliative care ○ sedation in the treatment of mental health conditions ○ sedation given as premedication for general anaesthesia or as postoperative analgesia ○ night sedation. • Patients having diagnostic or therapeutic procedures under general anaesthesia.
Intervention	Sedation for diagnostic or therapeutic procedures
Comparison	<p>The following comparisons will be included.</p> <ul style="list-style-type: none"> • pharmacological + non-pharmacological versus pharmacological
Outcomes	<p>Outcomes for efficacy and safety as detailed in outcomes section of this chapter and the following additional outcome(s) for sedation sparing:</p> <ol style="list-style-type: none"> 1. volume (dose) of the sedation agent used in each arm
Search strategy	<p>The databases searched were Medline (from 1950 to Jan 18th 2010), Embase (from 1980 to Jan 18th 2010), The Cochrane Library (all dates available to 2009 Issue 4) and CINAHL (from 1982 to Jan 18th 2010).</p> <p>Studies were restricted to English language only.</p> <p>Searches were not restricted by study design.</p>
The review strategy	<p>The methods of reviewing are detailed in Chapter 2..</p> <p>The review for efficacy will be based on RCT evidence only. Study details, methodology and results will be extracted into an Access database. Further statistical analysis and meta analysis will be conducted where possible and</p>

carried out in Rev Man as required. T An evidence profile and quality assessment will be then entered into GRADE.

The review for safety will be based upon both RCT and non-RCT observational evidence. For RCT evidence, study details, methodology and results will be extracted into an Access database. Further statistical analysis and meta analysis will be conducted where possible and carried out in Rev Man as required. For non-RCT observational evidence, study details and results will be extracted into tables and rates of adverse events will be calculated as required. All evidence will be reviewed by the GDG. An evidence profile and quality assessment will be then entered into GRADE.

7 Appendix I - AGREE Tool

See separate file

8 Appendix J – Licensing indications

The table that follows provides a summary reference guide to pharmacological treatment. They were prepared from data available in September 2010. Prescribers should refer to the 'British national formulary for children' and summary of product characteristics for each drug for full and up-to-date details of licensing. Informed consent should be obtained and documented for the use of any drug outside the licensed indications.

Drug	Indication	Licensed use (taken from the 'British national formulary for children' [BNFc] 2010/11, correct at the time of publication)
Chloral hydrate	Sedation	Not licensed for sedation in painless procedures. However, dosing for painless procedures in children from neonates to 18 years is given in the BNFc; by mouth or by rectum.
Diamorphine	Acute pain in an emergency setting; short painful procedures	Not licensed for intranasal route, but listed in the BNFc as follows: Acute pain in an emergency setting or short painful procedures; intranasally in child heavier than 10 kg.
Fentanyl	Analgesia and enhancement of anaesthesia and for deep sedation	Licensed for use in children older than 1 month with spontaneous respiration for analgesia, and during operations for enhancement of anaesthesia by intravenous injection over at least 30 seconds. If deep sedation is needed fentanyl may be used. It should be used only under the supervision of a specialist experienced in its use.
Ketamine	Anaesthesia (lower doses are used for sedation than for anaesthesia for surgery)	Licensed for use in anaesthesia for all ages; intravenous and intramuscular. If deep sedation is needed ketamine may be used. It should be used only under the supervision of a specialist experienced in its use.
Midazolam	Sedation	Not licensed for use in children younger than 6 months for premedication and conscious sedation.

		<p>Not licensed for use by mouth or by buccal administration.</p> <p>Intravenous midazolam is not licensed for use in children younger than 6 months for conscious sedation.</p> <p>No UK marketing authorisation for oral or intranasal midazolam for sedation. However, dosing for children from age 1 month is given in the BNFc.</p>
Morphine	Analgesia and sedation	<p>Licensed for analgesia in all ages; subcutaneous or intravenous.</p> <p>Other routes have restricted licensing:</p> <ul style="list-style-type: none"> • Oramorph solution not licensed for use in children younger than 1 year • Oramorph unit dose vials not licensed for use in children younger than 6 years • Sevredol tablets not licensed for use in children younger than 3 years • MST Continus preparations licensed to treat children with cancer pain (age range not specified by manufacturer) • MXL capsules not licensed for use in children younger than 1 year. <p>If deep sedation is needed, morphine may be used. It should be used only under the supervision of a specialist experienced in the use of these drugs.</p>
Nitrous oxide	Sedation	<p>50% nitrous oxide licensed for use in sedation for all ages; inhalation.</p> <p>Nitrous oxide in concentrations greater than 50% is not licensed for analgesia without loss of consciousness.</p>
Opioids		<p>The BNFc stipulates that if deep sedation is needed a general anaesthetic (for example, propofol or ketamine), or a potent opioid (for example, fentanyl) may be used. However, they should be used only under the supervision of a specialist experienced in the use of these drugs.</p>
Propofol	Anaesthesia	<p>Licensed for use in children older than 1 month in doses of 0.5% or 1%; intravenous.</p>
	Sedation	<p>Licensed for use in people older than 17 years. The GDG decided to recommend off-label use of propofol for sedation in children of all ages. This was because propofol is widely used in the UK for sedation in children of all ages and the doses used for sedation are much lower than those used for anaesthesia.</p> <p>If deep sedation is needed, propofol may be used. However, it should be used only under the supervision of a specialist experienced in its use.</p>
Sevoflurane	Anaesthesia	<p>Licensed for use in anaesthesia for all ages; inhalation.</p>

	Sedation	Sedation is outside the licensed use. The GDG decided to recommend off-label use of sevoflurane for sedation in children of all ages. This was because sevoflurane is widely used in the UK for sedation in children of all ages and the doses used for sedation are much lower than those used for anaesthesia.
Triclofos sodium	Sedation	Licensed for use in sedation for all ages; by mouth.